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Thesis Abstract
Throughout this thesis, metabolic profiling using a global mass spectrometry-based ap-
proach was utilised to explore cholangiocarcinoma (CCA) metabolic signature in urine and
serum. CCA is an aggressive disease with a poor prognosis. The geographical distribution
of CCA cases is markedly uneven and it closely mirrors the prevalence of its predisposing
risk factors. CCA is most commonly seen in Southeast Asia where liver fluke infection is
endemic, whereas in Western countries it is a rare malignancy with an unknown aetiology in
most cases. To date, a multi-disciplinary approach with multi-modal tools are often applied
for the diagnosis of this complex disease.
The primary aim of this thesis was to provide insights into the perturbed biological path-
ways underlying cholangiocarcinogenesis as a mean to identify metabolite biomarkers to
improve CCA screening and diagnosis. The first four results chapters describes the urinary
metabolome associated with liver fluke induced-CCA and sporadic CCA in patients from
Thailand and the UK, respectively. Overall, CCA induces a metabolic profile change that can
distinguish patients from healthy and control groups with various hepatobiliary pathologies.
Dysregulation in acylcarnitine, bile acid, steroid and purine metabolism was characteristic
of the CCA urinary metabolic signature in both populations. A panel of 10 metabolites (pri-
marily acylcarnitine and steroid species) achieved a diagnostic accuracy of 93.4% and AUC
value of 98.8% (CI= 96.3%-100%) in distinguishing CCA cases from healthy participants.
Phenotypic disparities between the two distinct populations were primarily related to differ-
ences in dietary practices and body composition. Furthermore, regardless of the underlying
aetiology, biological perturbations associated with the CCA urine metabolome signature ap-
peared to be influenced by gut microbial community metabolism. Sporadic bile duct disease
3
4exhibited altered nucleotide metabolism, possibly indicating differences in mitochondrial en-
ergy production pathways related to differences in CCA underlying aetiology.
Similarly, the serum metabolic patterns were differential in bile duct cancer, compared to
healthy participants and individuals with benign and malignant hepatobiliary diseases. Im-
paired phospholipid homoeostases was particularly observed in CCA serum profiles, pos-
sibly suggesting influence of genetic variants that impair biliary phospholipid secretion on
circulating lipids. A common metabotype, primarily indicative of inflammatory signature, was
found to be associated with liver pathologies, both benign and malignant.
Overall, it is possible to conclude that metabonomic profiling can identify disease-related
metabotypes and may possibly contribute to uncovering novel candidate diagnostic biomark-
ers in CCA.
5To the people who have been touched by cholangiocarcinoma,
to everyone who made this possible and to you.
With love and gratitude.
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Chapter 1
INTRODUCTION
1.1 Cholangiocarcinoma
Cholangiocarcinoma (CCA), or bile duct carcinoma, is a malignancy that originates from the
cholangiocytes lining the biliary tree. It is the second most common primary liver malignancy,
following hepatocellular carcinoma (HCC), accounting for 10–20% of all hepatic cancers
(Shaib and El-Serag, 2004). Based on where the tumour arise in the biliary tree, CCA
tumours are classified into intrahepatic (iCCA) and distal (dCCA), tumours arising in the
bile duct bifurcation are anatomically extrahepatic and are classified as perihilar (pCCA),
as illustrated in (Figure 1.1). The majority of CCA tumours are in the perihilar and distal
region, and only 10% are intrahepatic (Razumilava and Gores, 2014). The typical age at
presentation is the seventh decade, with a slight male predominance (Banales et al., 2016).
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Figure 1.1: Locations of cholangiocarcinoma on the biliary tree.
Intrahepatic cholangiocarcinoma arise within the hepatic biliary ducts, perihilar in the bile duct bifurcation and
distal tumours arise anywhere along the common biliary duct outside the liver.
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1.1.1 Epidemiology
Recent studies have shown an unexplained global increase in CCA incidence and mortality.
For instance, in England the number of CCA deaths increased from 1,720 in 2010 to 2,161
in 2013 (NCIN, 2015). A similar trend was found in the United States, the incidence rate
of iCCA increased by 165% in 30 years, from the 70s to the 90s, from from 0.32 per 100
000 to 0.85 per 100 000 (Shaib and El-Serag, 2004). The geographical distribution of CCA
cases is uneven, (Figure 1.2), and it closely mirrors the prevalence of its predisposing risk
factors. The vast majority of CCA cases in the West have a sporadic nature. Primary
sclerosing cholangitis (PSC), a chronic condition causing biliary obliterative fibrosis, is the
commonest risk factor in Western countries, however, it is associated with only 10% of the
cases, indicating the diversity of influencing factors on disease risk (Zabron et al., 2013).
The highest reported CCA incidence internationally is in the Northeast of Thailand, 118.5
per 100 000, in Khon Kaen, which is 100 times higher than the global rate. The high CCA
burden is associated with liver fluke infestations that is endemic to countries through which
the Mekong River traverses on its route from Yunnan Province in China through to its delta
in southern Vietnam (Bragazzi et al., 2011).
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Figure 1.2: Estimated global cholangiocarcinoma incidence.
World map showing cholangiocarcinoma incidence per 100 000 (left), (Bragazzi et al., 2011), and incidence of
cholangiocarcinoma and prevalence ofOpisthorchis viverrini in Thailand from 1990–2001 (right), adapted
from (Sripa et al., 2007).
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Liver fluke infection is caused by water-borne parasites, Opisthorchis viverrini (O.viverrini),
Clonorchis sinensis (C.sinensis), and Opisthorchis felineus (O.felineus) which are transmit-
ted to humans by the consumption of raw, pickled or under-cooked infected fish. O.viverrini
is generally common lower of the Mekong Basin region, including Thailand, Laos, central
Vietnam and Cambodia, whereas in Korea, China and northern Vietnam C.sinensis is more
prevalent. O.felineus is reported to be endemic in the former Soviet Union, Kazkastan and
Ukraine (Keiser and Utzinger, 2005).
The distribution of biliary duct carcinoma in Thailand shows high variability (Figure 1.2);
regions with high O.viverrini endemicity show higher CCA burden. In Southern Thailand
where O.viverrini infection is sparse, the incidence is 5.7 per 100 000 compared to 14.6 per
100 000 and 85 per 100 000 in the North and Northeast where O.viverrini infect 19.3% and
15.7% of the population, respectively (Sripa et al., 2007).
1.1.2 Risk factors and pathogenesis
1.1.2.1 Liver flukes
Leiper reported the first human cases of O.viverrini infection in the cadavers of Thai prison-
ers in the early 90’s (Leiper, 1915). Eight decades later in 1994, O.viverrini was classified,
along with C.sinensis, as a type-1 carcinogen by the International Agency for Research on
Cancer (IARC) based their strong association to hepatobiliary carcinomas (IARC, 1994).
The majority of Opisthorchiasis and Clonorchiasis cases are found in the Mekong River
basin villages where the flukes infect around 90–95% of cyprinid fish (fish with scales), and
eating freshly caught fish raw is a long-standing tradition enjoyed among the locals (Vichasri
et al., 1982). Koi pla (raw fish salad), pla som (fermented fish), are a few of the most com-
mon infective dishes eaten surrounding the 4,350 km long river, where fishing is one of the
main sources of food and livelihood, and fish is the cheapest source of animal protein for
the majority of the 67 million inhabitants of the Mekong basin (Ziegler et al., 2013). They are
also amongst the poorest in the world with an average income of less than one dollar per
day (Cogels, 2004). Sithithaworn and collogues named the fluke infestation and its deadly
consequences ”the fatal disease of the poor” (Sithithaworn et al., 2012).
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Mortality from liver and bile duct cancer is the leading cause of death in Thai males and third
in females, causing a total of 28,000 deaths in 2004. The highest number of liver cancer
mortality cases is reported in the Northeast of Thailand, comprising 70% of the cases (Sripa
and Pairojkul, 2008). O.viverrini is endemic in the wetland south of the Mekong region af-
fecting eight million people in Thailand and two million in Laos. Until recently the endemicity
level in Cambodia was uncertain, however, a large surveillance examining 16,082 faecal
samples showed that the infection is highly endemic, reaching an alarming 65.1% in one of
the villages in the Southern region. Eating raw fish in endemic areas was reported in 70% to
100% of the locals (Miyamoto et al., 2014). An estimated 601 million people are currently at
risk of infection with C.sinensis, 570 million are in China and Taiwan alone, and 67.3 million
people are at risk of O.viverrini infection (Keiser and Utzinger, 2005).
Figure 1.3: Liver Flukes Life Cycle.
Courtesy of Centers for Disease Control and Prevention (CDC, 2012).
The fluke life cycle is complex, involving two intermediate hosts (snail to fish) and several
morphological changes, (Figure 1.3). After the ingestion of fish containing viable metac-
ercariae, infected humans excrete the eggs produced by the mature adult worms in their
faeces. If the egg reaches freshwater, the larva (or miracidia) that hatches from the egg is
ingested by snails. The Infected snails shed thousands of cercariae into the water, which
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penetrate the skin between the scales of freshwater fish, and encyst forming metacercariae.
In 21 days they become infective metacercariae, and when ingested by humans, they excyst
in the duodenum and ascend to the bile duct via the ampulla of Vater. Using its two suckers
and body contraction,the metacercariae migrates further into the smaller, proximal bile ducts
where it becomes a mature worm within a month and is able to sexually reproduce. Adult
worms, (measures 10–25 mm long and 3–5 mm wide), are able to produce 1000-5000 eggs
per day, and is estimated to survive up to 25 years in the biliary tree causing only mild symp-
toms (IARC, 1994, 2012). Conventional diagnosis of liver flukes is based on microscopic
examination of the faeces for eggs. The infection is usually asymptomatic in mild cases, i.e.,
fewer than 100 flukes. Malaise, abdominal discomfort, and diarrhoea sometimes present in
early infection (Kaewpitoon et al., 2008).
Long-term complications associated with chronic infection include, hepatomegaly, cholecys-
titis, gallstones and periportal fibrosis. The severity of such manifestations are linked to
the intensity and duration of infection. Chronic inflammation is found to be a major aeti-
ological precursor of hepatobiliary malignancy, predominantly CCA. Carcinomas typically
present 30–40 years after infection, prognosis is generally poor and death tends to occur
within 3–6 months after diagnosis (Sripa et al., 2007). Praziquantel, an anthelmintic drug,
is used to eradicate the worms. Although it is an effective therapy, praziquantel does not
reverse periductal fibrosis and inflammation in all patients, subsequently, may not prevent
the progression to CCA (Mairiang et al., 1993). In addition, the cycle of infection, dosing
with praziquantel and reinfection is recognised as a major challenge (Saengsawang et al.,
2016). Repeated infection cycles, typically by regular self-dosing with praziquantel after the
initial infection to eradicate the worms, can potentially increase the susceptibility to cholan-
giocarcinogenesis due to oxidative stress and inflammatory responses (Saengsawang et al.,
2016). Chronic host inflammatory responses may persist even after the eradication of the
liver flukes through the eggs they produce, which can remain entrapped in the periductal
tissue causing granulomatous inflammation (Saengsawang et al., 2016; Sripa et al., 2007).
Therefore, comprehensive assessment of reinfection rate and eradication potential is difficult
to establish.
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The association between the biliary parasitosis and CCA is well-established, and extensively
reviewed in the last two decades (Kaewpitoon et al., 2008; Sripa et al., 2007). CCA genesis
is hypothesised to be initially induced via multifactorial mechanistic pathways: i) mechanical
damage cause by the fluke suckers, ii) fluke toxic secretary products and iii) immunopatho-
logical host response. All of these factors resulting in chronic inflammation and hepatobiliary
abnormalities, which trigger a proliferative response and formation of precursor lesions (e.g.
epithelial and adenomatous hyperplasia, and goblet cell metaplasia) (Sripa et al., 2007).
Gene–environment interactions play an important role in the individual’s susceptibility to car-
cinogenesis, as an example, genetic polymorphism of glutathione-S-transferase (GSTM1),
a detoxifying enzyme, is found to be associated with seropositivity for opisthorchiasis, and
may in turn alter the individual’s risk to CCA (Honjo et al., 2005).
Nitrosoamines, known carcinogens found in foods, such as fermented food and commonly
used fish paste in Northeastern Thailand and Laos, pla ra, add an additional risk factor (Sripa
et al., 2007). Some authors hypothesised that nitrosoamines compounds are a primary
carcinogen leading to hepatobiliary tumours (Kaewpitoon et al., 2008).
1.1.2.2 Primary sclerosing cholangitis
PSC, a progressive cholestatic biliary disease with unknown aetiology, is characterised
by chronic inflammation that leads to destruction of the intra- and extrahepatic bile ducts
(Karlsen and Boberg, 2013). PSC incidence range from 0 to 1.3 per 100 000 people/year in
Western countries (Boonstra et al., 2012). The disease is asymptomatic in the majority of
the patients, and is often diagnosed incidentally through routine check up (e.g. elevated liver
enzymes). Fatigue is the most common symptom, whereas pruritus and jaundice occur in
advanced stages as a result of cholestasis. Inflammatory bowel disease is highly common
in PSC patients, up to 80%, and often diagnosed prior to hepatobiliary disease (Lindor et al.,
2015; Tyson and El-Serag, 2011).
The mean age at diagnosis with PSC is 40 years, with a median life expectancy of 9-12
year from diagnosis. PSC is associated with portal hypertension, cirrhosis and hepatobiliary
and colorectal cancer. Progression to CCA is unrelated to the duration of the inflammation,
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it tends to be diagnosed in 6%-36% of PSC patients within a few years after diagnosis,
making CCA from PSC onset at a younger age (⇠ 34 years old), compared to the general
population where biliary carcinoma commonly present in the seventh decade of life (Tyson
and El-Serag, 2011). The only curative treatment to date for PSC is liver transplantation
(Lindor et al., 2015).
1.1.2.3 Biliary stones
Stones formed anywhere in the biliary tree are generally associated with increased CCA
risk, substantially when the stones arise in the intrahepatic bile ducts, or hepatolithiasis,
where it is estimated that 10% of the patients progress to develop iCCA. Hepatolithiasis
rarely predispose CCA in Western patients, but is a relatively common risk factor in several
Asian countries, where the incidence ranges from 2% to 25% (Kim et al., 2015). Presence
of intrahepatic biliary stones was found in nearly 70% of CCA patients undergoing surgical
resection in Taiwan (Chen, 1999). Hepatolithiasis is typically concomitant with bile stasis,
cholangitis, strictures and bacterial infections, subsequently, leading to prolonged inflamma-
tory status and biliary injury, which in turn trigger malignant cholangiocyte growth in some
cases (Kim et al., 2015).
Cholecystolithiasis (gallbladder stone) and choledocholithiasis (stones in the common bile
ducts) were found to be associated with increased intrahepatic cholangiocarcinogenesis with
an odds ratio of 4.0 and 23.97, respectively in a large-scale Danish case-control study (n=
764 iCCA cases and n= 3056 population controls), (Welzel et al., 2007).
1.1.2.4 Choledochal cysts
Choledochal cysts are a rare congenital dilatation of the biliary tree (incidence of 1 per 100
000 people). The cysts can be single or multiple, and arise in the intra- or extrahepatic bile
ducts. The disease is idiopathic, and is mostly common in Asian females. Several hepato-
biliary complications can present with choledochal cysts including: cholelithiasis, cholecys-
titis, cholangitis, cirrhosis, portal hypertension, pancreatitis, pancreatic duct obstruction and
CCA. The risk of CCA in patients with choledochal cyst is 10-30%, and even though surgi-
cal resection of cysts reduces the risk to 0.7-6%, malignant transformation can still occur,
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and life-long follow up is recommended for the majority of the patients (Soreide et al., 2004;
Tyson and El-Serag, 2011). Moreover, the coincidence of abnormal pancreaticobiliary duct
junctions increases the possibility of cholangiocarcinogenesis. Pancreatic enzymes reflux,
cholestasis and elevated bile acid concentrations can further induce malignant proliferation
in patients with choledochal cysts (Soreide et al., 2004).
1.1.2.5 Chemical carcinogens
Exposure to Thorotrast, a radiographic contrast agent banned in the 1960s, is reported to be
associated with a 300 fold increased risk of CCA, occurring 16-45 years after exposure (Kato
and Kido, 1987). Thorotrast is primarily deposited in the liver (approximately 60%), and con-
tinues a lifelong emission of internal radioactive partials, as it has a biological half-life of 400
years (Kaul and Muth, 1978). Pathogenesis from Thorotrast exposure to carcinogenesis has
not been fully proven. Radiation-induced liver insult has been shown to promote hepatocyte
remodelling, genomic instability, DNA methylation and disrupt the liver architecture. Few ge-
netic mutations have been reported to be associated with Thorotrast induced hepatobiliary
malignancy, e.g. K-ras-2 and TP53 (Wang et al., 2005). In addition, occupational exposure
to a halogenated hydrocarbon solvent, 1,2-dichloropropane, was found to be associated with
CCA among printing factory workers in Japan where the substance is used in ink removal.
Long term exposure (via inhalation and dermal contact) was linked to CCA induction among
the young factory employees. The substance was categorised as class-1 carcinogen in 2014
by the IARC (Kumagai et al., 2013).
1.1.2.6 Other risk factors
Other hepatic diseases associated with CCA include alcoholic liver disease, cirrhosis and
cholangitis with odds ratio of 19.22, 75.9, 6.3, respectively reported in a Danish cohort
(Welzel et al., 2007). CCA risk in viral hepatitis was recently investigated in a Korean study,
n= 276 CCA cases, hepatitis B virus (HBV) significantly increased iCCA risk with odds ratio
of 4.1. The risk is greater in presence of diabetes (odds ratio= 12.2), and diabetes inde-
pendently was associated with both intra- and extrahepatic biliary carcinoma (Lee et al.,
2015). Obesity was unrelated to CCA risk in both the Korean and Danish cohorts. Yet, a
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meta-analysis by Li et al. reported a significant association between obesity and CCA risk
with OR of 1.52 (95% CI 1.13–1.89) (Li et al., 2014). Inflammatory bowel disease is also
implicated in cholangiocarcinogenesis. This however might be confounded by the presence
of PSC which is often not controlled for. Data on alcohol intake and smoking in association
to CCA risk are inconsistent, however, they are both recognised as potential risk factors
(Tyson and El-Serag, 2011). Several genetic polymorphisms related to cellular DNA repair,
protection against toxins or immunological surveillance have been implicated in biliary tract
carcinogenesis (Razumilava and Gores, 2014).
1.1.3 Tumour phenotypes
CCA is an extremely heterogeneous group of malignancies in its genomic, histological, mor-
phological, biological, and clinical features. Apart from the anatomical classification (that
is, intrahepatic, perihilar or distal) of tumours, they are further divided into mass-forming,
periductal and intraductal, based on their gross appearance, as illustrated in (Figure 1.4).
CCAs can present as a single or multiple growth type, e.g. periductal infiltrating plus mass-
forming. The most common growth type is mass-forming, accounting for 40–42% of tumours
(Leong et al., 2007).
Mass froming Periductal infiltrating Intraductal
Figure 1.4: Morphologic classification of cholangiocarcinoma.
The gross appearance of cholangiocarcinoma tumours can present with three patterns of growth:
mass-forming; periductal infiltrating; and intraductal.
Histologically, more than 90% of CCA are adenocarcinomas. Other microscopic types in-
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clude adenosquamous and squamous carcinoma, and rare subtypes (Khan et al., 2012).
The tumours show various grades of differentiation, poor, moderate and well. Those with
low-grade or well differentiated type have better prognosis and lower incidence of distal
metastases than with high-grade carcinomas (Leong et al., 2007). Combined hepatocellular-
cholangiocarcinomas can present within the same liver. It is a rare type of primary liver can-
cer that shows histopathological features of both HCC and CCA, and accounts for 1-15% of
all CCAs (Khan et al., 2012).
Various risk factors of CCA and associated pathologies, diverse histological features and tu-
moral genomic heterogeneity, cast doubt on the tumours cellular origin. Additionally, due to
the fact that CCA can arise as result of hepatocyte injury, such as viral hepatitis and alcoholic
liver disease, it is hypothesised that CCA can arise from hepatocyte, and not invariably from
the cholangiocytes lining the biliary tree (Fan et al., 2012). CCA carcinogenesis from hep-
atocytes was observed incidentally via the activation of the oncogenes, NOTCH and AKT,
in vivo. Evidence from hepatocyte fate-tracing experiments, which enables tracking of the
fate of cells in living mice, showed that activated NOTCH signalling, in combination with AKT
overexpression, promotes tumorigenesis in the early stages of intrahepatic bile ducts carci-
nomas (Fan et al., 2012). NOTCH signalling is also known to play an important role during
the embryonic development of liver architecture, including cholangiocyte differentiation and
biliary duct development.
Genome-wide analysis studies revealed the global gene expression patterns and transcrip-
tion mutations in CCA. Intrahepatic tumours showed greater genomic heterogeneity than
tumours arising outside the liver (2,354 genes with altered expression vs. 545) (Miller et al.,
2009). To further capture CCA molecular profile, somatic mutational screening studies iden-
tified several mutated genes. KRAS mutations and loss-of-function mutations of TP53 are
the most commonly altered genes in CCA, reported in around 10-45% and 21% of cases,
respectively. Multiple gene alterations were identified by various molecular profiling tech-
niques, and described molecular heterogeneity of CCA tumours. Different molecular ex-
pression profiles were associated with the tumour anatomical location, and several mutations
were shown to be significantly associated with poor prognosis. The molecular mutations that
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characterise CCAs include IDH1, IDH2, ARID1A, PIK3CA, BAP1, and NRAS (Ruzzenente
et al., 2016).
Overall, tumoral phenotypic characterisation (genomic, epigenetic and molecular) is asso-
ciated with tumour aggressiveness, prognosis, and response to therapy, thus indicating the
best therapeutic approach to tailor personalised treatment for each patient. Therefore, it is
key to identify new potential therapeutic targets of treating CCAs based on their phenotypic
signature, and enable patients stratification (Banales et al., 2016).
1.1.4 Diagnosis
CCA diagnosis is often complex and requires the use of multiple diagnostic modalities to: i)
establish strictures anatomical location, ii) distinguish between benign and malignant stric-
tures, iii) differentiate CCA from gallbladder, other primary liver tumours and combined
hepatocellular-cholangiocarcinomas, v) stage and grade the tumours and vi) plan treatment
approach. This is often difficult owing to the tumour anatomical location, desmoplastic na-
ture, and lack of definitive diagnostic tests (Bridgewater et al., 2014; Khan et al., 2012).
1.1.4.1 Clinical presentation
Clinical symptoms and signs of CCA are often dependant on where the lesions originate
on the biliary tree, and typically absent in early stage tumours. Malignant strictures orig-
inating within the right or left intrahepatic bile ducts tend to cause non-specific symptoms
(e.g. weight loss, abdominal discomfort and malaise). Jaundice, pruritus and pale stool are
associated with lesions originating from the hilar and distal biliary ducts; when the tumour is
large enough to obstruct the biliary flow (Khan et al., 2012).
1.1.4.2 Blood tests
To date, there is no blood test available to diagnose CCA. Conventional liver function mark-
ers such as direct bilirubin, alkaline phosphatase and aminotransferase enzymes are ele-
vated in presence of biliary obstruction or/and infection, and are not indicative of malignancy
(Van Beers, 2008). Serum tumour markers, carbohydrate antigen (CA) 19-9, CA-125 and
carcinoembryonic antigen (CEA), are the most widely used markers for suspected CCA.
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They are clinically used in conjunction with other diagnostic tools, and should not be used
alone due to their poor diagnostic performance and inherent limitations (Khan et al., 2012).
For example, CA 19-9, the most used marker, is non-specific to CCA and is elevated in pan-
creatic, colorectal and gastric cancers, also in non-malignant conditions such as PSC and
obstructive jaundice. In a follow up study, 37% of PSC patients with elevated CA 19-9 were
negative for CCA (Sinakos et al., 2011). Patients lacking Lewis antigen, 10% of the general
population, can not produce CA 19-9 and will not benefit from CA 19-9 testing. The sensitiv-
ity and specificity of CA 19-9 in CCA patients range from 40-70% and 50-80%, respectively,
with a positive predictive value of 16-40% (Khan et al., 2012).
CEA is raised in 30% of patients with CCA, whereas CA-125 is elevated in around 40–50%.
Both markers are non-specific and insufficient for accurate diagnosis (Khan et al., 2012).
Several other potential serum tumour markers have been linked to CCA (e.g. CYFRA 21-1,
CA-195, CA-242, DU-PAN-2, IL-6, and trypsinogen-2), but their clinical utility is still unclear,
and they are not in routine use (Bridgewater et al., 2014; Khan et al., 2012).
1.1.4.3 Imaging and other techniques
In suspected CCA, ultrasonography (US) is initially used to exclude gallstones, assess bil-
iary dilatation and localise the obstruction site. Yet, US alone is insufficient to confirm di-
agnosis; it is operator dependant, can not accurately define tumour extent and may miss
small tumours. High resolution imaging, computed tomography (CT) and magnetic reso-
nance imaging (MRI), provide greater sensitivity for CCA detection than US but may not
be readily accessible in Thailand and resources limited sittings. MRI with cholangiopancre-
atography (MRCP) is the technique of choice to visualize the ductal and vascular structure,
define tumour extent and detect distant metastases. Advantages of the procedure is its high
sensitivity and specificity, non-invasiveness and no risk of radiation (Van Beers, 2008).
Endoscopic retrograde cholangiopancreatography (ERCP) and percutaneous transhepatic
cholangiography (PTC) are more invasive, however, they offer therapeutic intervention as
well as diagnostic assessment. They allow sampling of strictures for brush cytology or tis-
sue biopsy, and stent insertion to relief biliary obstruction. These sampling methods are
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highly specific (100%), but have a low sensitivity (46%–73%). Cytology is positive in less
than 50% of CCA cases, hence, negative result do not exclude malignancy. Biopsy, in addi-
tion to cytology, can enhance positive finding to 40–70%, but is not always easy to obtain due
to the desmoplastic tumours nature and risk of tumour seeding (Khan et al., 2012). Once
CCA is confirmed, comprehensive staging must be carried out to screen for metastatic dis-
ease. The above diagnostic techniques are complementary and selection is dependant on
the individual’s clinical needs. Multiple imaging techniques might be necessary for surgical
assessment of resectability.
1.1.5 Treatment and prognosis
Surgical resection is the only curative therapy for CCA. Patients with intrahepatic tumours
are candidate for partial hepatectomy, whereas pancreato-duodenectomy is most suitable
for distal tumours. For perihilar CCA, the extent of surgical intervention required is based
on Bismuth-Corlette classification, and it is generally associated with the worst resectability
rate compared to distal tumours (56% vs. 91%) (Nakeeb et al., 1996). Figure 1.5, describes
the therapeutic options available for CCA patients.
Cholangiocarcinoma
Resectable Non-resectable
Pallative
Biliary drainage
Stent
Chemotherapy
Radiotherapy
+/-
Pre-operative management
Biliary drainage
Portal vein embolization
Surgery
Adjuvant therapy
+/-
Resection
Liver transplant
Local-regional	
therapy
Figure 1.5: Treatment algorithm for cholangiocarcinoma.
The majority of CCA cases present too late for surgical intervention. The latest treatment
guidelines recommend a combination of Gemcitabine and Cisplatin chemotherapy for inop-
erable cases (Bridgewater et al., 2014). This approach was adapted following encouraging
results from two large randomized studies, ABC-02 in the UK and BT22 in Japan (Okusaka
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et al., 2010; Valle et al., 2010). The regimen is acceptable standard first-line therapy for
patients with advanced biliary tract cancer; where in some cases it was successful to down-
stage tumour to operable state and improve survival (Furuse et al., 2011; Khan et al., 2012).
There is currently no evidence to support the routine use of radiotherapy postoperatively or
for unresectable disease (Banales et al., 2016; Khan et al., 2012).
Srinagarind Hospital, the leading centre in CCA treatment in the Northeast of Thailand, pub-
lished a prospective study on Thai CCA patients outcome. Out of 163 patients with biliary
carcinoma, only 10 cases, (6.1%), were eligible for curative resection. The vast majority
presented too late for any intervention, stage IV, and were referred to palliative care from
the first visit. The overall median survival was 4 months, however, patients who received
surgical resection with negative tumour margins had 100% 4-year survival rate (Luvira et al.,
2016). The prognosis for inoperable Thai patients with bile duct cancer receiving palliative
chemotherapy is poor. Gemcitabine chemotherapy has a median survival of 10.0 months
(Butthongkomvong et al., 2013). Moreover, resection margins are important prognostic fac-
tors, and complete surgical resection at early stage is the only treatment that significantly
improves patient survival. Long-term survival and recusance rate post hepatic resection
were examined in a Korean retrospective study, iCCA recurred in 60% of cases either in the
remnant liver and lymph node or as distant metastasis, commonly in the lung. Tumour size,
lymph node metastasis and multiple tumours were significant predictors of recurrence (Gil
et al., 2015).
Orthotopic liver transplantation was contraindicated for the treatment of iCCA in most cen-
tres. However, since the Mayo Clinic have shown encouraging results (5-year survival of
87%) using a strict selection procedure and a neoadjuvant chemoradiation protocol the ap-
proach regained attention (Heimbach et al., 2004; Mantel et al., 2016). In a retrospective
study, the European Liver Transplant Registry was used to identify patients who underwent
liver transplantation for hCCA (Mantel et al., 2016). Of 147 patients identified, 28 met the
selection criteria of the Mayo Clinic protocol and achieved a five-year survival rate of 59%
(Mantel et al., 2016).
Molecular therapies for solid biliary tumours are generally complex to develop owing to their
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therapeutic resistance, and anatomical, histological and phenotypic heterogeneity (Razu-
milava and Gores, 2014). Elucidation of the molecular mechanisms and pathways underly-
ing cholangiocarcinogenesis may expedite development of personalised therapy for patients
based on their particular tumour phenotype.
1.1.6 Molecular pathways and interactions
Multiple mechanisms have been proposed to be involved in the malignant transformation
of cholangiocytes. CCA initially develops in a background of chronic inflammation and
cholestatic conditions with consequent injury to cellular constituents (Fava and Lorenzini,
2011). The activation of inflammatory pathways and overexpression of cytokines triggers
and maintains the proliferation of malignant cholangiocytes. Proinflammatory factors, such
as interleukin-6 (IL-6), promotes tumour growth and survival in CCA by altering gene ex-
pression via autocrine processes, such as the oncogenic mitogen-activated protein kinases
(MAPKs) signalling pathways (Wehbe et al., 2006). Moreover, IL-6 modulates the apoptotic
process of malignant cholangiocytes by upregulating myeloid leukaemia cell differentiation
protein Mcl-1 (MCL1), a critical anti-apoptotic Bcl-2 family member protein responsible for
apoptosis-inducing ligand (TRAIL) resistance in CCA (Kobayashi et al., 2005). Suppression
of IL-6 activities decreases Mcl-1 expression and consequently increases the sensitivity to
TRAIL mediated apoptosis in resistant cells (Kobayashi et al., 2005). This suggests potential
therapeutic strategies for targeting IL-6 signalling for the treatment of CCA. For instance, a
number of antibodies targeted directly against IL-6, such as olokizumab and sirukumab, are
currently in clinical trials, and warrants further investigation as a potential drug candidates
for CCA (Rizvi et al., 2014).
Furthermore, obstruction of bile acid flow in cholestatic conditions appears to modulate and
expedite carcinogenesis processes by promoting biliary proliferation and inflammation. Bile
acids, proinflammatory cytokines and oxysterols (oxidation products of cholesterol) induce
the expression of the enzyme cyclooxygenase-2, which has been implicated in the carcino-
genesis of CCA (Banales et al., 2016; Yoon et al., 2004). The inhibition of cyclooxygenase-2
by celecoxib has been shown to attenuate proliferation and enhance apoptotic cell death in
bile duct cancer (Banales et al., 2016).
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Significant progress has been made in understanding prevalent genetic drivers of CCA-
genesis. These genetic alterations affect key networks such as tyrosine kinase signalling
(KRAS), DNA repair (TP53), epigenetic (IDH1 and IDH2) and deregulated Notch signalling
(described in Section 1.1.3) (Banales et al., 2016). Further advances in understanding the
mutational landscape will elucidate therapeutically relevant targets and offer directed, per-
sonalized treatment options for CCA.
1.1.7 Screening strategies
Screening strategies for CCA vary according to the disease aetiology, where it moves from
small-scale, high risk patients surveillance, e.g. for PSC patients, to large community-based
screening programmes as in the O.viverrini prevention campaign in Thailand.
1.1.7.1 Cholangiocarcinoma screening in Western countries
Established risk factors account for less than a third of CCA cases in the West (Khan et al.,
2012). Due to the disease rarity and the ambiguous definition of asymptomatic at-risk pop-
ulation, surveillance guidelines of sporadic CCA are yet to be established. Patients with
predisposing hepatobiliary disease undergo series of annual screening tests. PSC patients
are typically screened for mainly CCA, but also HCC and colorectal cancer. If biliary domi-
nant strictures are present, regular ERCP with brush cytology is recommended. This is in-
deed not ideal for surveillance; it is invasive, costly and has low diagnostic accuracy (Lozada
et al., 2015). Solely screening for CCA might not be feasible. To overcome this limitation it
is proposed to design a multi-cancer detection panel that combine CCA markers with other
markers of uncommon respiratory and digestive tract cancers or aerodigestive cancers. This
screening modality may justify and permit CCA screening in countries with low incidence
(Lozada et al., 2015).
1.1.7.2 Cholangiocarcinoma screening and control in Thailand
Approximately, 36% of the Thai population (23 million) live around the Mekong river wetlands,
and are at potential risk of opisthorchiasis (Mahasarakarm, 2007). Primary prevention of
CCA via opisthorchiasis control began in Thailand in 1950 as a local treatment units in few
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high endemic provenances. When praziquantel was introduced in the early 80s, the Thai
Ministry of Health started four opisthorchiasis treatment units, which examined over half a
million people and treated 400 452 cases (Jongsuksuntigul and Imsomboon, 2003). In 1987,
a national-scale opisthorchiasis screening program began as a part of the country’s national
health plan. Over 5 million stool samples were examined, and 1.8 million positive cases were
identified and treated in the Northeastern region. The program expanded to cover provinces
in the North and Central Thailand in 1992, resulting in a fall in the national opisthorchiasis
prevalence, from 63.6% to 9.6% in 2001 (Jongsuksuntigul and Imsomboon, 2003).
Despite the intensive health campaigns targeting O.viverrini prevention, the prevalence re-
mains remarkably high is some parts in Thailand (Figure 1.6a), subsequently, CCA burden
remains alarmingly high (Figure 1.6b). Opisthorchiasis prevalence reached 42.2% in the
latest epidemiological surveillance, named ”Cholangiocarcinoma Screening and Care Pro-
gram (CASCAP)”. CASCAP was developed by the Medical Faculty of Khon Kaen University
in cooperation with the Cholangiocarcinoma Foundation, as a community level screening
program that aims to elucidate the current status of opisthorchiasis-related CCA in the re-
gion (Khuntikeo et al., 2015).
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Figure 1.6: Opisthorchiasis-related cholangiocarcinoma temporal profile. Adapted from
(Kaewpitoon et al., 2007)
a) Opisthorchis viverrini prevalence in Northeast Thailand, and b) Cholangiocarcinoma incidence in Khon
Kaen.
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Repeated infection is likely to occur after the administration of praziquantel, and might ex-
plain the persistent high infection rate. In an animal model, repeated infection of hamsters
with O.viverrini expedited inflammatory response and showed higher levels of parasite-
specific antibody, which positively correlated with greater degree of fibrosis (Pinlaor et al.,
2004). About 89% of the CASCAP cohort had previously eaten raw or fermented fish
(Khuntikeo et al., 2015), indicating poor response to the educational campaigns against
raw fish consumption among rural communities. Moreover, the vast majority are farmers
(79.9%), and raw fish based-diet is embedded in their cultural identity. The magnitude of
the problem is greater than telling people to ”stop eating raw fish”, it has social, political and
environmental implications. Additionally, the political tension between rural Northeast and
the capital may have created resistance in accepting the health promotion messages com-
municated from the government to villages (Asavarut et al., 2016). Re-infection cycles are
also influenced by poor sanitation practice and lack of sewerage infrastructure. Commonly,
during important growing/harvest cycles in the rice-fish Mekong Basin cultures, temporary
homes are used, typically huts with no latrines (Jongsuksuntigul and Imsomboon, 2003).
Currently, the screening modality used in Thailand is US imaging based, which has several
limitations. Experienced radiologists are required, and the effectiveness of the diagnosis
depends on the operator skills. US is time consuming, and not suitable for rapid screening of
at risk people in endemic areas. The rate of early tumour detection using US is unknown, and
repeated US procedure is required for at risk patients every 6-12 months, therefore, storage
of the digital information require reliable server and network infrastructure. On the other
hand, US is non-invasive, and with extensive training, optimising sonographic equipment
and procedure standardisation, US was shown to have early CCA detection potential by the
detection of periductal fibrosis (Chamadol et al., 2014).
The absence of prognostic techniques limits therapeutic options. Therefore, there is an
urgent unmet demand for the development of biomarkers that hold clinical potential for timely
diagnosis of the CCA in Thailand and neighbouring countries. CCA incidence in Thailand
appears to be increasing, not decreasing according to the hospital-based cancer registry
published by the National Cancer Institute (Khuntikeo et al., 2016), and even if the worm
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is eradicated, it will take 20-30 years to achieve CCA-free population. Hence, those with
history of parasitosis are still at risk of developing malignant biliary tumours.
1.1.8 Potential new biomarkers for cholangiocarcinoma
The mortality from CCA remains equal to the disease incidence. New biomarkers for screen-
ing, diagnosis, staging, and prognosis would be crucial in the management of CCA, as cur-
rent methods are ineffective in detecting small tumours. To date, several serum markers,
including the clinically available (i.e. CA 19-9 and CEA) and potential markers such as,
CA242, mucin glycoproteins, cytokines, etc., have been reported to be adequate diagnos-
tic and prognostic markers for CCA (Wongkham and Silsirivanit, 2012). Yet, the diagnostic
accuracy of such markers is not sufficient for a timely and reliable diagnosis of CCA. A
high-throughput ”omics” approach and the development of multi-marker panel is proposed
to introduce a new diagnostic window into CCA. Metabolic phenotyping of CCA can shed
light on understanding environmental interactions underpinning CCA genesis, and may lead
to the discovery of diagnostic markers in biofluids. The role of metabolic profiling in biomark-
ers discovery, and the previous literature describing CCA metabolic signature are discussed
in sections (1.2.3 and 1.2.4), respectively.
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1.2 Metabolic Profiling
Metabolic profiling, metabonomics or metabolomics are terms coined in the late 90s, and
emerged as the newest ”omics” technology (Nicholson et al., 1999). It utilises spectroscopic
analytical platforms, mainly, Nuclear Magnetic Resonance spectroscopy (NMR) and Mass
Spectrometry (MS), to acquire a snapshot of metabolites, the end products of a complex
biological system. Metabolic profiling enables the the detection, quantification and charac-
terisation of metabolites in biofluids, cells and tissues. The source of those compounds can
be endogenous, microbial or of exogenous origin, such as dietary or xenobiotic. This re-
sults in generating extensive, multivariate spectroscopic data that require specific statistical
manipulation, typically performed using chemometric and pattern recognition techniques,
to reduce its dimensions, facilitate its biological interpretation and allow sample classifica-
tion and biomarker discovery. Consequently, it is possible to study the dynamic metabolic
changes in response to disease, intervention or environmental conditions (Nicholson et al.,
1999).
Metabonomic studies are applied generally at an individual or an epidemiological level.
Metabolome-Wide Association (MWA) studies are based on large-scale metabolic profiling
of specific populations, and aims to discover novel markers associated with health conditions
(Bictash et al., 2010). Population-based studies successfully demonstrated an association
between candidate metabolites and diseases risk such as cancer, diabetes and hyperten-
sion (Bictash et al., 2010; Holmes et al., 2008). The discovery of these metabolites exhibit
potential as diagnostic targets in disease screening applications. At the individual level,
metabolic profiling provides the possibility of personalised healthcare, which aims to deliver
targeted therapies and predict individual’s response to treatment (Wishart, 2016). Applica-
tions of metabonomics in medical science are highly diverse; it can be applied in vivo (using
imaging or live cells) or in vitro (using extracts or biofluids), and it is capable of analysing a
wide range of bioproducts, including solids (tissues), liquids (blood, urine, faecal water, bile
and cell extracts) and gases (breath) (Wishart, 2016).
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1.2.1 Spectroscopic platforms
Comprehensive metabolome coverage requires a broad array of instrumentation as each
spectroscopic platforms provides coverage of different classes of organic compounds. The
most popular techniques in metabonomic are NMR and MS (coupled with liquid or gas chro-
matography; LC and GC, respectively), each of these technologies has their own strengths
and weaknesses, summarised in (Table 1.1). Numerous studies have shown the particular
use of each technology, and various reported standardised protocols to ensure high repro-
ducibility inter- and intra-laboratories (Beckonert et al., 2007; Lenz and Wilson, 2007).
Table 1.1: A comparison of different spectroscopic platforms.
 
  NMR LC-MS GC-MS 
Sensitivity Not sensitive (LOD=5ʅM) Superb sensitivity (LOD=0.5nM) 'ood sensitivity (LOD=0.5ʅM) 
Reproducibility High  Less reproducible Less reproducible 
Quantification High  Not very quantitative Quantitative (with calibration) 
Time/sample Fast (2ʹ3min per sample) Slow (12ʹ40min per sample) Slow (20ʹ40min per sample) 
Sample volume Relatively large; (0.1ʹ0.5 mL) Small (10ʹ100ʅL) Modest (0.1ʹ0.2mL) 
Sample consumption Non-destructive Destructive Destructive 
Sample preparation Limited  Often extensive  Requires sample derivatization 
Separation Not required  
Can be done with direct 
injection  
Required  
Metabolites annotation 
Most spectral features are 
identifiable 
Most spectral features are not 
yet identifiable  
 Large body of software and 
databases for metabolite 
identification 
Initial cost  High  (>US $1 million) High (>$300,000) Modest (~$150,000) 
 GC-MS, gas chromatography mass spectrometry; LC-MS,  liquid chromatography mass spectrometry; NMR, nuclear magnetic resonance.
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1.2.2 Global and targeted profiling
Metabolic profiling studies are generally divided into targeted and untargeted analytical de-
signs. The global or untargeted approach attempts to detect and identify as many molecular
compounds as possible, and is primarily hypothesis generating. It aims to capture the over-
all molecular signal patterns, and disrupted pathways (Patti et al., 2012). Targeted analysis
focuses on known, small group of metabolites of interest, e.g. lipids, carnitines, bile acids,
etc., or a mixed panel of distinct compounds. The approach tends to be driven by a spe-
cific biochemical question or hypothesis that directs further perusal of a particular biological
pathway. The method is highly robust, and offers absolute quantification of molecules. How-
ever, the initial method development requires extensive work in order to cater to the specific
requirements of the targeted compounds (Patti et al., 2012). Global and targeted metabo-
nomics are indeed complimentary, and can be used simultaneously to discover and validate
disease biomarkers. Ideally, comprehensive profiling of specimen of interest is generated
using both global and targeted approach, as well as multiple spectroscopic platforms (Lenz
and Wilson, 2007).
1.2.3 Metabolic profiling in biomarker discovery
Interest in metabolites as biomarkers of disease progression have gained wide popularity in
the last decade. The discovery of biomarker candidates for cancer screening and diagno-
sis in particular is no exception; a search in the PubMed database for papers including the
keywords “metabolomics”, “cancer”, and “biomarker” found 1 paper in 2003, 58 in 2010 and
154 in 2015, a total of 787 papers. The basic concept of the approach is that cancer has
several years of asymptomatic latency period before it is clinically diagnosed. During this
phase, there is deregulation of cellular energetics and a profound state of metabolic dysreg-
ulation in various pathways. The pathogenesis of cancer can lead to alterations in metabolite
levels in the body, which in turn, influence the metabolite levels in biological fluids. Hence,
metabolite levels can reflect the pathophysiological condition of the host (Vermeersch and
Styczynski, 2013).
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The pipeline of metabonomics in biomarker discovery is illustrated in (Figure 1.7). Ini-
tially, the discovery phase aims to establish the disease metabolic signature and trace key
metabolic pathways altered in response to the disease. This can be followed by an in-depth,
quantitative analysis on validated compounds and ultimately, a targeted, diagnostic assay
that is focused on a subset of biomarkers can be designed.
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Figure 1.7: Metabolic profiling pipeline.
Very often, small sample size is chosen arbitrarily based on sample availability due to the
lack of widely accepted methods for power analysis and sample size computation in global
metabonomics studies. Sample size determination can also be driven from pilot data or
extrapolated from the literature (Blaise et al., 2016). Metabolic profiling approach is hypoth-
esis free; size of the desired effect and which metabolites might be affected is unknown.
In addition, some challenges encountered are unique to the metabolic field which limits the
use of sample size determination tools employed in earlier ”omics” techniques. For exam-
ple, the number of detected analytes in a given experiment is unknown a priori and largely
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affected by the analytical instrument, together with the dynamic range of metabolite concen-
trations. Furthermore, available statistical tools for sample size estimation (such as the one
implemented in MetaboAnalyst (Xia et al., 2015)) do not account for the strong correlation
structure observed between variables in metabolic phenotyping driven datasets.
Blaise et al., proposed a new comprehensive approach for power analysis in metabolic pro-
filing studies by extracting the effect size from pilot data and estimating the corresponding
sample size to reach the desired level of power (Blaise et al., 2016). First, the model simulate
a large dataset with similar characteristics to the ones observed in the pilot data (e.g. dis-
tributions and correlation structure). The algorithm employs multivariate simulation, which
preserves the strong correlations and effectively accounts for the high-dimensionality ob-
served in metabonomics data. An artificial effect is then introduced, and finally different
sample sizes are modelled by randomly selecting data sets of various sizes from the simu-
lated data (Blaise et al., 2016). Ultimately, to precisely detect and estimate the magnitude of
a metabolic effect, it is highly recommended that sample size estimations based on available
pilot data is implement in the design of the analytical pipeline.
1.2.4 Cholangiocarcinoma metabolic signature
There is a relatively few number of metabonomics studies addressing CCA, nine studies
were identified from 2005 to 2016. The early studies (n= 5) were mainly focused on bile
NMR profiling, where as recent publications are MS-based, Table 1.2. Khan et al., pub-
lished one of the first studies in 2005, which aimed to characterise the bile composition of
hepatopancreaticobiliary patients compared to non-malignant controls. NMR resonances
corresponding to phosphatidylcholine were depleted in presence of malignancy (Khan et al.,
2005). Following studies also augmented the findings (AbdAlla et al., 2011; Albiin et al.,
2008; Sharif et al., 2010), phosphatidylcholine was consistently found lower in CCA bile
samples. Low levels of biliary taurine, lipids, lactate, cholesterol, and elevated bile acids
were associated with the CCA metabotype (AbdAlla et al., 2011; Albiin et al., 2008; Sharif
et al., 2010; Wen et al., 2010). When compared to conventional markers, biliary metabolite
markers showed better diagnostic preference, with sensitivity of 88% and a specificity of
81% in a Korean study by Wen and colleges (Wen et al., 2010).
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Table 1.2: Summary of previous cholangiocarcinoma metabolic profiling studies.
Sample Platform Cohort size Country Upregulated Downregulated Reference 
Bile 
31P NMR 
& 
 1H NMR 
n= 25 
Healthy (2)  
BBD (18) 
CCA (3) 
Other malignancies (2) 
UK - Phosphatidylcholine Khan et al., 2005 
Bile 1H NMR 
n= 38 
BBD  (29)  
CCA (16) 
Sweden  - 
Phosphatidylcholine 
Taurine 
Lipids 
Lactate 
Albiin et al., 2008 
Bile 1H NMR 
n= 25 
BBD (20) 
CCA (5) 
UK 
Glycine-conjugated 
bile acids 
7β primary bile acid 
Phosphatidylcholine 
 
Sharif et,al., 2010 
Bile  1H NMR 
n= 38 
BBD (21) 
Hepatobiliary cancer 
(17) 
Korea Unspecified bile acids - 
Wen et,al.,  2010 
Bile  1H NMR 
n= 29 
BBD (21) 
CCA (8) 
UK 
Egypt  
Taurine- and 
glycine-conjugated 
bile acids 
Phosphatidylcholine 
 
AbdAlla et,al.,  2011 
Tissue  CE-TOFMS 
n= 16 
iCCA (10)  
HCC (6) 
Japan Hypoxanthine  Taurine  - 
Murakami et,al.,  
2015 
Serum LC-MS 
n= 261  
Control (85) 
dCCA (90) 
iCCA (86) 
 
n = 225, validation 
dCCA (116) 
iCCA (109) 
China Bilirubin LysoPC(15:0) 
21-Deoxycortisol 
LysoPC(14:0) 
Liang et,al., 2016 
Plasma LC-MS, lipidomics 
n= 292 
Control (109) 
HCC (85)    
iCCA (98) 
China 
PE(19 : 0/0 : 0) 
PC(14 : 0/0 : 0) 
PC(18 : 0/0 : 0) 
PE(18 : 2(9Z,12Z)/0 : 0)  
 
Liang et,al., 2015 
Urine LC-MS 
n= 160 
control (60) 
dCCA (60) 
China 
Citrate  
Indoleacetate 
Aminomalonate 
Glutarate 
N-Acetylornithine 
Allantoin 
Glycocholic acid 
Homogentisate 
Pyruvate 
Taurine 
Methylsuccinate 
Methylhistidine 
Cytosine 
Salicyluric acid 
L-Methionine 
Ursodeoxycholic acid 
Histamine 
L-Kynurenine 
Sarcosine 
Zhang et al., 2016 
BBD, benign biliary disease; CCA, cholangiocarcinoma; dCCA,  distal cholangiocarcinoma ; HCC,  hepatocellular carcinoma; 
iCCA, intrahepatic cholangiocarcinoma; LC-MS, liquid chromatography mass spectrometry; NMR, nuclear magnetic resonance.   
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Population differences in the biliary metabolic profile were investigate by Hisham AbdAlla
el al., bile spectral profiles of CCA patients from United Kingdom showed higher levels of
phosphatidylcholine compared to Egyptian CCA participants; suggesting different underlying
pathogenesis (AbdAlla et al., 2011). A pitfall of some of the bile profiling studies is that
the contrast agent used while collecting biliary secretion during ERCP often complicated
metabolite annotation due to signal overlap. Additionally, it is unknown as to whether the
presence of cholestasis influenced the results, as it wasn’t controlled for in the majority of
the studies. Bile profiling might provide an insight to disease mechanism, however, it is not
ideal for continuous monitoring of disease progression as collection methods are invasive.
A multi-omics approach, integrating metabonomic and transcriptomic datasets, was able to
distinguish between iCCA and HCC tumours (Murakami et al., 2015). The study highlighted
that hypoxanthine and taurine had distinct expressions that differentiated iCCA from HCC,
and from non-tumour samples. iCCA showed larger genetic distance than HCC; the au-
thors speculated that this is associated with the diverse expression of four amino acids,
lysine, proline, leucine in iCCA. Several mRNAs were distinct in iCCA. To facilitate bio-
logical interpretation, the integrated molecular pathway level analysis was calculated, and
two main pathways were found to be implicated in CCA; glucose-lipid synthesis pathway
and miRNA related pathways (RNA transport, ribosome biogenesis in eukaryotes, protein
export, RNA polymerase, and Aminoacyl-tRNA biosynthesis). Although iCCA and HCC tu-
mours showed distinct metabotype, they shared some characteristic metabolic features, de-
crease in amino acid metabolism and increase in glycerol-3-phosphate metabolism, indicat-
ing a shift towards glycolysis and significant upregulation of fatty acid catabolism (Murakami
et al., 2015). In a recent Chinese study by Liang and colleagues, serum LC-MS metabo-
nomics showed promising discrimination ability between CCA patients and benign controls.
A panel of 4 serum metabolites (21-deoxycortisol, bilirubin, lysoPC(14:0) and lysoPC(15:0))
had 99% diagnostic accuracy between 176 CCA patients and 85 non-malignant controls.
predominant pathways involved were related to disrupted glycerophospholipid metabolism,
retinol metabolism and sphingolipid metabolism (Liang et al., 2016). Lipidomic profiling us-
ing plasma samples by the same group, investigated the discrimination ability of lipidomics
to distinguish between iCCA and HCC. Molecules belonging to two lipid species, phos-
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phatidylethanolamines (PEs) and phosphatidylcholines (PCs), were used to distinguish be-
tween HCC and iCCA. PE(19:0/0:0), PC(14:0/0:0) and PC(18:0/0:0) were associated with
iCCA, whereas PE(18:2(9Z,12Z)/0:0) was upregulated in HCC. Lipids play a key role as sig-
nalling molecules and energy reserves, as well as fulfilling a role as structural components
of cellular membranes (Liang et al., 2015).
Characterisation of the urinary CCA metabolome was explored using LC-MS global profil-
ing. The urine metabolic phenotype of dCCA was characterised by higher concentrations
of metabolites related to TCA cycle (citrate and pyruvate), taurine metabolism (taurine),
bile acid metabolism (glycocholic acid), tryptophan metabolism (indoleacetate), arginine and
proline metabolism (N-acetylornithine), purine metabolism (allantoin), tyrosine metabolism
(homogentisate), fatty acid metabolism (methylsuccinate and glutarate) and amino acid
metabolism (aminomalonate, sarcosine), and lower concentrations metabolites of histidine
metabolism (histamine and 3-methylhistidine), pyrimidine metabolism (cytosine), secondary
bile acid biosynthesis (ursodeoxycholic acid), and related to excretion of xenobiotics (salicy-
lurate) (Wang et al., 2016).
Previous CCA metabolic profiling studies provide sufficient evidence that cholangiocarcino-
genesis alter the metabolite levels in biofluids. A key limitation identified from these reports,
is that they mainly investigated CCA with unspecified aetiology, which does not allow for
identification of causal mechanisms of disease. Also missing in many studies is an indepen-
dent population sets to validate the proposed biomarkers; without the ability to reproduce
the discovery results in diverse populations, biomarkers will not accelerate the pipeline to-
wards clinical setting consideration. External validation of candidate markers in early CCA,
CCA with different aetiologies and other tumours controls are critical to augment these initial
findings.
Discovery of CCA metabolic markers still require further research, for example, no study
to date investigated liver fluke-associated CCA metabolic profiles. Characterisation of the
metabolic signature of CCA is essential in different populations and patients with different
predisposing risk factors. Additionally, the metabotype associated with CCA anatomical
location remains ambiguous.
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1.2.5 Early stage liver cancer and metabonomics
The liver is the metabolic hub for the metabolism of carbohydrates, fats and proteins, and
also has a crucial role in detoxification and hormone production. Hence, metabolic profiling is
highly relevant in liver disease, particularly in detecting metabolic dysregulation in malignant
conditions. Metabonomic technologies have been proven to be able to shed the light on
the aetiology and mechanisms of liver cancer, and showed promising diagnostic potential
(Kimhofer et al., 2015).
It is worth noting that CCA candidate biomarkers were identified in CCA and non-malignant
controls, which reflect the typical metabolic phenotypes of CCA after the occurrence of tu-
mours. There are currently no reports testing the biomarkers’ ability to detect early CCA
tumours, however, HCC metabonomics research showed that it is possible to detect small
tumours using a panel of metabolic markers.
In an animal HCC model, the dynamic metabolic changes in hepatocarcinogenesis in the
rats serum metabolome were tested using LC-MS global profiling (Tan et al., 2012). Sev-
eral compounds reflecting biological pathways such as fatty acid, bile acid, amino acid and
phospholipid, were deregulated during carcinogenesis in serum metabolite profiles. Among
these metabolic alterations, three metabolites, taurocholic acid, lysoPE 16:0, and lysoPC
22:5, were found to distinguish between the different stages of hepatocarcinogenesis. The
metabolite panel was tested in a human cohort of patients with small HCC tumours, cir-
rhosis and chronic hepatitis B, and showed superior diagnostic performance compared to
the conventional marker ↵-fetoprotein with area under the curve (AUC) of 0.88 vs. 0.64,
respectively (Tan et al., 2012). A similar stepwise metabonomics study (from animal models
to patients) using capillary electrophoresis-time of flight mass spectrometry (CE-TOF/MS)
identified a metabotype associated with effective classification of small HCC tumours. The
ratio of serum creatine:betaine distinguished small HCC tumours from precancerous cirrho-
sis with an AUC of 0.93. This biomarker pattern, which reflects disturbed hepatic methylation
equilibrium, was refined out of hundreds of differential compounds, and retained statistical
significant in discriminating HCC from high-risk patients in two independent human cohorts
(Zeng et al., 2015).
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1.3 Research rationale and aims
1. CCA remains a fatal disease, especially in the East of Asia, where current surveillance
methods are not efficient, and patients present late with advanced, incurable disease.
There is an urgent need for effective and minimally invasive biomarkers of CCA. Identi-
fication of a metabolite panel associated with cholangiocarinogenesis in blood or urine
would be invaluable in this context.
2. Metabolic phenotyping has been shown to be a successful approach in the oncology
field for diagnosis, prognosis and evaluation of therapy. However, few studies looked
into CCA metabolite profile compared benign and malignant control groups. There-
fore, i am to apply mass spectrometry-based global screening method, coupled with
multivariate modelling, to identify the biochemical signature of CCA.
3. The majority of previous metabolic profiling publications of CCA have been undertaken
in patients with sporadic aetiology, no previous study compared CCA with known risk
factor (liver fluke) to sporadic tumours (Western population). Thereby, a secondary
aim will be to establish whether it is possible to classify CCA samples according to
their underlying aetiological factors.
1.4 Hypothesis
1. The presence of biliary tumours results in altered blood and urine metabolic profiles,
which in turn, can be characterised using mass spectrometry-based spectroscopic
profiling.
2. This approach will provide an insight into the perturbed biological pathways underly-
ing hepatobiliary disease as a mean to identify metabolic biomarkers to improve CCA
diagnosis.
Chapter 2
METHODOLOGY
2.1 Mass Spectrometry
MS is a powerful, sophisticated analytical technique that is widely employed in various re-
search areas such as food safety, forensic sciences, environmental and biomedical science.
The basic principle of any mass spectrometer is simple. A mass spectrometer can only
analyse ions, and they must be in the gaseous phase. The ionisation allows the measure-
ment of the mass-to-charge ratio (m/z) of the resulting ions. The uses of these functions are
highly versatile and the sample can be analysed in different state of matter: solid, liquid, and
gaseous. Moreover, mass spectrometers can give qualitative (structural) and quantitative
information on the elemental, isotopic, and molecular composition of organic and inorganic
samples (de Hoffmann and Stroobant, 2007).
Historically, the origin of MS dates back to the early 1900s, and was mainly in the domain of
physicists and physical chemists. The technology underwent progressive improvements and
revolutionary changes that earned several Nobel prizes. In the late 1960s, the commercial-
isation of the interfacing of GC with MS enabled the separation of complex mixtures so that
individual molecules could be admitted sequentially into the mass spectrometer (de Hoff-
mann and Stroobant, 2007). The first paper employing MS in metabonomics context was by
Robinson and Pauling in 1971, entitled ”Quantitative Analysis of Urine Vapor and Breath by
Gas-Liquid Partition Chromatography” (Pauling et al., 1971).
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A typical mass spectrometer consists of 6 major components: a sample inlet (e.g. LC or GC
interface); an ion source; one or more mass analysers; a vacuum pump and a data system
(Figure 2.1), which allow the instrument to perform the following processes:
1. Ions are created from a sample in the ionisation source, (B).
2. Ions enter the mass analyser where they are separated according to their mass-to-
charge ratio, (C).
3. The mass analyser (used in this project) fragments the selected ions and analyses the
fragments in a second analyser.
4. Ions are detected as electrical signals in proportion to their abundance as they emerge
from the mass analyser, (D).
5. A mass spectrum of the molecule is produced, (G).
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Figure 2.1: Basic sequence of events in a mass spectrometer.
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2.1.1 Sample introduction/liquid chromatography
Liquid chromatography (LC) is a popular MS separation technique employed in metabolic
profiling studies, and was the analytical method of choice in this thesis; biological sam-
ples are aqueous, composed of involatile, polar compounds, and often of high molecular
mass, preventing their analysis by GC-MS. In addition, LC-MS requires small sample volume
and minimal sample preparation, and unlike GC-MS, does not require sample derivatisation
(Want et al., 2010).
The basic function of the sample introduction system is to inject a sample from the au-
tosampler into a moving stream of the mobile phase (solvent mixture), and transfer it to the
chromatographic column, or the stationary phase. The separation is generally based on an
analyte’s relative affinity for the mobile phase versus the stationary phase. LC separation
utilises different types of chromatographic columns summarised in (Table 2.1).
Table 2.1: A comparison of phase characteristics used with different chromatographic meth-
ods.
Chromatographic mode 
Stationary phase  
[particle] 
Mobile phase  
[solvent] 
Normal-phase  Polar 
(i.e. silica or alumina) 
 
Non-polar 
(hydrocarbons such as hexane, 
heptane, no water) 
Reversed-phase  Non-polar 
(C18, C8, C4, etc.) 
Polar 
(i.e. јwater, љacetonitrile) 
Hydrophobic-interaction Polar 
(i.e. silica or alumina) 
Relatively non-polar  
(i.e. љwater, јacetonitrile) 
 
2.1.1.1 Normal-phase chromatography
In normal-phase columns, the mobile phase is a non-polar solvent and the stationary phase
is polar. Molecules elute according to their polarity, polar analytes are retained by the sta-
tionary phase, whereas hydrophobic analytes moves faster with the non-polar mobile phase.
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2.1.1.2 Reversed-phase chromatography
Reversed-phase (RP) chromatography is the opposite of normal-phase. A polar mobile
phase and a non-polar stationary phase are used (Figure 2.2).
Sample
Mobile phase
LC column
porous particle
Stationary phase
time
seperated compounds
more polar less polar
Figure 2.2: Separation in reversed phase liquid chromatography.
RP is more popular than normal-phase, because it is efficient, stable and has retention
power for non-polar analytes which are typically present in biological fluids. A C18-bonded
silica column is commonly used for low-molecular weight analytes (<5kDa molecules), such
a column is tightly packed with coating material. A high pressure pump (high or ultra-high
pressure), is used to sustain constant liquid flow at high pressure through the small porous
particle bed coating the column. Hence the name, ultra performance liquid chromatogra-
phy (UPLC), which produces higher resolution chromatograms compared to the traditional
LC system (operating at pressure of 15,000 psi vs. 5,800 psi, respectively) (Fountain, 2011).
The size of particles is another important factor that can maintain the column at high pres-
sure.
Gradient elution is used to deliver solvents at varying proportions to elute molecules at dif-
ferent times. The eluotropic strength of the solvent is progressed linearly as the analysis
progresses, starting at high aqueous rate (99–100% water), and increasing gradually to high
organic content (95–100%; i.e. acetonitrile), typically over 5 to 30 minutes. The separated
mixture is then carried into the ionisation source (Want et al., 2010).
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2.1.1.3 Hydrophilic interaction liquid chromatography
Highly polar metabolites are poorly retained in RP chromatography; they elute very early
with the polar solvent and are separated ineffectively from each other. In hydrophilic interac-
tion liquid chromatography (HILIC), similar to normal-phase chromatography, the stationary
phase is polar. However, the mobile phase is comprised of a relatively hydrophilic solvent,
thus, it enhances the retention and separation of extremely polar compounds analytes. To-
gether, RP and HILIC provide complementary metabolite information and better metabolome
coverage.
2.1.2 The ion source
Chromatographic separation ensures a constant stream of molecules are entering the ion
source, rather than a large bundle at the same time. In the ion sources, the molecules
are ionised prior to entering the mass spectrometer because they cannot be manipulated
by electrical or magnetic fields in their neutral state. There are various forms of ionisation
methods compatible with LC-MS system. The selection is mainly based on the physico-
chemical characteristics of the analyte of interest. Some ionisation types are highly energetic
and cause extensive fragmentation of the chemical bonds (hard ionisation; i.e. electron
ionisation). Other methods do not have strong means of separation; the energy used is only
sufficient to produce adduct ions and not cause fragmentation (de Hoffmann and Stroobant,
2007).
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Figure 2.3: The electrospray ionisation process.
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Electrospray ionisation (ESI) is a soft ionisation technique. ESI transfers the ions gently
from solution (sample plus solvent mixture) to the gas phase as illustrated in (Figure 2.3)
via the following process: i) a high voltage is applied to the tip of the Taylor cone, ii) sample
is dispersed from a fine jet needle into an aerosol of highly charged droplets, iii) the charged
droplets enter a strong electric field created by the high voltage, iv) a stream of drying gas
evaporates the solvent from the charged droplets, v) the high density of the charged droplet
and the repulsive forces between the ions causes the droplet to disintegrate into smaller
droplets, vi) eventually, vapour phase analyte ions are released from the droplet and left
free in an atmosphere of drying gas (de Hoffmann and Stroobant, 2007). For all the studies
presented in this thesis, ESI was used.
The ionisation is soft; a very little residual energy is retained by the analyte (Banerjee and
Mazumdar, 2012). Generally, no fragmentation occurs upon ionisation and the mass spec-
trum produced is dominated by protonated [M+H]+, deprotonated molecules [M-H]  and
adducts (e.g. [M+Na]+, [M+Cl] . The adduct formation of the salt ions is highly undesirable
as it generates multiple peaks corresponding to each charge state which interfere with the
interpretation of the mass spectra (Banerjee and Mazumdar, 2012). The method also pro-
vides only molecular weight information. Therefore, the use of ESI-MS in combination with
collision activation to induce fragmentation of selected ions for structural annotation appli-
cations has considerably increased (Demarque et al., 2016). Better understanding of the
gas-phase fragmentation reactions under ESI-MS/MS conditions is critical to support the
structural elucidation of analytes.
2.1.3 Mass analyser
The basic function of the mass analyser is to separate the ions according to their m/z val-
ues and transfer these ions into a detector. Different mass analysers separate the ions
by a variety of methodologies, choice depends on the type of data required (structural or
quantitative), resolution and mass accuracy. Quadrupole coupled with time-of-flight (Q-TOF)
mass analyser, (Figure 2.4) regarded commercially as the most successful hybrid analysers
(Gross, 2004). A hybrid instrument combines different types of mass analysers in a single
instrument.
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Time-of-ﬂightanalyte ions
Figure 2.4: Principle of quadrupole time-of-flight instrument.
The quadrupole consist of four metal rods set parallel to each other (Figure 2.5). It separates
ions based on the stability of their trajectories in the varying electric fields applied to the
rods. The ions accelerate down the analyser in a controlled electric field, allowing ions of
one particular m/z to pass through the length of the quadrupole. The main function of the
TOF analyser is to provide accurate mass data on the molecular species. The ions mass is
resolved by the time to traverse a known distance, before striking the detector.
+
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(detected) ion
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(ﬁltered out) ion
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Ion souce
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Figure 2.5: Quadrupole mass analyser.
The quadrupole can be used in narrow or wide band pass mode to determine which ions
are passed into the collision region and then into the TOF analyser. In full scan mode,
the quadrupole is set in wide band pass mode so all ions are transferred into the TOF
analyser, and there is no gas in the collision cell. The narrow pass mode is operated when
fragmentation of a selected ion with known m/z is required. The quadrupole will act as a
filter; allowing the passage of ions with particular m/z.
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Fragmentation of an ion of known m/z, is named tandem mass spectrometry or MS/MS.
Collision-induced dissociation (CID) cell, usually placed after the quadrupole, is filled with
an inert gas such as argon. Ions are selectively passed into the cell whereupon a voltage
is applied which results in fragmenting the ion into its constituents. Most ions will produce
a signature fragmentation pattern which may be identifiable using databases or chemical
standards. The Q-TOF system features high mass accuracy together with the possibility of
tandem mass spectrometry, which is ideal for non-targeted profiling applications.
2.1.4 Ion detector and vacuum system
A detector has three vital functions: amplification of the very low electrical current produced
by the ions arriving to the detector, counting the ions emerging and transforming them into
a usable signal. A high vacuum pump (low pressure) in a mass spectrometer is intended to
prevent the loss of ions in the various chambers of the instrument, and to direct the ions to
the detector without undergoing collisions with other gaseous molecules.
2.1.5 Data presentation
The LC-MS system produces 3-dimensional data that in combination are called a molecu-
lar feature, the m/z (weight), retention time (speed), and the relative intensity (quantity) of
each analyte detected in a sample. Three chromatographic plots are generated per sample
(Figure 2.6); 1) total ion chromatogram (relative intensity vs. the retention time over the
whole analytical run). It provides general view of the detected range of masses, however,
analytes can elute simultaneously which leads to obscuring their signal. 2) The extracted ion
chromatogram (one or multiple analyte peaks with similar m/z value, but different retention
times), and 3) mass spectrum (relative intensity vs. m/z of a single analyte at a specific
retention time).
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Figure 2.6: Three dimension visualisation of electrospray ionisation chromatogram, mass
chromatogram and mass spectrum.
2.1.6 Pre-processing of raw spectral data
Pre-processing of spectral data produced by LC-MS system is a necessary step before any
statistical analysis. The process aims to transform the raw data (in analogue format) to a
tabular matrix, correct for instrumental variation, filter the dataset (reduce noise), and extract
the molecular features from each sample. XCMS software provides a relatively automated
processing pipeline tailored for untargeted LC-MS metabolic profiling data. The software is a
robust and a very popular platform (+1500 citations in literature), and was chosen to process
the MS data in all the studies presented in this thesis.
The outcome of the MS analysis is the generation of a spectrum for each sample. The
software initially identifies peaks detected in each sample, then extracts and reports their
m/z values. Peak integrals are then created by grouping and binning the peaks. The corre-
sponding peaks from run to run are then matched and grouped. The drift in analyte retention
time from run to run is calculated and corrected by ”peak alignment”. The peak alignment
algorithm corrects for retention time drifts by calculating a median retention time from ”well-
behaved” peaks. Some groups may be missing peaks from some of the samples; because
an analyte is not present or was not detected in the previous peak detection step (due to its
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low concentration, bad peak shape or a mistake in the identification algorithm), are corrected
for by recovering the missing signals from raw data via ”peak filling” method. Without using
a gap filling algorithm the final extracted feature set contains many zero intensity values,
which may falsely impact data analysis and results in incorrect biomarker identification as
‘true’ zeros and peaks missed by the algorithm are given the same zero value.
Finally, the data are normalised to refine confounding variation arising from experimental
sources, while preserving relevant biological variation. The normalisation process scales
the data so that different samples in a study can be compared with each other. This is a key
step for the urinary matrix; urine volume changes result in significant variation in the dilu-
tion of analytes concentrations across samples (Veselkov et al., 2011). Median fold change
normalisation (which adjusts the median of log fold changes of peak intensities between
samples in a set of experiments to be approximately zero) is least compromised by the bio-
logically induced changes in a sample and is thus preferable. Other normalisation methods,
including total intensity, locally weighted scatter plot smoothing, and quantile normalisations,
are based on the assumption that there are equal number of metabolites with increased and
decreased signals, which limits there use as metabolites have asymmetrically increasing or
decreasing abundances in biological fluids (Veselkov et al., 2011).
2.1.7 Quality control
A pooled sample from equal portions of all samples is used as a quality control (QC) sample.
A QC is injected in every batch throughout the whole run, and is used to assess: the signal
intensity, peak shape, retention time drifts, separation resolution and mass accuracy.
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2.1.8 Data matrix
After pre-processing the spectral data, XCMS generates a peak intensity table (Figure 2.7),
which is then imported to statistical analysis software.
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Figure 2.7: The data matrix.
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2.2 Multivariate analysis
Similar to the other ”omics” disciplines, metabolic profiling generates large and complex
datasets that require sophisticated statistical approaches to reduce its dimension and ac-
count for intra- and inter-sample variance. Typically, hundreds or even thousands of mul-
ticollinear metabolic features are produced by LC-MS for each sample. Each metabolite
detected can generate several isotopes, adducts and fragments. Moreover, multiple cor-
relations are present among the metabolites that are biochemically interrelated (Xi et al.,
2014).
The dataset requires reduction of variables, with a selection and visualisation statistical
approach. The statistical method used needs to account for correlation as the data are
collinear. Dimension reduction methods summarise and transform thousands of features
into a few key components that capture the variance or discriminatory covariance in the
data.
Here, the data are initially explored with principal components analysis (PCA), and orthogo-
nal partial least squared discriminant analysis (OPLS-DA) for feature selection.
2.2.1 Principal components analysis
Principal components analysis (PCA) is a statistical technique for finding patterns high di-
mensional data. The method is unsupervised; it does not require any input related to class
information, and is used to project the data to highlight the maximum sources of variance
using a minimal number of principal components (PCs). This approach has the advantage
of reducing the number of dimensions, without much loss of the biological information by
removing the noise and redundancy in the data.
The new PCs correspond to an uncorrelated, linear combination of the original variables.
The model uses the variability and correlation of each variable (i.e metabolites) to create a
simplified set of new variables (PCs). The PCA reduce the number of variables in a dataset,
however, it still accounts for as much of the total variation in the original data as possible
(Bartel et al., 2013).
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The data are visualised as scores and loadings plots. In the scores plot (Figure 2.8), which
maps the distribution of samples and allows inherent similarities between samples to be
detected, the horizontal axis represents the first PC, which explains the largest variation.
The vertical axis represents the the second-most variance or PC2, and it is orthogonal to
the PC1 axis. If there are x variables in a dataset, it is possible to add up to x PCs. Usually
the most interesting observation can be seen in the first few components, the remaining PCs
are either uninteresting or noise (Bartel et al., 2013).
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Figure 2.8: Principal components analysis scores plot.
The PCA is plotted with colour codes assigned to each group to elucidate relationship be-
tween observations. Close clustering trends between observations within the same group
indicates similar underlying metabotypes. Observations outside the 95% confidence interval
(the magenta circle) are identified as a potential outliers, and require further examination of
their original spectra.
2.2.2 Orthogonal projections to latent structures-discriminant analysis
Supervised modelling using OPLS-DA is mainly used to maximise separation between pre-
defined sample classes in order to view discriminatory metabolites. The in-built orthogonal
signal correction filter removes confounding variations not related to class separation (e.g.
within group variation, age, gender, diet, etc.), which may be observed in PCA models.
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Variation that is unrelated to the class response is described in the orthogonal compo-
nent(s)(Trygg et al., 2007). Similar to PCA, OPLS-DA models take into account the joint
effect of all metabolites and utilise their correlation structure with the additional aim of max-
imising the variance related to the biological class (or y variable). A corresponding “loadings
plot” can explain which variables (or loadings) are different between samples, and thus caus-
ing separation between groups (i.e. cancer vs. control).
Model evaluation and cross-validation is critical to avoid ”over-fitting” the OPLS-DA model
and prevent false positive results. Over-fitting the model can show excellent results, how-
ever, the outcome might not be reproducible. Internal and external validation is required
to overcome this issue. The goodness of fit and prediction can be evaluated by assess-
ing the R2 and Q2 model statistics, respectively. Additionally, a permutation test, which is
a leave-one-out cross validation procedure can assess the model validity. The permutation
test compares the goodness of fit of the original model with the goodness of fit of sev-
eral randomly permuted models (re-sampling Y-observations, while the X-matrix is intact).
Analysis of variance testing of cross-validated predictive residuals (CV-ANOVA, p-value <
0.05) tests can also be performed to determine significant differences between groups in the
OPLS-DA models (Eriksson et al., 2008). Feature selection only proceed if the models are
robust to identify relevant and putative biomarkers. An OPLS-DA with Q2Y less that 20%
and CV-ANOVA greater than 0.05 is considered as a non-discriminatory model.
Variable importance of projection (VIP) scores were used to select the most differential
metabolites from the supervised OPLS-DA model. VIP scores are used to estimate the
importance of each variable in the projection used in the OPLS model, which allow to clas-
sify the X-variables according to their explanatory power of Y (class information). A variable
with a VIP Score close to or greater than 1 can be considered important in a given model.
Univariate significance tests and fold change (FC) were then performed on the selected
features to estimate the magnitude of change between the groups.
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2.3 Metabolite annotations
The data obtained by LC-MS are merely a series of peaks without any chemical identity,
therefore, following the selection of important, discriminant features their interpretation in
a biological context is limited only by the extent to which their precise chemical identity is
known. A single metabolite can produce multiple features, and its identification is not always
straight forward because the feature is not always observed as protonated or deprotonated
ion but rather as adducts or fragments. Initial examination of the metabolite chromatographic
data is key to determining the true monoisotopic parent in a cluster of masses detected at
the same retention time.
The identification of metabolites is labour-intensive, time-consuming and a major bottleneck
in the interpretation of MS results. The gold standard for metabolites assignment is to use in-
ternal isotope–labeled standard, or spiked-in nonlabeled authentic standards. However, for
untargeted metabolic profiling, the comparison of each detected metabolite with the com-
pound standard is not feasible due to the cost and commercial availability of standards.
Currently the best approach for metabolite annotations is to use the molecular feature infor-
mation (m/z, retention time and MS/MS) to determine its chemical identity against a number
of freely available online databases, such as human metabolome database (HMDB) (Wishart
et al., 2012), METLIN (Smith et al., 2005), LipidMaps (Sud et al., 2007), and to MS data
available from earlier publications. The potential assignments returned from the database
search of a mass is then carefully examined for molecular formula and structure match, as
well as, to the molecule biological relevance to the human metabolome. Nevertheless, many
of the peaks cannot be assigned to a metabolite. They are labelled as ‘unknown’ and not
characterised further.
CHAPTER 2. METHODOLOGY 75
2.4 Project workflow
The flowchart below provides an overview of the thesis result chapters:
Chapter 3
CHARACTERISATION OF THE URINARY METABOLIC PROFILE OF LIVER
FLUKE-ASSOCIATED CHOLANGIOCARCINOMA - COHORT I.
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3.1 Abstract
Background Human infection with O.viverrini, a carcinogenic liver fluke that inhabit the biliary tree
where it matures and replicates, is endemic in North-East Asia. Chronic infection with O.viverrini is
associated with a fatal complication, cholangiocarcinoma (CCA), a late-presenting and aggressive
malignancy. Currently, the annual mortality rate from CCA mirrors its trend in incidence; mainly due
to the limited availability of efficient prognostic and early diagnostic biomarkers.
Methods With the ability to detect thousands of urinary metabolites using metabonomics, the urine
metabolome holds great potential in providing an insight into system-level alterations in carcinogene-
sis and in identifying metabolic markers altered in response to disturbed homeostasis in CCA. Global
molecular profiling using reversed-phase ultra-performance liquid-chomatography mass spectrome-
try (RP-UPLC-MS) was utilised to acquire the spectral profile of 137 spot urine samples (48 at high
risk of infection, 41O.viverrini infection, 34 periportal fibrosis and 14 CCA) from Khon Kaen, Thailand.
Results Multivariate statistical analysis identified perturbation in several molecular classes related to
purine metabolism and lipid metabolism in the CCA urine metabolome. These markers mainly reflect
changes in energy metabolism to support proliferation (increased fatty acid oxidation and purine
recycling), DNA methylation and hepatic injury.
Conclusion Several metabolites of biological interest were discovered from this proof-of-principle
dataset. Augmenting these findings is essential to accelerate the development of urinary metabolic
markers in CCA.
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3.2 Introduction
2015 marked 100 years of the human opisthorchiasis discovery in Thailand and despite
the availability of effective treatments and control programs, which have been in place for
decades, O.viverrini and/or C.sinensis remain highly endemic in all countries of the Lower
Mekong Basin (Sithithaworn et al., 2012). It is reported that up to 20 000 new cases with
liver fluke-induced CCA are subjected to surgery annually in Thailand alone (Khuntikeo et al.,
2016). Khuntikeo and colleagues also reported that O.viverrini infection landscape is begin-
ning to shift among school children as a result of school eduction and community control
programmes in Thailand (Khuntikeo et al., 2014). Accordingly, they predicted that CCA
prevalence will decline within the next decade or two. However, this is not true for other
endemic regions; data regarding the impact of liver fluke control programs, if any, on age-
specific prevalence is lacking. The authors hoped that their encouraging data will motivate
their colleagues in Lao PDR, Cambodia, Vietnam, Russia, China and Korea to adapt similar
strategies to impact the disease (Khuntikeo et al., 2016).
To date, liver fluke-induced CCA incidence is still alarmingly high and will likely kill hundreds
of thousands of people in the coming decades, affecting the poorest of the poor. There
is an urgent, unmet demand for the development of non-invasive, efficient biomarkers that
can hold clinical potential for timely diagnosis of O. viverrini-related hepatobiliary diseases
(Sithithaworn et al., 2012). Human metabolic profiling studies of biofluids from CCA patient’s
have identified a number of altered metabolites related to several metabolic pathways impli-
cating changes in hepatic function, lipid metabolism and bile acid metabolism, (reviewed in
Chapter 1.2.4). No publication to date has examined the urinary metabolic profile of liver
fluke-induced CCA. Urine contains a wealth of information, small metabolites (<1000 Da)
pass through the renal glomerulus as an ultrafiltration of the blood and escape proximal
tubular reabsorption. These metabolites are subsequently excreted in the urine, resulting in
a metabotype or a metabolic ”fingerprint” pattern of the host physiological statues. Thailand
is the hotspot for CCA research in the region. This project was built on an existing collab-
oration initiated in 2011 between Imperial College London and Khon Kaen University, Khon
Kaen, Thailand. The samples were received in 2013 and analysed by 1H NMR spectroscopy
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as part of previous PhD project aimed to investigate CCA metabolic signatures. Multivariate
statistical analysis showed resonances of glucose and drug-related analytes that overlapped
with other endogenous metabolites of interest. Therefore, global profiling using the more
sensitive UPLC-MS instrument was performed in my study with the aim of eliminating those
overlapping signals. The primary objective of this proof-of-concept study was to investigate
whether urine MS spectral profiles from patients with hepatobiliary malignancies are different
compared to a non-malignant control population.
During my PhD studies, I visited Khon Kaen University twice. The first visit was to partici-
pate in a workshop organised by Imperial College London in collaboration with Khon Kaen
University entitled, “Cholangiocarcinoma: Shared Disease Burden in the UK and Southeast
Asia”, in March 2014, Figure 3.1. The main objective of my participation was to meet the re-
search team in Khon Kaen to build on the collaboration and to plan the strategy for samples
to be collected for analysis during my PhD project. The next visit took place in November
2015 to present my study results and accelerate sample collection for a second dataset (Co-
hort II, Chapter 4) to augment the findings. Limitations associated with Cohort I, including
small sample size and lack of clinical data were discussed to successfully overcome such
limitations in the next study.
Figure 3.1: Photographs of the cholangiocarcinoma workshop, Khon Kaen University, Thai-
land, March 2014.
A) The workshop delegates and host university members, B) poster presentation session, C&D) fish market in
Khon Khaen selling fish possibly infected with liver flukes.
80
3.3 Methodology
3.3.1 Sample collection
The study samples were collected from the ”Isaan” people, who are an ethnic community
native to the Northeastern region of Thailand. Raw fish dishes are distinctive to their cultural
cuisine. Patients with CCA were recruited from the in-patient population in Khon Kaen Hos-
pital, Khon Kaen, Thailand. Malignant strictures were diagnosed by CT or MRI and further
confirmed by histology at surgical operation. Spot urine samples were collected from each
participant prior to the patient undergoing any treatment. The control groups were collected
from the CASCAP field screening programme in endemic Northeastern region (Khuntikeo
et al., 2015). Isaan Thais of  40 years old who were known to have any of the following
were eligible to be included in the study: i) ever been infected with liver fluke; ii) ever been
treated for liver fluke and/or iii) ever have eaten uncooked freshwater fish with scales. Once
consent had been obtained, the participants were enrolled in the CASCAP program and
their baseline demographic information, ultrasound examination and parasitological faecal
test (for O.viverrini eggs), were collected.
The samples were grouped into 3 sub-sets: 1) participants positive for O. viverrini eggs in
their stool and with normal ultrasonography; 2) participants positive for periportal fibrosis
(PPF) and 3) participants at high risk of opisthorchiasis (negative ultrasound findings and
stool test). Participants were categorised according to the findings from faecal and ultra-
sound examination defined below.
3.3.1.1 Faecal examination for O. viverrini
On recruitment, all stool samples were examined for opisthorchiasis using standard, quan-
titative formalin/ethyl acetate concentration technique (FECT)(Allen and Ridley, 1970). For-
malin was used to fix and preserve the protozoan eggs, larvae and cysts, whereas the
addition of ether acts to adsorb the faecal debris. The parasitic elements were separated,
then sedimented from the faecal debris by centrifugation. This resulted in the formation of
four layers: ether, plug of debris, formalin and sediment. The first three layers were removed
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and the remaining sediment was microscopically examined and counted for the fluke egg
numbers (Allen and Ridley, 1970).
3.3.1.2 Ultrasound criteria
A mobile, high-resolution ultrasound was used to assess hepatobiliary abnormalities. The
liver normal sonographic appearance is typically homogeneous with visible portal and hep-
atic veins. Normal hepatic artery and bile ducts are usually non-echoic due to their thin walls
and small size. In periportal fibrosis, collagen accumulation in the periportal space shows
as a thick and echoic wall of the portal vein. Portal vein wall thickness was measured and
graded according to the method recommended by the WHO to diagnose schistosomiasis-
related PPF (Chamadol et al., 2014). Ultrasound findings were classified into: 0= ultrasound
negative; 1= ultrasound positive grade 1, (PPF+); 2= ultrasound positive grade 2, (PPF++);
3= suspected CCA, (Figure 3.2).
Figure 3.2: Ultrasound grading of Periportal fibrosis (PPF).
Normal echo pattern of the liver (A-C) with arrow pointing at: (A) the right hepatic vein; (B) right portal vein
and (C) left portal vein. (D) PPF+, is ”starry sky appearance”, which is bright echogenic dots along branches
of portal vein (arrow), (E) PPF++, is ring echoes around vessels in cross-section, pipe-stems parallel with
portal vein (arrow), and (F) PPF+++, is echogenic ruff around portal bifurcation and main stem; main portal
vein vessels wall thickening (arrow). Figure reproduced with permission of the copyright owner (Chamadol
et al., 2014).
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3.3.2 Ethical considerations
Urine samples were obtained from the Specimen Bank of the Liver Fluke and Cholangio-
carcinoma Research Center, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thai-
land. The study was approved by the Human Research Ethics Committee, (reference no.
HE571283 and HE521209). Written informed consent was obtained from each participant.
3.3.3 Sample transport and preparation
The samples were transported with a courier service from Khon Kaen University, and kept
frozen on dry ice until received and frozen at -80  C at the Liver Unit in St. Mary’s Hospital
in London. Before analysis, frozen urine samples were left to thaw at room temperature,
then vortex mixed and centrifuged at 16089g for 10 minutes. After randomisation, an aliquot
of 250µL of each sample were transferred into 96-well 350 µL plates with cap mats from
Waters (Milford, MA, USA). Prepared samples were kept in a 0-4  C fridge and then at 4  C
throughout the analysis in the autosampler.
3.3.4 Quality control
Quality control (QC) samples were prepared by pooling 50µL of each urine sample into a Fal-
con tube (Sigma-Aldrich, Dorset, UK). A 200µL aliquot was then transferred to an analytical
MS well plate to enable acquisition of a QC spectrum every 10 samples.
3.3.5 Chromatographic conditions
The samples spectra were acquired using ACQUITYTM UPLC system (Waters Ltd. El-
stree, U.K.) coupled to a LCT PremierTM mass spectrometer (Waters MS Technologies,
Ltd., Manchester, U.K.). RP-UPLC-MS was performed with electrospray ionisation (ESI) in
both positive and negative modes. The conditions were optimised using the QC samples in
terms of peak shape, reproducibility and retention time. Table 3.1 summarises the UPLC-
MS conditions used.
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Table 3.1: Ultra-performance liquid chromatography mass spectrometry conditions.
Parameter Speciﬁcations Gradient elution 
Time (min) A (%) B (%) 
Column 2.1 X 100 mm (1.7 μm) HSS T3 AcquityTM (Waters)                                                                0 99 1
Injection volume    5 μL                                                                                                           1 99 1 
Flow rate           0.5 mL min  -1                                                                                                 3 85 15 
Sample temperature 4 оC 6 50 50 
Column temperature 40 оC 9 5 95 
Mobile phases       
A: 0.1% formic acid in water 10 5 95 
B: 0.1% formic acid in acetonitrile 10.1 99 1 
 
3.3.6 Tandem mass spectrometry
Tandem mass spectrometry (MS/MS) analysis was performed using a quadrupole time-of-
flight (TOF) PremierTM instrument (Waters MS Technologies, Manchester, UK). Collision-
induced dissociation (CID) experiments of the QC sample were performed for structural
elucidation of detected ions in each ionisation mode. This was conducted subsequent to
the original profiling run to save time and limit analytical variations in retention time and
performance that can occur when returning to the instrument for CID analysis.
Two complementary MS/MS acquisition modes were used to ensure sufficient MS/MS cov-
erage of ions of interest, data-dependent acquisition (DDA) and acquisition with no precur-
sor ion selection, or data-independent acquisition (MSE). The DDA experiment was set to
switch automatically from the MS to MS/MS mode using data dependent criteria. It triggered
MS/MS on the most abundant ions in each MS scan and provided fragments specifically
attributed to the precursor ion. In MSE mode, eluting peaks were subjected to both high and
low collision energies in the collision cell of the mass spectrometer, with no prior precursor
ion selection (Xiao et al., 2012).
3.3.7 Metabolite assignment verification
The molecular mass, retention time and fragmentation spectrum of the discriminant features
were compared against on-line spectral libraries such HMDB (www.hmdb.ca) (Wishart et al.,
2012) and METLIN (https://metlin.scripps.edu)(Smith et al., 2005). Metabolites were classi-
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fied as either: (a) identified compounds confirmed with an authentic standard (example in
Figure 3.3); (b) putatively annotated compounds (such as those based upon fragmentation
pattern and/or spectral similarity with spectral databases); (c) putatively identified to match
a certain chemical class (such as those based on spectral similarity to known compounds of
a chemical class); or (d) as unknown compound.
 
 
Purple= authentic hippurate standard  
Green= hippurate in QC sample 
Hippurate 
experimental 
MS/MS 
Hippurate database 
MS/MS 
77.0399 
134.0607 
Formula: C9H9NO3 
Monoisotopic molecular weight: 179.058 
Average molecular weight: 179.172 
 
 
Theoretical accurate mass: 178.05097 
Measured accurate mass: 178.0504 
Figure 3.3: Example of metabolite identification using tandem mass spectrometry (MS/MS).
Spectral overlay between authentic hippurate standard peak and measured hippurate peak in QC sample (top
right), hippurate experimental MS/MS (bottom left), and hippurate database (Metlin) MS/MS (bottom right).
3.3.8 Pre-processing
The raw LC-MS data files were converted to CDV format by MassLynxTM version 4.1 ap-
plication manager (Waters Corporation, Milford, U.S.A.) and then imported into R Project
version 3.1.0 (The R Foundation for Statistical Computing, 2014) for pre-processing using
XCMS package version 2.14. (Bioconductor). Computational scripts written in-house were
applied to: 1) filter and identify peaks; 2) correct for retention time drift; 3) match peaks
across samples; and 4) fill in missing peaks.
3.3.9 Statistical analysis
SIMCA-P+ version 13.0.2 (Umetrics, Sweden) was used for multivariate statistical analysis
of the processed data. Initial analysis was performed using unsupervised principal com-
ponent analysis (PCA) to explore variation in the dataset, examine clustering patterns, or
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trends in the dataset, based on metabolic profile similarities or differences. Following PCA,
orthogonal projections to latent structures discriminant analysis (OPLS-DA) was performed
to maximise separation between predefined sample classes in order to view discriminatory
features. Feature selection was based on the variable importance in projection (VIP) coeffi-
cients, which allow the X-variables to be classified according to their explanatory power of Y
(class information). Features with high VIP value, larger than 1, were found to be the most
relevant for explaining Y class information. The top 30 features were selected and identified
for each model.
Validating multivariate models is essential to avoid over-fitting the data (discussed in Chap-
ter 2.2.2). The model statistics, R2X, Q2Y, permutation test and CV-ANOVA p-value, were
used to evaluate the models robustness. Permutation testing (with 100 permutations) was
calculated for every OPLS-DA model using SIMCA-P+ version 13.0.2 (Umetrics, Sweden).
Univariate significance tests were then performed on the selected features using ANOVA
with post-hoc tests (Tukey’s HSD) which is designed to account for multiple comparisons.
Significant features were presented graphically as box and whisker plots.
3.3.9.1 Correlation with hierarchical clustering order
R Project version 3.1.0 (The R Foundation for Statistical Computing, 2014) using corrplot
package version 0.77, (CRAN) was used to perform hierarchical cluster analysis of Spear-
man’s correlation coefficient matrix. The cluster analysis was used to investigate correlations
among the identified biochemical components. The correlation matrix was represented as
a heatmap with rows and columns ordered according to a hierarchical clustering analysis.
Hierarchical clustering is an unsupervised method. No class information was given to cal-
culate the model, which was found to be suitable for exploratory data analysis. Positively
and negatively correlated analytes were displayed in blue and red colors, respectively. A
circle was used to represent correlations between pairs of compounds. The circle diameter
and color intensity were proportional to the correlation coefficients, and indicate statistically
significant correlations (< 0.05). The circle diameter and colour intensity were proportional
to the correlation coefficients. Non-significant correlations were represented as an X.
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3.4 Results
3.4.1 Urine RP-UPLC-MS chromatogram
A non-targeted metabonomics approach using LC-MS was applied to fingerprint the urinary
metabo-lome of CCA patients in comparison to controls. A total of 1,993 and 1,224 features
were detected in the positive and negative ESI modes, respectively. Given that urine is a
complex biological fluid, those features can represent metabolic breakdown products from
dietary intake, drugs use, endogenous waste metabolites, gut microbiota by-products and
environmental contaminants. Figure 3.4 shows an example of detected compounds in LC-
MS positive (A) and negative (B) ionisation mode.
proline betaine 
0.58
creatinine 
0.51
uric acid
1.03
nicotine
1.06 paracetamol
2.46
butyrylcarnitine 
2.83
hippurate
3.81
caﬀeine 
3.72
2,6 dimethylheptanoyl carnitine
5.63
glycocholic acid
6.23
A
B
citrate
1.01
hippurate
3.79
indoxylsulfate
3.80
taurocholic acid
5.91
glycocholic acid
6.23
1-methylxanthine
2.52
phenylacetylglutamine
3.83
Figure 3.4: Example of compounds detected in the non-targeted liquid chromatography
mass spectrometry.
A) positive and B) negative electrospray ionisation mode.
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3.4.2 Demographics, clinical data and cohort description
A total of 137 Thai participants were recruited to form the training set. CCA patients (n=14),
were older compared to controls and comprised mostly of males (71.4%). Similarly, male
gender was greater in all control groups: high risk (75%), O. viverrini (63%) and PPF (56%).
The majority of CCA patients presented with intrahepatic tumours, but, no additional infor-
mation regarding the patient’s blood biochemistry tests, tumour’s stage/grade, liver func-
tion and co-morbidities was available. Out of (n= 34) patients, (n= 8) participants had ac-
tive opisthorchiasis, (n= 27) had moderate fibrosis (PPF+) and (n= 7) were diagnosed with
PPF++. The opisthorchiasis group egg count ranged from 6 to 880 eggs per gram of faeces.
Although data regarding tobacco smoking was not available for the CCA group, nicotine-
related analytes were present in statistical analysis; higher urinary concentrations of smok-
ing compounds were detected in the control groups compared to the cancer patients. Patient
characteristics are summarised in Table 3.2.
Table 3.2: Demographics of study population.
Characteristic Cholangiocarcinoma  High risk  Opisthorchiasis Periductal fibrosis  
Participants, n 14 48 41 34 
Age, mean, (range), y 60.3 (29-77) 58.6 (44-80) 58.9 (40-86) 51.1 (40-74) 
Male, % 71.4 75.0 63.4 56.9  
Smoking, (n)      
  Smokers - 10 17 12 
  Non-smokers - 26 19 17 
  Not available  14 12 5 5 
Tumour location     
  Intrahepatic 
  Hilar 
  Distal 
  Gallbladder 
  Unspecified 
6 
2 
1 
3 
2 
- - - 
O. viverrini FECT*, n     
  0  48 0 26 
  1-50  0 17 5 
  51-100 - 0 11 2 
  >100  0 13 1 
Fibrosis severity, n     
  PPF+ 
  PPF++ 
- - - 
 27 
7 
*Formalin/ethyl acetate concentration technique (FECT), eggs per gram of faeces.  
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3.4.3 Global overview of study samples
An initial PCA model was calculated from all samples acquired using positive (Figure 3.5a)
and negative (Figure 3.5b) modes to provide a global overview of the data. No clear cluster-
ing pattern was observed between the groups (high risk, O.viverrini infected, PPF and CCA),
which might be due to high intra-class variability. The percentage of explained variance was
18% and 25% for the positive and negative modes, respectively.
(a) PCA scores plot - positive mode
R2X= 18% and Q2X= 10% from 2 PC model.
(b) PCA scores plot - negative mode
R2X= 25% and Q2X= 5% from 2 PC model.
Figure 3.5: PCA scores plots of test samples derived from UPLC-MS urinary data (n= 137
participants) for (a) positive and (b) negative ion mode.
3.4.4 Environmental influences
3.4.4.1 Drug exposure
Paracetamol or acetaminophen (APAP) is a widely used non-prescription analgesic drug.
Following initial data exploration, peaks corresponding to APAP urinary metabolism prod-
ucts were found to be discriminant between cancer patients and control groups. Features
with correlation coefficients higher than 0.8 with the most predominant APAP product were
examined and excluded in both positive and negative ionisation modes. APAP (M+H, m/z
152.071) is mainly metabolised via conjugation and renally excreted as APAP-glucuronide
(M+H m/z 328.103, APAP-sulfate (M+H, m/z 232.028) and APAP- N-acetylcysteinylate (M-
H, m/z 311.076). The peaks of APAP and its urinary products were excluded to enable
identification of biological relevant features from endogenous metabolites.
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3.4.4.2 Impact of dietary exposure
Dietary information from the 24-hr dietary recall regarding the intake of meat (pork, beef,
chicken and fish), vegetables, herbs, tea and coffee was used to identify markers related
to foods and dietary pattern. Difference in the detected metabolic profiles based on food
intake was only pronounced between individuals who had reported to consume tea or coffee.
Urinary caffeine excretion is common and is expected to be detected by LC-MS in metabolic
profiling studies. Dietary intake of caffeinated beverages is the most common source of
urinary caffeine, but caffeine-containing medications can also be another source (Rybak
et al., 2015). Caffeine and its metabolites were predominant in the control groups. A high
degree of correlation was observed among caffeine analytes, as shown in the heatmap
(Figure 3.6). The heatmap also shows clear clustering between purine metabolites which
are present in the caffeine pathway and purines, such as xanthine, hypoxanithne and uric
acid, which are in the purine metabolism pathway.
Figure 3.6: Heatmap of metabolites related to caffeine and purine metabolism.
The blue circles represent positive correlations whereas the red ones show the negative correlations. The
larger the circle diameter the higher the correlation (the X indicates no significant correlation, p >0.05).
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3.4.4.3 Tobacco smoking
Nicotine metabolites were found to be discriminant between the control and cancer groups.
Therefore, a model using spectral data from smokers (n= 39) versus non-smokers (n= 62)
was calculated to examine the impact of smoking on the metabolic profiles. Nicotine metabo-
lites (nicotine, hydroxycotinine and cotinine) were found in greater concentrations in urine
samples from smokers and were detected in the positive mode, Q2Y=35%, Figure 3.7c. As
most of the smokers were males (3 females out of 39 smokers), gender-related metabolites
were also found to influence the model. After excluding nicotine-related metabolites from
the OPLS-DA model, the cross-validation statistics of the positive spectral data were not
predictive (R2Y=64%, R2X= 14% and Q2Y=14%), possibly indicating mild tobacco exposure
impact on the endogenous metabolic profile of the smokers.
(a) PCA scores plot - positive mode
R2X= 18% and Q2X= 10% from 2 PC model.
(b) PCA scores plot - negative mode
R2X= 25% and Q2X= 5% from 2 PC model.
(c) OPLS-DA scores plot - positive mode
R2Y= 68%, R2X= 15% and Q2Y= 35% ,
from one predictive and one orthogonal components model.
(d) OPLS-DA scores plot - negative mode
R2Y= 54%, R2X= 22% and Q2Y= 17% ,
from one predictive and one orthogonal components model.
Figure 3.7: PCA scores plots for (a) positive and (b) negative ion mode urine mass spectra
of smokers vs. non-smoker. The corresponding OPLS-DA scores plots for (c) positive and
(d) negative ion mode data.
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3.4.5 Gender effects
Gender difference is a known co-founder in metabonomic studies (Kochhar et al., 2006).
When first examined, the nicotine metabolite, hydroxy-nicotine, was the most discriminant
feature between males and females (VIP 9.3). Therefore, nicotine-related metabolites were
excluded to examine genuine gender-related differences. A separation trend between males
and females (Q2Y=31%) was observed only in the positive mode spectral data (Figure 3.8b).
The metabolites that contributed to the separation between males and females are listed in
Table 3.3.
(a) PCA scores plot - positive mode
R2X= 17% and Q2X= 11%, from 2 PC model.
(b) OPLS-DA scores plot - positive mode
R2Y= 71%, R2X= 18% and Q2Y= 31% ,
Figure 3.8: PCA scores plots for (a) positive and (b) negative ion mode mass spectra of
males and females. The corresponding OPLS-DA scores plots for (c) positive and (d) nega-
tive ion mode data.
Table 3.3: Gender discriminant compounds - positive mode.
m/z RT Tentative assignment Adduct Trend VIP p-value Identiﬁcation* 
114.065 0.51 Creatinine M+H Male 8.2 0.017 a 
144.102 0.58 Proline betaine M+H Male 7.4 0.159 b 
229.155 0.99 Leucyl proline M+H Male 6.7 0.014 b 
105.033 3.81 Hippurate Fragment Male 6.1 0.055 a 
188.071 3.16 3-amino-2-naphthoic acid M+H Female 5.0 0.368 b 
229.119 0.60 Prolylhydroxyproline M+H Female 4.9 0.010 b 
169.036 1.03 Uric acid M+H Male 4.4 0.266 a 
132.068 0.59 4-Hydroxyproline M+H Female 4.2 0.00015 b 
265.118 3.85 Phenylacetylglutamine M+H Male 4.1 0.194 b 
232.155 2.83 Butyrylcarnitine (C4) M+H Male 4.0 0.177 a 
RT= retention time;  VIP= variable importance in projection score. 
*Level of metabolite identiﬁcation: (a) Identiﬁed compound; (b) putatively annotated compound; (c) putatively characterised 
compound class; and (d) Unknown. 
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3.4.6 Cancer patients vs. high risk group
The PCA model of urine samples from high risk Thai participants versus cancer patient
samples showed a clustering trend between the two groups in positive, but not in negative
modes, whereas, OPLS-DA statistics showed enhanced separation in both modes with good
reproducibility (Figure 3.9c, positive Q2Y= 65% and Figure 3.9d, negative Q2Y= 50%). A
permutation test, (Figure 3.9e&f, p-value <0.001.), was used to evaluate the robustness of
the OPLS-DA model, and ensure that theQ2Y and R2Y values were not random or overfitted.
(a) PCA scores plot- positive mode
R2X= 20% and Q2X= 1% from 2 PC model.
(b) PCA scores plot - negative mode
R2X= 24% and Q2X= 1% from 2 PC model.
(c) OPLS-DA scores plot - positive mode
R2Y= 89%, R2X= 18% and Q2Y= 65% ,
from one predictive and one orthogonal components
model.
(d) OPLS-DA scores plot - negative mode
R2Y= 77%, R2X= 17% and Q2Y= 50% ,
from one predictive and one orthogonal components
model.
(e) Permutation test - positive mode
CV-ANOVA <0.001.
(f) Permutation test - negative mode
CV-ANOVA <0.001.
Figure 3.9: PCA scores plots for (a) positive and (b) negative ion mode data of CCA patients and healthy
controls. OPLS-DA scores plots showing group separation for both (c) positive and (d) negative ion mode data
and the corresponding permutation tests for (e) positive and (f) negative ion mode data.
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3.4.7 Cancer patients vs. opisthorchiasis cases
A clear clustering pattern was observed in the positive mode PCA between patients with
biliary tumours and O.viverrini infected cases, (Figure 3.10a). Supervised analysis showed
high model predictive ability withQ2Y= 70% and 55% in positive (Figure 3.10c) and negative
(Figure 3.9d) ionisation modes, respectively. The permutation validation plots assured that
the OPLS-DA models were reliable as original points (right) were lower than the permuted
points (left) and p <0.001, (Figure 3.10e&f).
(a) PCA scores plot - positive mode
R2X= 21% and Q2X= 5% from 2 PC model.
(b) PCA scores plot - negative mode
R2X= 27% and Q2X= 0.14% from 2 PC model.
(c) OPLS-DA scores plot - positive mode
R2Y= 89%, R2X= 19% and Q2= 70% ,
from one predictive and two orthogonal components
model.
(d) OPLS-DA scores plot - negative mode
R2Y= 76%, R2X= 23% and Q2= 55% ,
from one predictive and one orthogonal components
model.
(e) Permutation test - positive mode
CV-ANOVA <0.001.
(f) Permutation test - negative mode
CV-ANOVA <0.001.
Figure 3.10: PCA scores plots for (a) positive and (b) negative ion mode data of CCA patients and O.
viverrini infected cases. OPLS-DA scores plots showing group separation for both (c) positive and (d) negative
ion mode data and the corresponding permutation tests for (e) positive and (f) negative ion mode data.
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3.4.8 Cancer patients vs. periportal fibrosis cases
Participants with PPF (fibrous tissue surrounding the hepatic portal vein and its branches),
which usually results from chronic O.viverrini infection showed good separation from the
CCA group. The positive mode statistics, R2Y=83%, R2X= 21% and Q2Y=59% and negative
mode R2Y=80%, R2X= 24% and Q2Y=51% as illustrated in (Figure 3.11c&d).
(a) PCA scores plot - positive mode
R2X= 23% and Q2X= 7% from 2 PC model.
(b) PCA scores plot - negative mode
R2X= 31% and Q2X= -0.6% from 2 PC model.
(c) OPLS-DA scores plot - positive mode
R2Y= 83%, R2X= 21% and Q2Y= 59%,
from one predictive and two orthogonal components model.
(d) OPLS-DA scores plot - negative mode
R2Y= 80%, R2X= 24% and Q2Y= 51%,
from one predictive and one orthogonal components model.
(e) Permutation test - positive mode
CV-ANOVA <0.001.
(f) Permutation test - negative mode
CV-ANOVA <0.001.
Figure 3.11: PCA scores plots for (a) positive and (b) negative ion mode data of CCA patients and periportal
fibrosis cases. OPLS-DA scores plots showing group separation for both (c) positive and (d) negative ion mode
data and the corresponding permutation tests for (e) positive and (f) negative ion mode data.
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3.4.9 Metabolites altered in cholangiocarcinoma
The relative intensities of several compounds, among which are purines (Figure 3.12),
carnitines (Figure 3.13), bile acids (Figure 3.14) and steroid glucuronide species (Figure
3.15), were found to drive the separation between the CCA and control groups, which im-
plicate changes in energy production, hepatic function, fatty acid metabolism and bile acid
metabolism. Univariate analysis on those compounds is illustrated in the Box-whisker plots
below. The differential metabolites between the groups are listed in Table 3.4 and Table 3.5
detected in ESI+ and ESI , respectively.
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Figure 3.12: Box-whisker plots showing altered purine compounds.
Key: CCA= cholangiocarcinoma, O.viverrini= Opisthorchis viverrini, PPF= periductal fibrosis.
*p 0.05, **p 0.01 and ***p 0.001
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Figure 3.13: Box-whisker plots showing altered acylcarnitine compounds.
Key: CCA= cholangiocarcinoma, O.viverrini= Opisthorchis viverrini, PPF= periductal fibrosis.
*p 0.05, **p 0.01 and ***p 0.001
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Figure 3.14: Box-whisker plots showing altered bile acid compounds.
Key: CCA= cholangiocarcinoma, O.viverrini= Opisthorchis viverrini, PPF= periductal fibrosis.
*p 0.05, **p 0.01 and ***p 0.001
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Figure 3.15: Box-whisker plots showing altered steroid compounds.
Key: CCA= cholangiocarcinoma, O.viverrini= Opisthorchis viverrini, PPF= periductal fibrosis.
*p 0.05, **p 0.01 and ***p 0.001
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CHAPTER 3. CHARACTERISATION OF THE URINARY METABOLIC PROFILE OF
LIVER FLUKE-ASSOCIATED CHOLANGIOCARCINOMA - COHORT I. 101
3.5 Discussion
The quest in this study was to employ MS-based metabolic global profiling and multivariate
statistics to investigate whether it is possible to generate biologically meaningful differential
urinary metabotype associated with patients with biliary duct tumours. Although the proof-
of-principle study was performed with a relatively small number of diseased subjects (n= 14),
several metabolites of biological interest were discovered from the dataset.
All participants were adult ”Isaan” Thais, living in North-eastern Thailand and at high risk
of developing biliary tumours as a result of dietary exposure to the carcinogenic liver fluke.
Unlike CCA in Western countries, where the at risk population is difficult to characterise; it is
possible to investigate the urinary metabolic signature during the disease development from
exposure to cholangiocarcinogenesis in a Thai cohort. Encountered confounding factors
(such as gender differences, dietary and environmental influences) were first examined to
allow interpretation of genuine biological differences.
3.5.1 Environmental influence on the metabolic profile
3.5.1.1 Identification of drug-related compounds
As with any adult diseased cohort, drug intake is inevitable and has to be controlled for, or
taken into account. The analgesic drug, paracetamol, was present in greater concentrations
in the CCA urinary metabolome compared to control groups. Using correlation analysis
between the most dominant drug feature and the metabolic profile, it was possible to identify
co-eluting isotopes, adducts, and fragments. To mitigate against these complications, these
analytes were all excluded from the analytical models.
The urinary excretion of the drug’s metabolic breakdown end-products were identified with
reference to previous publications on drug metabolism (Johnson and Plumb, 2005). How-
ever, it was difficult to study the impact of drugs on the endogenous metabolite levels; drugs
are metabolised differently from person to person, and without a pre-dose sample it is dif-
ficult to know the impact of drug treatments on the metabolic profile even after excluding
urinary eliminated metabolites of the drug in question. For example, in individuals with in-
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creased bacterially-mediated p-cresol generation, reduced post-dose urinary ratios of parac-
etamol sulfate to paracetamol glucuronide were identified. The reduced capacity to sulfonate
paracetamol results from the competitive O-sulfonation of p-cresol (Clayton et al., 2009).
3.5.1.2 The influence of tobacco exposure
Tobacco exposure-related biological perturbations were investigated extensively to finger-
print the metabolome of cigarette smokers. A distinct metabolic pattern induced by oxidative
stress and cell damage was characteristic of smokers, and these alterations were evident
in their urine, serum and saliva metabolic profiles (Garcia-Perez et al., 2014; Kaluarachchi
et al., 2016; Mueller et al., 2014). Smoking can dominate the urinary metabolome through
the elimination of tobacco-derived toxins, such as nicotine and its metabolites and by altering
the endogenous metabolism of smokers. In a study by Garcia-Perez et al., capillary elec-
trophoresis–mass spectrometry was applied to profile urine samples of cigarettes smokers
and non-smokers (Garcia-Perez et al., 2014). Perturbations of glutathione pathway interme-
diates, such as glycine, cystine and serine, were significantly decreased in smokers, com-
pared to non-smokers which was hypothesised to be modified by glutathione depletion and
oxidative stress resulting from smoke toxicants (Garcia-Perez et al., 2014). In the present
study, no difference was found between smokers compared to non-smokers after carefully
excluding nicotine-related metabolites from the OPLS-DA model.
3.5.1.3 Dietary influences
Exogenously- (xenobiotic) and endogenously-eliminated metabolites, related to caffeine-
containing foods, and possibly medications, were detected in greater concentrations in the
control groups compared to patients with CCA. The assessment of caffeine intake in epi-
demiological study on the US population using LC-MS profiling of spot urine, detected sev-
eral caffeine-related metabolites (Rybak et al., 2015). The detection rates of caffeine elimi-
nation in urine was over 80% in people who had reported to consume caffeine (from foods,
beverages, and dietary supplements) in the 24-hr dietary recall interview. Caffeine was
mainly excreted as either 1-methylxanthine and 1-methyluric acid or as 3-methylxanthine,
7-methylxanthine and 3,7-dimethylxanthine in the study samples (Rybak et al., 2015). In the
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current study, the relative concentrations of several caffeine analytes, such as 1-methylxanthine,
3-methylxanthine and 1-methyluric acid, were highly correlated. Urinary hippurate was also
positively correlated with caffeine metabolism products (Figure 3.6).
−1
−0.8
−0.6
−0.4
−0.2
0
0.2
0.4
0.6
0.8
1
p−
Cr
es
ol 
su
lfa
te
N−
Su
lfo
ox
yb
en
zo
at
e
m
/z 
26
0.
02
2
St
er
oid
 g
luc
ur
on
ide
 (C
25
H3
8O
8)
Te
tra
hy
dr
oa
ldo
ste
ro
ne
−3
−g
luc
ur
on
ide
11
−b
et
a−
Hy
dr
ox
ya
nd
ro
ste
ro
ne
−3
−g
luc
ur
on
ide
Co
rto
lon
e−
3−
glu
cu
ro
nid
e
Gl
yc
ou
rs
od
eo
xy
ch
oli
c a
cid
Gl
yc
oc
ho
lic
 a
cid
 su
lfa
te
Ph
en
yla
ce
tyl
glu
ta
m
ine
Ur
ic 
ac
id
m
/z 
34
5.
15
4
Ta
ur
oc
ho
lic
 a
cid
Gl
yc
oc
ho
lic
 a
cid
N−
m
et
hy
lur
ic 
ac
id
N−
dim
et
hy
lur
ic 
ac
id
Iso
cit
ra
te
Ci
tra
te
Py
ro
ca
te
ch
ol 
su
lfa
te
O−
m
et
ho
xy
ca
te
ch
ol−
O−
su
lph
at
e
Hi
pp
ur
at
e
Va
nil
lin
 4
−s
ulf
at
e
4−
Hy
dr
ox
yh
ipp
ur
at
e
In
do
xy
lsu
lfa
te
St
er
oid
 g
luc
ur
on
ide
 3
31
.1
75
p−Cresol sulfate
N−Sulfooxybenzoate
m/z 260.022
Steroid glucuronide (C25H38O8)
Tetrahydroaldosterone−3−glucuronide
11−beta−Hydroxyandrosterone−3−glucuronide
Cortolone−3−glucuronide
Glycoursodeoxycholic acid
Glycocholic acid sulfate
Phenylacetylglutamine
Uric acid
m/z 345.154
Taurocholic acid
Glycocholic acid
N−methyluric acid
N−dimethyluric acid
Isocitrate
Citrate
Pyrocatechol sulfate
O−methoxycatechol−O−sulphate
Hippurate
Vanillin 4−sulfate
4−Hydroxyhippurate
Indoxylsulfate
Steroid glucuronide 331.175
Figure 3.16: Heatmap of Spearman’s correlations between urinary metabolites detected in
ESI  mode.
The circle diameter and color intensity are proportional to the correlation coefficients. Non-significant
correlations (> 0.05) are represented as an X.
Additionally, urinary hippurate was found associated with healthy metabotype and signifi-
cantly correlated with polyphenols detected in the negative ESI mode (Figure 3.16). Polyphe-
nol dietary intake, from tea consumption in particular, was shown to be a major source of
urinary hippurate and to increase the urinary abundance of phenylsulfate substances includ-
ing pyrocatechol sulfate, O-methoxycatechol-O-sulphate and vanillin 4-sulfate (van der Hooft
et al., 2012). In the liver, hippurate (or benzoylglycine) is synthesised by the conjugation of
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benzoic acid with glycine. Renal clearance of hippurate is influenced by two dietary sources,
the consumption of foods containing benzoic acid and by the degradation of phenolic com-
pounds by the gut microbiota (Lees et al., 2013).
The bacterial metabolism of tea polyphenols, such as catechins, which are not signifi-
cantly absorbed in the small intestine, are broken-down by the colonic microbiota to smaller
bioavailable phenolic molecules. Via  -oxidation, the colonic microbiota converts phenolic
degradation products, such as phenylpropionic acids, to benzoic acid which are then elim-
inated as hippurate (Walsh et al., 2007). A healthy diet, containing whole grains, fatty fish,
and bilberries, has been shown to increase phenolic metabolites levels (such as hippurate
and pyrocatechol sulfate) in blood (Hanhineva et al., 2015).
Proline betaine was found significantly (p <0.001) up-regulated in cancer patients urinary
profiles, compared to control groups. This betaine derivative, or trimethylated amino acid, is
proposed to play an osmoprotective role for the kidney (Chambers and Kunin, 1987). Greater
urinary elimination of proline betaine has also been found in patients with other malignant
tumours, such as lung cancer (Duarte et al., 2013) and HCC (Chen et al., 2009). Proline
betaine is abundant in citrus fruits and was recently recognised as a putative marker of their
dietary consumption (Heinzmann et al., 2010). Without comprehensive dietary intake data
available for CCA patients, it is difficult to draw any firm conclusions on this observation.
3.5.2 Gender influence on the metabolic profile
Variation in the genetic background, physiology, muscle bulk, lifestyle and dietary habits
between men and women translate into intrinsic phenotypic differences between the two
genders, an issue that has been addressed in several metabonomics studies (Baxmann
et al., 2008; Kochhar et al., 2006; Rasmussen et al., 2012). Males showed greater urinary
excretion of creatinine (p 0.017) and leucylproline (p 0.014). Higher levels of creatinine in
urine were found to be associated with the metabolic signature of male gender (Kochhar
et al., 2006), lean individuals (Kochhar et al., 2006) and high protein diet (Baxmann et al.,
2008; Rasmussen et al., 2012) and was directly correlated with muscle mass and moder-
ate/intense physical activity (Baxmann et al., 2008). Leucylproline (a dipeptide formed from
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the amino acids leucine and proline) loss in the urine is hypothesised to be a product of
incomplete breakdown of protein digestion, and possibly excreted due to cancer cachexia
(Wang et al., 2010).
The study participants were mainly farmers from the outskirts of Khon Kaen. Men there
are typically fishermen, a job requiring muscular strength and high physical activity. They
also tend to eat freshly caught fish as convenient and affordable source of protein during
the working day. The nature of their job and greater protein intake possibly contributed
to this observation between Thai men and women. Urine from females contained higher
amounts of two markers of bone collagen degradation, prolylhydroxyproline (p 0.010) and 4-
hydroxyproline (p< 0.001). Urinary prolylhydroxyproline was assessed as diagnostic marker
of osteoporosis in postmenopausal women and yield a sensitivity of 74.3% and specificity
of 90.8% (AUC= 0.903) at the cut-off value of 10.2 µmol/mmol of creatinine (Husek et al.,
2007).
3.5.3 The effect of opisthorchiasis and periportal fibrosis on the metabolic profile
Supervised OPLS-DA models, calculated to examine difference between the control groups
were not predictive. Individuals with opisthorchiasis showed similar metabolic fingerprint to
those at risk. OPLS-regression model was trained using faecal egg counts as a continuous
outcome variable to identify urinary metabolites associated with liver fluke infection, but,
it did not produce a positive result. This was expected due to a number of confounding
factors: 1) the at risk group are potentially harbouring O. viverrini ; at a low worm burden
(< 20 worms) the FECT test fails to detect eggs in faeces; 2) egg counts of opisthorchiasis
participants ranged between 6-880 eggs per gram of faeces, indicating a light to moderate
infection with a worm burden of <15 to 62 worms, whereas the worm load detected in severe
cases reached greater number (up to 651 worms producing 50,000 eggs); 3) the number of
O. viverrini eggs detected in faeces do not necessarily correlate with the severity of infection
as repeated treatment with the anti-helminthic, Praziquantel, could falsely impact the results
(Sithithaworn et al., 1991).
Similarly, the multivariate models calculated using the spectral profiles of participants with
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positive ultrasound screening for PPF against the spectral profiles from individuals with neg-
ative ultrasonography (the at-risk and opisthorchiasis groups) were non-discriminant. How-
ever, an increase in urinary acylcarnitine excretion was observed in PPF individuals com-
pared to CCA patients and normal controls in univariate analysis.
3.5.4 The metabolic profile associated with cholangiocarcinoma
Supervised analysis using OPLS-DA was calculated to examine group differences after ex-
cluding exogenous metabolic features and xenobiotics attributed to the exposure to drugs,
caffeine and nicotine from the raw spectral data. Pronounced urinary metabolic signature
characterised by perturbations in purine metabolism and alterations in lipid classes including
bile acids, acylcarnitines and steroids was associated with patients bearing biliary malignant
tumours.
3.5.4.1 Purine metabolism
Purine metabolism has been implicated in carcinogenesis and reported to be altered in the
urine biochemical profiles of liver cancer patients (Kim et al., 2016; Kimhofer et al., 2015). In
CCA patients, urinary elimination of uric acid was found to be significantly up-regulated while
hypoxanthine and 1-methylhypoxanthine (a hypoxanthine with methyl group) were down-
regulated, compared to the control group. Uric acid is a renal breakdown product, derived
from the oxidation of hypoxanthine by the enzyme xanthine oxidoreductase (XOR), Figure
3.17, an enzyme associated with oxidative stress, cancer aggressiveness and poor clinical
outcome (Fini et al., 2012).
Murakami, Y. et al. compared the metabolic profiles of resected intrahepatic CCA tumours
to their corresponding benign tissues and to tissues from HCC tumours in a Japanese co-
hort (Murakami et al., 2015). Only hypoxanthine and taurine (both over-expressed) allowed
iCCA to be distinguished from HCC and from their adjacent non-cancerous tissue (Murakami
et al., 2015). Interestingly, hypoxanthine phosphoribosyltransferase 1 (HPRT1) was recently
identified as an internal reference gene candidate in CCA and adjacent non-neoplastic tis-
sue (Yang et al., 2016). Hypoxanthine-guanine phosphoribosyltransferase (HPRT), enzyme
encoded by the HPRT1 gene, is involved in the generation of purine nucleotides through the
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purine salvage pathway, Figure 3.17 (Duan et al., 2004). Thus, elevated hypoxanthine in
tissue could result from increase HPRT activity and suggests that the purine de novo syn-
thesis could have been substituted by the salvage pathway to support proliferative activity in
CCA; salvaging the purine ring is preferential as long as hypoxanthine is available for energy
conservation and it is more efficient in terms of ATP equivalents (Kondo et al., 2000).
salvage
breakdown
synthesisde novo PRPPRibose-5-P
IMP
Inosine
Hypoxanthine
HPRT
PRPP
GMP
Xanthine
Uric acid
XOR
XOR
Guanine
HPRT
AMP
Adenine
PRPP
Figure 3.17: Metabolic scheme of purine metabolism.
Key: a-D-5-phosphoribosyl-1-pyrophosphate (PRPP), xanthine oxidoreductase (XOR), hypoxanthine
phosphoribosyltransferase (HPRT).
Urinary 7-methylguanine, a methylated purine, was found in greater quantities in patients
with biliary carcinoma. Human exposure to methylating genotoxic agents, such as N-nitros-
amines (including tobacco-specific nitrosamines), results in the formation of DNA adducts,
of which 7-methylguanine is produced in the greatest abundance in various biological spec-
imens such as white blood cells (van Delft et al., 1992), DNA (Haque et al., 1997) and
urine (Chao et al., 2005). In animal models, the concentration of 7-methylguanine was
greater in urine of rats bearing malignant ascites (Hanski and Stehlik, 1980). Increased 7-
methylguanine is possibly linked to dietary N-nitrosamine exposure in the Thai population
as discussed in Chapter 1.1.2.1, rather than nicotine smoking as reported by Chao and col-
leagues (Chao et al., 2005). In their experiment, urinary 7-methylguanine was found to be
significantly (P < 0.01) up-regulated in smokers (4215 ±1739 ng/mg creatinine) compared
to non-smokers (3035 ± 720 ng/mg creatinine).
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In this cohort, the relative concentration of 7-methylguanine did not differ between smokers
and non-smokers in each of the control groups (Figure 3.18.A) and the greatest urinary lev-
els were found in the CCA group followed by non-smokers with opisthorchiasis. In the urine
metabolome from smokers, cotinine negatively correlated with 7-methylguanine (r= -0.04,
Figure 3.18.B). Additionally, associations between between 7-methylguanine and nicotine-
related analytes were observed only with cotinine Figure 3.18.C. However, although the
correlation between the urinary elimination of cotinine and 7-methylgunine was statistically
significant (p <0.05), the correlation coefficient (r= 0.37) suggest that the relationship be-
tween the two compounds was not biologically related.
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Figure 3.18: Impact of tobacco smoking on 7-methylguanine relative abundance in urine.
A) the relative abundance of urinary 7-methylguanine between smokers and non-smokers; B) correlation
between urinary levels of 7-methylguanine and cotinine for smokers; and C) heatmap showing correlation
between the urinary levels of nicotine-related analytes and 7-methylguanine.
3.5.4.2 Acylcarnitine metabolism
Acylcarnitine derivatives were present at different concentrations in the urine of CCA patients
compared to levels reported in the urine of controls, particularly compared to patients with
biliary fibrosis. Acylcarnitines are intermediates in the energy metabolic pathway of fatty
acid  -oxidation, which is a key pathway in tumorigenesis (Carracedo et al., 2013). They
play prominent roles in transporting long-chain fatty acids across the mitochondrial mem-
brane, a tightly regulated system known as the “carnitine shuttle”. This involves a multi-step
process, initiated once fatty acids enters the cellular cytosol and are subsequently activated
by esterification to Coenzyme A before they can undergo oxidative degradation (Ramsay
et al., 2001). The carnitine shuttle facilitates the transport of the impermeable long-chain
acyl-CoAs into the inner-mitochondrial membrane via their corresponding carnitine ester
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forming fatty-acylcarnitine, a process occurring at the outer mitochondrial membrane where
carnitine palmitoyltransferase 1 (CPT1) exchanges the CoA moiety for carnitine. In the intra-
mitochondrial matrix, carnitine palmitoyltransferase 2 (CPT2) converts acylcarnitine back to
acyl-CoA, thereby providing substrates for  -oxidation, which generate ATP via the TCA and
respiratory chain (Ramsay et al., 2001).
Perturbation in acylcarnitines have been implicated in various pathological conditions, in-
cluding cancer. Their profile in malignant disease appears to be specific to tumour pheno-
types. In cell lines from colon cancer, the levels of acyl-, isovaleryl- , butyryl- and isobutyryl-
carnitine were greater than in ovarian cancer cells. This was also combined by an increase
in deoxycarnitine, a carnitine precursor (Halama et al., 2015). The urinary excretion of acyl-
carnitine in individuals with kidney cancer was found to be grade-dependent; acylcarnitines
were depleted in early stage, then steadily increased in the urine of patients with grades 2
and 3 tumours. The abundance of carnitine species derived from amino acid catabolism, 2-
methylbutyrlycarnitine (C5), hydroxyisovalerylcarnitine (C5-OH), isobutyrylcarnitine (isoC5)
and glutaroylcarnitine (C5-DC) and from fatty acid oxidation (C2 and C3) significantly cor-
responded to tumour grade status in kidney cancer, particularly between grade 1 and the
other advanced grades (Ganti et al., 2012).
Kim et al. investigated the metabolic linkage between the urinary metabotype and encoding
genes in bladder cancer. The urinary levels of carnitine and several acylcarnitines (e.g.
isovalerylcarnitine and octenoylcarnitine) were increased, and melatonin, glutarylcarnitine,
and decanolycarnitine, were decreased in bladder cancer compared to healthy controls. The
tissue mRNA expression related to acylcarnitine and carnitine metabolism (CPT1, CPT2,
CACT, carnitine/acylcarnitine translocase (CACT)) were down-regulated, which the author
proposed to result in elevated urinary acylcarnitine excretion from bladder cancer tissue (Kim
et al., 2014).
In my study, acylcarnitines were mainly depleted in CCA urine samples and considerably
increased in presence of biliary fibrosis. In the contrast, urinary short- and medium-chain
acylcarnitines were significantly increased in HCC patients compared to patients with cir-
rhosis (Shao et al., 2014). The authors identified butyrylcarnitine (C4) and hydantoin-5-
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propionic acid as potential markers to distinguish between HCC and cirrhosis with AUC of
0.786 and 0.773 for discovery and validation datasets, respectively. Using serum LC- and
GC-MS metabolic phenotyping, Bell et al. identified increase in several medium- and long-
chain acylcarnitines, along with an increase in circulating free fatty acids in cholestatic bil-
iary diseases (primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) (Bell
et al., 2015). They attributed this observation to mitochondrial impairment and to decreased
fatty acid oxidation, which have been shown to play a key role in long-term cholestasis (Ar-
duini et al., 2012). The serum metabolome characterisation in potentially pre-malignant
cholestatic conditions could provide an insight into the changes observed in PPF patients
in my study. It is unknown whether in this cohort patients with PPF were cholestatic, but,
cholestatic damage is a common biliary tract complication secondary to liver fluke infection
(IARC, 2012). Thus, in PPF patients altered hepatic lipid metabolism could be similar to
those observed in cholestasis. An acylcarnitine assay is a promising prognostic approach
to detect liver damage induced by O. viverrini, and may hold diagnostic utility to distinguish
between CCA and PPF patients.
3.5.4.3 Cholesterol and its metabolites
Cholangiocarcinogenesis had a profound impact on the urinary elimination of cholesterol-
related lipid classes, bile acids and steroid hormones. Glycine- and taurine-conjugated bile
acids were significantly increased in urine from CCA patients compared to all control groups.
Studies investigating bile metabolic profiles differentiated between benign biliary disease and
CCA, with bile acids significantly elevated in bile from patients with CCA (AbdAlla et al., 2011;
Sharif et al., 2010). Urinary elimination of bile acids is likely to be related to jaundice, which
is a common manifestation of CCA and results from an obstruction to bile flow caused by
the growing tumour (Sripa et al., 2007). Thus, bile acids per se are unlikely to be biologically
relevant as a biomarker of early tumour activity.
In line with the disturbed metabolism of bile acids, the presence of cancerous bile duct tu-
mours had a profound impact on steroidogenesis. Three glucuronidated steroids in negative
ESI mode (cortolone-3-glucuronide, tetrahydroaldosterone-3-glucuronide and 11 -hydroxy-
androsterone-3-glucuronide) and two unidentified metabolites (m/z 465.2 and m/z 331.1)
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with fragmentation pattern of steroids (m/z 113, 95, 85, and 75) were depleted in the urine
profiles of CCA patients. Urinary steroids have been implicated in hepatic toxicity in ani-
mals (Kumar et al., 2012). Steroid species were first discovered, in association with CCA,
using UPLC-TOF-MS then quantified by GC- and CE-MS in rats with induced-hepatic toxi-
city by Kumar and colleagues (Kumar et al., 2012). They demonstrated decreased urinary
concentrations of 11 -OH-androsterone, epiandrosterone and oestrone, and elevated levels
of 11-dehydrocorticosterone following hepatotoxicity. The authors attributed the increase in
corticosteroids to stress conditions, and the decrease in androgens and oestrogens to liver
damage.
Global profiling of the urinary metabolic signature in patients with cirrhosis identified a num-
ber of significantly depleted steroid glucuronides compared to healthy controls (Wang et al.,
2012). The same group further investigated such changes in a targeted, quantitative analy-
sis of the steroid metabolome (Dai et al., 2014). A decreased urinary steroid hormone pat-
tern was associated with cirrhotic and early HCC patients. Two steroid markers (epitestos-
terone and allotetrahydrocortisol) successfully detected early HCC from cirrhosis (AUC=
0.94), compared to the standard serum tumour marker, ↵-fetoprotein (AFP) (AUC= 0.60).
The data obtained prompted the authors to hypothesise that hepatocellular injury and re-
duction of hepatic blood flow impaired the liver capacity to biotransform lipophilic substrates
via phase I (introduction of functional groups) and phase II (conjugations) to hydrophilic,
readily excretable metabolites.
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3.6 Conclusions
This exploratory study provides proof-of-concept to further pursue development of urinary
metabolic markers of CCA. The progression from liver fluke infection to accumulation of scar
tissue around the bile ducts was associated with a marked increase in acylcarnitine species.
The metabolic shift in presence of malignant biliary tract tumours was more pronounced.
Metabolic reprogramming to cope with the high energy demand in proliferation was evident
in CCA urinary metabolome. The perturbation in purine metabolism intermediates suggest
shifting from de novo purine synthesis to a more efficient salvage pathway for synthesis of
nucleic acids to support CCA-genesis. A metabolic switch to promote fatty acid oxidation
could explain the depletion of acylcarnitine metabolites in CCA; a mechanistic approach to
support cancer cells in hypoxic microenvironment (Ackerman and Simon, 2014). Compro-
mised lipid metabolism, in bile acid and steroid homeostasis, is potentially a reflection of
jaundice status and hepatic injury, respectively.
It is worth noting that the identification of biomarker candidates, per se, is not problem-
atic. The difficulty lies in the validation and preclinical verification of these putative markers.
Therefore, with great effort from the collaborators at Khon Kaen University, an external sam-
ple set was collected, with greater sample number, to augment the findings (Chapter 4).
Chapter 4
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4.1 Abstract
BackgroundGlobal LC-MS profiling in a Thai population identified a urinary metabolic signature inO.
viverrini-induced cholangiocarcinoma (CCA), primarily characterised by disturbance in acylcarnitine,
bile acid, steroid and purine metabolism. However, the detection of thousands of analytes by MS in
a biological sample in a single experiment potentially introduce false discovery error. To verify these
metabolic perturbations, a second dataset from the same population was profiled in similar fashion.
Methods Reversed-phase ultra-performance liquid-chomatography mass spectrometry (RP-UPLC-
MS) was utilised to acquired the global spectral profile of 98 spot urine samples (from 46 healthy
volunteers and 52 CCA patients) recruited from Khon Kaen, Thailand.
Results Metabolites were differentially expressed in the urinary profiles from CCA patients. High
urinary elimination of bile acids was affected by the presence of obstructive jaundice. The urine
metabolome associated with non-jaundiced CCA patients showed a distinctive pattern, similar but
not identical to Cohort I. A panel of 10 metabolites achieved a diagnostic accuracy of 93.4% and
AUC value of 98.8% (CI= 96.3%-100%).
Conclusion Global characterisation of CCA urinary metabolome identified a number of metabolites
of biological interest in two cohorts. Analyses of the diagnostic utility of the discriminant metabo-
lites showed excellent performance, compared to the conventional tumour marker, CA 19-9, which
have been reported to have a sensitivity and specificity of 40-70% and 50-80%, respectively in CCA
patients.
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4.2 Introduction
In the previous chapter, a number of metabolic derangements were found to be characteris-
tic of CCA urinary metabotype. Mass spectrometry is a key analytical platform for metabo-
nomics; it offers sensitive and precise metabolite recovery from a given biospecimen. How-
ever, the simultaneous detection of thousands of analytes in a relativity small sample set can
potentially introduce false positive findings despite correction for multiple testing using Bon-
ferroni or similar test. (Parker and Borchers, 2014). As a result, rigorous biomarker testing is
required prior to their clinical implementation. The biomarker discovery pipeline consists of
a sequence of preclinical phases, starting with an exploratory phase in a small pilot dataset
(e.g. 10 samples) then typically followed by a verification phase on a set of 10–50 samples.
Quantifying key biomarkers (e.g. <10) on 100-500 samples is then recommended before
the final clinical validation, ideally on 500–1000 biological samples (Parker and Borchers,
2014).
I made a planned visit to Khon Kaen University on November 2015 to discuss limitations en-
countered in Cohort I with the research team. Providing sufficient clinical data and greater
sample size were the most important factors to overcome in this cohort. The outcome of
the discussion was a second sample set (n= 100) which was received in December 2015 to
augment the findings. A total of 52 urine specimens from patients with CCA were collected
from the Specimen Bank of the Liver Fluke and Cholangiocarcinoma Research Center, Fac-
ulty of Medicine, Khon Kaen University, similar to Cohort I. However, it was not possible
because of time and resource restrictions to collect control samples from the field screening
program across North-East Thailand (CASCAP), therefore, healthy volunteers were selected
from Khon Kaen as a control group for the study. The same metabolic profiling pipeline was
implemented throughout the study from sample preparation to analytical procedures and
statistical analysis.
An important aspect of this study was to promote the transitioning from biomarker discovery
to biomarker validation and to assess the reproducibility of the assay in detecting metabolic
alterations associated with the urine metabolome in CCA patients.
116
4.3 Methodology
4.3.1 Sample collection
The study consisted of 98 spot urine sample, (n= 52) from participants with CCA and (n= 46)
from healthy volunteers. Patients with CCA were recruited from the in-patient population of
Khon Kaen Hospital, Khon Kaen, Thailand. CCA was diagnosed by CT or MRI and further
confirmed by histology after surgical operation. Healthy volunteers were recruited from Khon
Kaen Hospital and Khon Kaen University staff and students. Both cohorts were collected
from ”Isaan” people, who are an ethnic community native to the Northeastern region of
Thailand.
4.3.2 Ethical considerations
Urine samples were obtained from the Specimen Bank of the Liver Fluke and Cholan-
giocarcinoma Research Center, Faculty of Medicine, Khon Kaen University. The study
was approved by the Human Research Ethics Committee, (reference no. HE571283 and
HE521209). Written, informed consent was obtained from each participant prior to recruit-
ment.
4.3.3 Sample transport, preparation and MS analysis
A courier service transported the samples (frozen on dry ice) from Khon Kaen University
to St. Mary’s Hospital, Liver Unit, London, UK. They were kept stored at -80  C at until
LC-MS analysis, using the same protocol outlined in Chapter 3. The spectra of the sam-
ples were acquired using the same MS instrument as described in the previous chapter,
ACQUITYTM UPLC system (Waters Ltd. Elstree, U.K.) coupled to a LCT PremierTM mass
spectrometer (Waters MS Technologies, Ltd., Manchester, U.K.). LC-MS conditions, spectral
pre-processing and metabolite annotation were as described in Chapter 3.
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4.3.4 Statistical analysis
The spectral data matrix was imported to SIMCA-P+ version 13.0.2 (Umetrics, Sweden) for
multivariate statistical analysis and feature selection. Univariate significance tests and cor-
relation analysis were performed in R Project version 3.1.0 (The R Foundation for Statistical
Computing, 2014), using the same methods defined in Chapter 3.
MetaboAnalyst v3.0 platform (http://www.metaboanalyst.ca/) was used to assess the clinical
utility potential of the biomarkers (Xia et al., 2015). The receiver operating characteristic
(ROC) curve and the area under the curve (AUC) were calculated for individual markers
and for possible marker combinations. In the univariate mode, the discrimination potential of
each feature was assessed by testing all possible cut-off values within all data points. The
sensitivity and specificity of each marker was then calculated at the best cut-off value.
The multivariate testing of marker combinations produced ROC curves, based on the cross-
validation performance of the Random Forest algorithm. Subsequently, the software pro-
duced a plot illustrating the order of the features, based on the ”frequency of being se-
lected”, which showed the stability of the rank of the metabolites. The confidence bounds
of the AUCs were measured, based on re-sampling approach, using bootstrapping for the
univariate AUCs or Monte Carlo cross-validation for the multi-panel biomarker analysis (Xia
et al., 2015).
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4.4 Results
4.4.1 Demographics, clinical data and cohort description
A total of 100 urine samples were acquired using global LC-MSmetabolic profiling in January
2016. Two samples were found to be mislabelled upon receiving the clinical information in
September 2016. One participant had ampullary carcinoma, whereas, the medical condition
of the second individual was not specified. Spectra from both individuals were excluded
from the subsequent statistical modelling processes. Patients with CCA were notably older
than the healthy group (mean age= 59 years vs. 31 years, respectively). Healthy volunteers
were comprised mostly of women with approximately 74%, compared to 46.3% women in
the CCA group, Table 4.1. The majority of CCA patients presented with tumours in the
intraheptic (44%) or perihilar (40%) bile ducts. Only 15% of the CCA cohort had distal
tumours. The age distribution was relatively similar among the groups. Patients with distal
tumours were mostly males (62.5%), whereas, the intrahepatic group had 47.8% males.
The serum levels of liver transaminases, ALT and AST, and alkaline phosphatase (ALP)
were greatly elevated in patients with distal biliary tumours, and close to the normal range in
patients with intrahepatic bile duct tumours (iCCA). Approximately half of the cases (46.1%)
presented with obstructive jaundice, particularly among patients with perihilar (pCCA) and
distal (dCCA) tumours. None of the iCCA patients were jaundiced.
Table 4.1: Demographics of study population.
Characteristic 
Cholangiocarcinoma  
Healthy 
All cases iCCA pCCA dCCA 
Participants,  n 52 23 21 8 46 
Age, mean, (range), y 59.0 (35–76) 59.7 (38–68)  59.0 (37–76) 55.4 (35–72) 31.1 (22-62) 
Male, % 53.7 47.8 57.1 62.5 26.1  
Serum biochemistry ,  mean, 
(range),      
Alanine aminotransferase,                           
(U/L)  57.4 (7 – 529) 30.2 (7 – 105) 67.1 (14 –163) 119.4 (20 –529) -  
Aspartate aminotransferase, 
(U/L) 73.6 (13 – >700) 37.8 (13 – 110) 82.5 (23 –311)  164.9 (32 –700) -  
Alkaline phosphatase, (U/L) 324 (49 – 1124)  144.6 (49 – 367) 295.6 (74–1124)  321.2 (63 – 843) -  
Biliary obstruction,  
(jaundice %) 46.1 0 85.7 75 0 
Abbreviations: intrahepatic cholangiocarcinoma (iCCA); perihilar cholangiocarcinoma (pCCA); distal cholangiocarcinoma (dCCA). 
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4.4.2 Global overview of study samples
A total of 109 samples, including 11 QCs in blue, were used to calculate PCA models for
the positive mode, Figure 4.1a, and negative mode spectral data, Figure 4.1b. Good QC
clustering trends in the middle of the PCA plots indicated good instrument reproducibil-
ity, but, CCA samples (in red), were scattered with several outlier samples outside the
95% confidence interval in both ESI modes. Upon examining their raw spectral profiles,
several features attributed to drug intake were present in high concentrations (Table 4.2).
Nine out of the top ten features that discriminated CCA patients from healthy controls us-
ing OPLS-DA were related to drug intake, predominantly antibiotics (Ceftriaxone, Metron-
idazole and Ofloxacin). Only one metabolite, hippurate, was endogenous and was found
greater in the urine metabolome from the healthy group, Table 4.2. Features of drug and
drug co-metabolites were excluded using correlation analysis between each feature and the
metabolic data matrix.
(a) PCA scores plot - positive mode
R2X= 31% and Q2X= 16% from 2 PC model.
(b) PCA scores plot - negative mode
R2X= 21% and Q2X= 1% from 2 PC model.
Figure 4.1: PCA scores plots of test samples and quality control (QC) samples derived from
UPLC-MS urinary data (n= 109 participants and n= 11 QCs) for (a) positive and (b) negative
ion mode.
Table 4.2: Differential metabolites between cholangiocarcinoma patients and controls.
m/z RT Compound Class Adduct Mass Error VIP
396.044 3.86 Ceftriaxone Antibiotic Fragment 1 6.2
172.072 2.89 Metronidazole Antibiotic M+H 1 6.1
555.054 3.86 Ceftriaxone Antibiotic M+H 1 6.1
128.045 2.89 Metronidazole Antibiotic Fragment 1 5.0
105.033 3.80 Hippurate Gut microbiota metabolite Fragment 2 4.4
362.151 3.98 Ofloxacin Antibiotic M+H 0 4.0
459.274 4.20 Prednisolone tebutate Steroid M+H 0 4.0
152.071 2.42 Paracetamol Analgesic M+H 2 3.9
289.227 5.01 Bupivacaine Local anaesthetic M+H 1 3.7
503.306 4.31 Unknown Drug 3.7
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4.4.3 Gender effect on the metabolic profile
PCA and OPLS-DA models were calculated using samples from men (n= 40) and women
(n= 58) to examine the impact of gender on the urine metabolome. The PCA did not show
any clustering trend, based on gender. The OPLS-DA was discriminant in positive mode,
Q2Y= 32%, (Figure 4.2c), and negative mode, Q2Y= 29%, (Figure 4.2d). Compounds
contributing to the gender discrimination are listed in Table 4.3.
(a) PCA scores plot - positive mode
R2X= 18% and Q2X= 9% from 2 PC model.
(b) PCA scores plot - negative mode
R2X= 20% and Q2X= 8% from 2 PC model.
(c) OPLS-DA scores plot - positive mode
R2Y= 80%, R2X= 18% and Q2Y= 32%,
CV-ANOVA <0.001, from one predictive and two orthogonal
components model.
(d) OPLS-DA - negative mode
R2Y= 74%, R2X= 18% and Q2Y= 29%,
CV-ANOVA <0.001, from one predictive and two orthogonal
components model.
Figure 4.2: PCA scores plots for (a) positive and (b) negative ion mode mass spectra of
males and females. The corresponding OPLS-DA scores plots for (c) positive and (d) nega-
tive ion mode data.
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4.4.4 The impact of age on the metabolic profile
OPLS models were calculated using age as continuous variable. The model was discrimi-
nant in positive mode, Q2Y= 57%, (Figure 4.3a), and negative mode, Q2Y= 55%, (Figure
4.3b). Compounds contributing to the age discrimination are listed in Table 4.4.
(a) OPLS scores plot - positive mode
R2Y= 74%, R2X= 16% and Q2Y= 57%
from one predictive and one orthogonal components model.
(b) OPLS scores plot - negative mode
R2Y= 79%, R2X= 15% and Q2Y= 55%
from one predictive and one orthogonal components model.
(c) Permutation test - positive mode
CV-ANOVA <0.001.
(d) Permutation test - negative mode
CV-ANOVA <0.001.
Figure 4.3: OPLS scores plots of (a) positive and (b) negative ion mode data computed
using age as a continuous Y variable.
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Table 4.3: Gender discriminant compounds.
m/z RT Tentative assignment Adduct Mass error VIP p-value Trend 
Identiﬁ
cation* 
328.248 6.12 Acylcarnitine - - 5.2 0.009 Male c 
287.1 3.83 Unknown - - 4.9 NS Female d 
188.071 3.15 3-amino-2-naphthoic acid M+H 2 4.8 NS Male b 
144.102 0.57 Proline betaine M+H 0 4.8 0.035 Male b 
132.077 0.52 Creatine M+H 1 4.5 0.006 Female b 
114.066 0.51 Creatinine M+H 1 3.9 NS Male a 
162.112 0.49 L-Carnitine M+H 2 3.7 0.025 Male a 
105.033 3.79 Hippurate Fragment - 3.6 NS Female a 
318.191 3.77 Acylcarnitine (C9-OH) M+H - 3.5 NS Male c 
314.232 5.62 Acylcarnitine (C10:1) M+H - 3.3 0.017 Male c 
 
212.001 3.72 Indoxyl sulfate M-H 6 6.9 NS Male a 
528.262 6.49 Glycochenodeoxycholate-N-sulfate M-H 3 5.4 0.014 Male b 
528.263 6.33 Glycochenodeoxycholate-N-sulfate M-H 1 5.1 NS Male b 
191.017 1.02 Citrate M-H 14 4.6 0.004 Female a 
178.05 3.79 Hippurate M-H 5 4.4 NS Female a 
204.98 2.72 Unknown - - 4.0 0.012 Female d 
287.021 4.08 DHPV O-sulfate M-H 7 3.8 0.039 Female b 
243.032 5.31 4-phenylbutanic acid-O-sulphate M-H 6 3.7 NS Male b 
510.252 6.73 Unidentiﬁed bile acid - - 3.4 0.002 Male c 
331.174 5.98 17α-hydroxyprogesterone M-H - 3.2 0.049 Female c 
RT= retention time;  VIP= variable importance in projection score; NS= not signiﬁcant. 
*Level of metabolite identiﬁcation: (a) Identiﬁed compound; (b) putatively annotated compound; (c) putatively characterised compound class; and 
(d) Unknown. 
Table 4.4: Age discriminant compounds.
m/z RT Tentative assignment Adduct Mass error VIP Trend† Identiﬁcation* 
105.033 3.79 Hippurate Fragment - 5.6 ↓ a 
144.102 0.57 Proline betaine M+H 0 4.6 ↑ b 
188.071 3.15 3-amino-2-naphthoic acid M+H 2 4.6 ↑ b 
114.066 0.51 Creatinine M+H 1 4.5 ↑ a 
310.201 5.20 Acylcarnitine (C10:3) M+H - 4.4 ↓ b 
328.248 6.12 Acylcarnitine - - 4.2 ↑ c 
287.1 3.83 Unknown - - 4.1 ↓ d 
286.201 4.93 Acylcarnitine (C8:1) M+H  4.1 ↓ b 
318.191 3.77 Acylcarnitine (C9-OH) M+H - 3.0 ↑ b 
300.217 5.24 Acylcarnitine  - - 2.9 ↓ c 
        
178.05 3.79 Hippurate M-H 5 6.6 ↓ a 
212.001 3.72 Indoxyl sulfate M-H 6 5.9 ↑ a 
528.262 6.49 Glycochenodeoxycholate-N-sulfate M-H 3 5.2 ↑ b 
331.174 5.98 17α-hydroxyprogesterone M-H - 4.2 ↓ b 
191.017 0.91 Isocitrate M-H 14 4.1 ↓ a 
263.102 3.83 Phenylacetylglutamine M-H 6 3.8 ↑ b 
191.017 1.02 Citrate M-H 14 3.2 ↓ a 
243.032 5.31 4-phenylbutanic acid-O-sulphate M-H 6 2.9 ↑ b 
287.021 4.08 DHPV O-sulfate M-H 7 2.8 ↓ b 
514.284 5.91 Taurocholic acid      M-H 0 2.8 ↑ a 
RT= retention time;  VIP= variable importance in projection score; NS= not signiﬁcant. 
*Level of metabolite identiﬁcation: (a) Identiﬁed compound; (b) putatively annotated compound; (c) putatively characterised compound class; and (d) 
Unknown. 
†Increase with age (↑) and decrease with age (↓) 
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4.4.5 Cancer patients vs. healthy volunteers
The PCA model of the urine metabolic profiles of healthy Thai participants compared to
CCA patients showed clustering trend between the two groups in both ESI modes, Figure
4.4a&b. The OPLS-DA statistics showed enhanced separation in both modes with excel-
lent reproducibility (Figure 4.4c, positive mode Q2Y= 76% and Figure 4.4d, negative mode
Q2Y= 65%). The permutation test and CV-ANOVA p-value(<0.001) confirmed the model
robustness, Figure 4.4e&f.
(a) PCA scores plot - positive mode
R2X= 18% and Q2X= 9% from 2 PC model.
(b) PCA scores plot - negative mode
R2X= 20% and Q2X= 8% from 2 PC model.
(c) OPLS-DA scores plot - positive mode
R2Y= 84%, R2X= 18% and Q2Y= 76%,
from one predictive and one orthogonal components model.
(d) OPLS-DA scores plot - negative mode
R2Y= 81%, R2X= 15% and Q2Y= 65%,
from one predictive and one orthogonal components
model.
(e) Permutation test - positive mode
CV-ANOVA <0.001.
(f) Permutation test - negative mode
CV-ANOVA <0.001.
Figure 4.4: PCA scores plots for (a) positive and (b) negative ion mode data of CCA patients and healthy
volunteers. OPLS-DA scores plots showing group separation for both (c) positive and (d) negative ion mode
data and the corresponding permutation tests for (e) positive and (f) negative ion mode data.
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4.4.6 Impact of tumour location on the metabolic profile
To address the impact of the anatomical location of CCA tumours on the endogenous
metabolite profile, OPLS-DA models were computed using the spectral data from iCCA,
pCCA and dCCA. All models projected poor classification (Table 4.5), particularly between
perihilar and distal tumours (ESI+, Q2Y= -85%, p= 1.0 and ESI , Q2Y= -58%, p= 1.0) in-
dicating a very similar urine metabolome. Perihilar and intrahepatic tumours also showed
relatively indistinguishable molecular profiles, based on the model statistics in positive (Q2Y=
4% and p= 0.770) and negative ionisation mode (Q2Y= 3% and p= 0.832).
The OPLS-DA model comparing the urinary metabolic profiles of patients with intrahepatic
against distal tumours generated Q2Y values of 18% and 15% in ESI+ and ESI , respec-
tively, but, their CV-ANOVA scores were not significant.
Table 4.5: Model statistics from OPLS-DA models computed based on the tumours anatom-
ical location.
 Statistics Perihilar Distal 
POS NEG POS NEG 
Intrahepatic 
Q2 4% 3% 18% 15% 
R2X 19% 17% 30% 29% 
R2Y 69% 73% 93% 90% 
CV-ANOVA 0.770 0.832 0.376 0.645 
Distal 
Q2 -85% -58%   
R2X 11% 17%   
R2Y 88% 65%   
CV-ANOVA 1 1   
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4.4.7 Cholangiocarcinoma patients with jaundice vs. non-jaundiced patients
To assess the impact of obstructive jaundice, a supervised model was calculated using the
spectral data from jaundiced patients, compared to non-jaundiced CCA patients. The model
was discriminant in both ESI modes ( positive Q2Y= 26% and negative Q2Y= 25%). The
CV-ANOVA p-value and the permutation test indicated reliable metabolic difference between
the two groups, Figure 4.5.
(a) PCA scores plot - positive mode
R2X= 23% and Q2X= 8% from 2 PC model.
(b) PCA scores plot - negative mode
R2X= 23% and Q2X= 2% from 2 PC model.
(c) OPLS-DA scores plot - positive mode
R2Y= 86%, R2X= 24% and Q2Y= 26% ,
from one predictive and one orthogonal components model.
(d) OPLS-DA scores plot - negative mode
R2Y= 82%, R2X= 24% and Q2Y= 25% ,
from one predictive and two orthogonal components model.
(e) Permutation test - positive mode
p value= 0.023.
(f) Permutation test - negative mode
p value= 0.033.
Figure 4.5: PCA scores plots for (a) positive and (b) negative ion mode data of cholangiocarcinoma patients
with jaundice and non-jaundiced patients. OPLS-DA scores plots showing group separation for both (c) positive
and (d) negative ion mode data and the corresponding permutation tests for (e) positive and (f) negative ion
mode data.
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Table 4.6 lists the discriminant metabolites generated from the OPLS-DA model of CCA pa-
tients with jaundice, compared to non-jaundiced CCA patients. The whisker plots (Figure
4.6) demonstrate the univariate significantly altered levels of representative urinary biomark-
ers (ANOVA p < 0.05) between CCA patients with jaundiced, non-jaundiced patients and the
healthy group.
A difference in urinary bile acid levels was most pronounced in patients with obstructive jaun-
dice. For instance, the mean relative abundance of urinary glycocholic acid was 68, 580 and
2356 in healthy, non-jaundiced and jaundiced CCA patients, respectively. Bile acids were
significantly altered between jaundiced and non-jaundiced patients as shown in Figure 4.5.
An increase in hydroxylated acylcarnitine (C9-OH and C10:2-OH) and vanilpyruvate, and
decrease in isocitrate was associated with the urine metabotype of jaundiced-CCA partici-
pants.
Table 4.6: The metabolic profile altered in cholangiocarcinoma patients with obstructive jaun-
dice.
m/z RT Metabolite Adduct Trend in jaundice VIP p value FC 
Identiﬁ-
cation*  
114.066 0.51 Creatinine M+H ↓ 2.5 0.851 -1.05 a 
132.077 0.53 Creatine M+H ↓ 2.4 0.659 -1.51 b 
144.102 0.58 Proline betaine M+H ↓ 2.6 0.577 -1.30 b 
191.018 0.91 Isocitrate M-H ↓ 4.4 0.034 -1.60 b 
191.017 1.02 Citrate M-H ↓ 1.8 0.680 -1.30 a 
232.154 2.80 Butyryl-L-carnitine (C4) M+H ↓ 2.3 0.271 -1.25 a 
211.058 3.29 Vanilpyruvate M+H ↑ 3.5 <0.0001 2.56 b 
318.191 3.78 Acylcarnitine (C9-OH) M+H ↑ 4.6 0.019 1.97 c 
178.05 3.80 Hippurate M-H ↓ 2.8 0.808 -1.23 a 
212.001 3.81 Indoxylsulfate M-H ↓ 10 0.437 -1.24 a 
243.032 5.31 4-phenylbutanic acid-O-sulfate M-H ↓ 2.8 0.424 -10.7 b 
514.284 5.91 Taurocholic acid M-H ↑ 4.1 0.008 75.0 b 
544.258 5.91 Glycocholic acid sulfate M-H ↑ 3.5 <0.0001 7.66 b 
328.248 6.13 Acylcarnitine (C10:2-OH) M+H ↑ 3.6 0.478 1.42 c 
624.338 6.14 Glycochenodeoxycholic acid 3-glucuronide M-H ↑ 2.8 <0.0001 12.5 b 
464.299 6.23 Glycocholic acid M-H ↑ 2.9 <0.0001 4.07 a 
466.316 6.24 Glycocholic acid M+H ↑ 3.8 <0.0001 4.52 a 
528.262 6.33 Glycochenodeoxycholate-N-sulfate M-H ↑ 7.4 0.0002 10.4 b 
528.262 6.50 Glycochenodeoxycholate-N-sulfate M-H ↑ 7.1 <0.0001 4.72 b 
FC= fold change; RT= retention time; VIP= variable importance in projection score. 
*Level of metabolite identiﬁcation: (a) Identiﬁed compound; (b) putatively annotated compound; and (c) putatively characterised 
compound class. 
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Figure 4.6: Box and whisker plots of metabolites altered in cholangiocarcinoma patients with
obstructive jaundice.
*p<0.05, **p<0.01 and ***p<0.001, calculated using ANOVA and post hoc test. The boxes extend from the
25th to 75th percentiles in the biomarker intensity distribution, while the 50th percentile (the median) is the
black horizontal line in the box. The whiskers extend from the upper and lower fence values.
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Figure 4.6: Continued from previous page.
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4.4.8 Non-jaundiced cholangiocarcinoma patients vs. healthy controls
The difference between the metabotype of non-jaundiced CCA patients in comparison to
healthy participants was examined, Figure 4.7. The supervised model was highly discrimi-
nant with Q2Y= 77% and Q2Y= 71% in the positive and negative ESI modes, respectively.
(a) PCA scores plot - positive mode
R2X= 21% and Q2Y= 10% from 2 PC model.
(b) PCA scores plot - negative mode
R2X= 20% and Q2Y= 5% from 2 PC model.
(c) OPLS-DA scores plot - positive mode
R2Y= 87%, R2X= 16% and Q2Y= 73% ,
from one predictive and one orthogonal components model.
(d) OPLS-DA scores plot - negative mode
R2Y= 88%, R2X= 23% and Q2Y= 67%,
from one predictive and two orthogonal components model.
(e) Permutation test - positive mode
CV-ANOVA <0.001.
(f) Permutation test - negative mode
CV-ANOVA <0.001.
Figure 4.7: PCA scores plots for (a) positive and (b) negative ion mode data of non-jaundiced cholangio-
carcinoma patients with jaundice and healthy controls. OPLS-DA scores plots showing group separation for
both (c) positive and (d) negative ion mode data and the corresponding permutation tests for (e) positive and
(f) negative ion mode data.
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The table below (Table 4.7) summarise the differential features between CCA patients (ex-
cluding jaundiced) and healthy participants. Box and whisker plots (Figure 4.8-4.10) shows
the significantly altered levels of urinary metabolites (p < 0.05) between healthy volunteers
and non-jaundiced CCA patients.
Table 4.7: The metabolic profile altered in non-jaundiced cholangiocarcinoma patients com-
pared to controls.
m/z RT Metabolite  Adduct Trend in CCA VIP p value FC 
Identiﬁ-
cation* 
144.102 0.58 Proline betaine M+H ↑ 5.9 0.006 2.74 b 
96.958 0.60 Sulfate M-H ↑ 3.0 0.996 1.02 b 
191.018 0.91 Isocitrate M-H ↓ 3.3 <0.0001 -1.29 b 
229.154 0.97 Leucyl-proline M+H ↑ 3.7 0.043 1.45 b 
191.017 1.02 Citrate M-H ↓ 3.0 0.294 -1.36 a 
166.072 1.11 7-Methylguanine M+H ↑ 2.7 0.040 1.30 b 
120.08 2.48 Phenylalanine† + ↓ 4.3 0.878 -0.92 b 
188.985 3.04 Pyrocatechol sulfate M-H ↓ 4.1 0.014 -2.06 b 
318.191 3.78 Acylcarnitine (C9-OH) M+H ↑ 2.3 0.166 2.24 c 
105.033 3.80 Hippurate † + ↓ 6.1 0.0003 -1.87 a 
178.05 3.80 Hippurate M-H ↓ 7.8 0.001 -1.96 a 
212.001 3.81 Indoxylsulfate M-H ↑ 8.4 0.843 1.38 a 
263.102 3.83 Phenylacetylglutamine M-H ↑ 2.9 0.213 1.25 b 
332.207 4.16 Acylcarnitine (C10-OH) M+H ↑ 2.5 0.004 3.13 c 
293.147 4.91 Unknown M+H ↓ 3.0 <0.0001 -1.91 b 
286.201 4.94 Acylcarnitine (C8:1) M+H ↓ 5.7 <0.0001 -2.91 c 
310.201 5.21 Acylcarnitine  (C10:3) M+H ↓ 5.4 <0.0001 -3.45 c 
300.217 5.24 Unidentiﬁed acylcarnitine M+H ↓ 3.3 0.162 -1.49 c 
539.248 5.25 Tetrahydroaldosterone-3-glucuronide M-H ↓ 2.0 <0.0001 -1.67 b 
243.032 5.31 4-phenylbutanic acid-O-sulfate M-H ↑ 4.4 0.350 7.31 b 
383.152 5.39 3b,16a-Dihydroxyandrostenone sulfate M-H ↓ 2.7 <0.0001 -4.03 b 
302.233 5.56 2,6 dimethylheptanoyl carnitine (C9:0) M+H ↓ 3.0 0.013 -1.77 b 
312.217 5.65 2-trans,4-cis-decadienoylcarnitine (C10:2) M+H ↓ 2.6 <0.0001 -3.75 b 
314.233 5.80 Acylcarnitine (C10:1) M+H ↓ 3.9 <0.0001 -2.02 c 
331.174 5.98 17α-hydroxyprogesterone M-H ↓ 3.1 0.066 -1.54 b 
367.157 6.33 Steroid sulfate (C19H28O5S) M-H ↓ 2.6 0.041 -3.53 c 
465.248 6.37 Steroid glucuronide (C25H38O8 ) M-H ↓ 2.3 <0.0001 -1.97 c 
528.262 6.50 Glycochenodeoxycholate-N-sulfate M-H ↑ 3.1 0.297 2.82 d 
495.295 6.58 Pregnanediol-3-glucuronide M-H ↓ 2.2 0.002 -4.20 b 
FC= fold change; RT= retention time; VIP= variable importance in projection score. 
*Level of metabolite identiﬁcation: (a) Identiﬁed compound; (b) putatively annotated compound; (c) putatively characterised compound 
class; and (d) Unknown.  
† m/z represents a fragment of this metabolite. 
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Figure 4.8: Box and whisker plots of acylcarnitine species altered in non-jaundiced cholan-
giocarcinoma patients.
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Figure 4.9: Box and whisker plots of steroid species altered in non-jaundiced cholangiocar-
cinoma patients compared to jaundiced patients and healthy controls.
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Figure 4.10: Box and whisker plots of other metabolites altered in non-jaundiced cholangio-
carcinoma patients compared to jaundiced patients and healthy controls.
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4.4.8.1 The diagnostic performance of candidate biomarkers
Table 4.8: The areas under the curves (AUCs) of receiver operating characteristic (ROC)
curves of individual markers.
Metabolite Trend in CCA AUC (%) 95% CI Cutoﬀ  
Sensitivity 
(%) 
Speciﬁcity 
(%) 
Acylcarnitine:       
2-trans,4-cis-decadienoylcarnitine (C10:2) ↓ 95.2 89.2 – 99.0 425 92.9 91.3 
Acylcarnitine  (C10:3) ↓ 94.4 88.6 – 98.1 1160 85.7 91.3 
Acylcarnitine (C8:1) ↓ 85.9 76.3 – 93.2 2240 78.6 80.4 
Acylcarnitine (C10-OH) ↑ 84.4 75.2 – 91.9 614 75.0 78.3 
Acylcarnitine (C10:1) ↓ 83.1 72.0 – 91.7 1880 71.4 84.8 
2,6 dimethylheptanoyl carnitine (C9:0) ↓ 74.0 62.1 – 85.6 1720 60.7 89.1 
Acylcarnitine (C9-OH) ↑ 68.6 56.2 – 80.3 822 64.3 65.2 
Unidentiﬁed acylcarnitine, 300.217 ↓ 70.9 56.4 – 82.8 2650 76.1 67.9 
Steroids:       
3b,16a-Dihydroxyandrostenone sulfate ↓ 88.4 79.9 – 88.8  775 84.8 85.7 
Steroid glucuronide (C25H38O8) ↓ 86.4 75.8 – 94.6 1810 84.9 85.7 
Tetrahydroaldosterone-3-glucuronide ↓ 83.5 72.9 – 91.7  1390 80.4 78.6 
Pregnanediol-3-glucuronide ↓ 78.9 67.5 – 88.6  414 60.9 85.7 
Steroid sulfate (C19H28O5S)  ↓ 78.4 65.8 – 88.7  496 69.6 75.0 
17α-hydroxyprogesterone ↓ 63.5 51.1 – 75.3 5230 67.9 56.5 
Other:       
Glycochenodeoxycholate-N-sulfate ↑ 85.5 75.1 – 94.3 464 78.6 82.6 
Hippurate ↓ 74.7 62.6 – 84.3 18800 71.4 67.4 
7-Methylguanine ↑ 72.9 59.0 – 83.6 5050 64.3 76.1 
Pyrocatechol sulfate ↓ 70.8 58.3 – 82.5 3150 53.6 78.3 
Leucyl-Proline ↑ 70.1 57.0 – 81.9  6290 63.0 78.6 
Isocitrate ↓ 65.1 50.7 – 77.9 11500 71.4 58.7 
4-phenylbutanic acid-O-sulfate ↑ 62.8 48.4 – 76.3 77 50.0 80.4 
Phenylacetylglutamine ↑ 61.6 47.5 – 73.9 19000 50.0 80.3 
Proline betaine ↑ 61.8 45.4 – 75.1 5390 53.6 89.1 
Phenylalanine ↓ 60.3 45.6 – 75.5 4390 57.1 73.9 
Indoxylsulfate ↑ 60.1 44.6 – 74.9 35700 57.1 58.7 
Sulfate ↑ 52.6 31.8 – 61.3 3810 50.0 58.7 
Citrate ↓ 52.4 39.1 – 67.6 4810 64.3 58.7 
AUC= area under the receiver operating characteristic curve; CI= conﬁdence intervals; CCA= cholangiocarcinoma.  
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Key: Var= variable (or metabolite), AUC= area under the curve and CI= confidence interval.
136
Predictive accuracies with different features
Number of features
P
re
di
ct
iv
e 
A
cc
ur
ac
y
88
.8
 %
90
.3
 %
92
.4
 %
93
.4
 %
92
.9
 %
93
.2
 %
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
2 3 5 10 20 25
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Figure 4.13: Predicted class probabilities for each sample using the 10 metabolites panel.
Misclassified samples are labelled (n= 3).
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Figure 4.14: The frequency of a metabolite being selected from the training data at each
cross-validation run.
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4.4.9 Variation between Cohort-I and Cohort-II
Overlay of two QCmass spectra from Cohort-I study showed excellent reproducibility through-
out the analytical run, Figure 4.15.A. Yet, some differences were noticeable between the
detected profiles across the two studies (Cohort I vs. Cohort II), Figure 4.15.B.
A)
B)
QC1_ Cohort II
QC1_ Cohort I
QC1_ Cohort I
QC2_ Cohort I
Figure 4.15: Variability in the urinary spectral profile between the two datasets.
A) Comparison between two quality control (QC) samples from Cohort-I and; B) comparison between QC
samples from Cohort-I and -II.
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4.5 Discussion
A total of 98 spot urine sample were used to characterise CCA signatures using MS-based
metabonomics approach. Clinical information including the anatomical location of the tu-
mours and the presence of obstructive jaundice were used to stratify the patients and explore
the effect on the detected metabolite profiles. The presence of obstructive jaundice had a
clear impact on bile acid urinary elimination, whereas no obvious difference was observed
based on the tumour anatomical location. Acylcarnitine perturbation was pronounced in
urine metabolic profile from CCA patients. Environmental and physiological factors (such as
drug intake, age and gender) were found to be the most influential confounding factors. The
differences between the spectral profiles in Cohort I (Chapter 3) and Cohort II presented in
this chapter were assessed first to examine the reproducibility and comparability between
the two studies.
Despite its promising potential, metabolic profiling holds some intrinsic flaws. The biological
and experimental limitations associated with such a system biology approach can challenge
its biological interpretation and clinical implementation. Various factors can be a source of
variability in the MS data matrix produced using the training and validation samples, they are
generally divided into: 1) pre-analytical and 2) instrumental or analytical-related (Parker and
Borchers, 2014).
4.5.1 Pre-analytical causes of variability
Pre-analytical factors leading to variation in the detected metabolic profiles can affect the
sample at any point from the sample selection and collection until the sample preparation for
chromatographic analysis. The stability of human urine specimens can be potentially jeop-
ardised as a result of sample-related elements, such as prolonged storage and freeze thaw
cycles (Sykes et al., 2007). Additionally, physiological factors, including age, gender, ethnic-
ity and disease statues, and environmental factors (e.g. diet, drugs, physical activity, diurnal
cycles, and the host-gut microbiota metabolic interactions) can increase inter-individual bi-
ological diversity and mask the true biomarker associations relative to the disease by the
addition of noise (Parker and Borchers, 2014). For example, the presence of drug-related
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analytes in a sample can affect the presence of metabolic features, as a result of sample
saturation and can potentially challenge the interpretation of the results.
It is therefore critical to study these non-disease-specific factors which can significantly in-
duce a high level of noise to the urinary metabolic profiles. The pre-analytical variability can
be partially controlled for by matching the participants on demographic characteristics (such
as age and gender), collection of sufficient metadata, and standardizing the dietary record-
ing and sample handling protocols. In the current study, some sources of variation were
identified, they included: i) the difference in the control group selection between Cohort-I
and -II; ii) the difference in gender/age distribution among the groups in Cohort II; and iii)
more drug-related metabolites were detected in Cohort-II, possibly due to the greater num-
ber of participants and therefore greater power of biomarker detection.
4.5.2 Analytical-associated variability
Sources of technical variability can be accounted for by standardising the analytical pipeline,
including the use of the same instrument, column type, solvent batch and instrument param-
eters (such as mass resolution and collision energy). Small variations between MS experi-
ments in retention times and accurate mass measurements are expected. Furthermore, it is
also possible to experience variation across the same analytical run such as retention time
drift over the run. Therefore, intermittent injection of quality control samples is routinely used
to assess the analytical variation in the MS system (Parker and Borchers, 2014).
Nevertheless, its difficult to assess precisely what influences the reproducibility and selectiv-
ity of untargeted MS signal detection. Ion suppression and/or ion-enhancement due to the
endogenous compounds within the sample (such as salts, proteins and lipids) and the pres-
ence of xenobiotic substances (such as drugs) are named ”matrix effects”. The suppression
or enhancement response of an analyte results when an analyte present in a sample, other
than the analyte of interest compete to be ionised. The volatility of compounds in a sample is
another factor that can impact the amount of ions detected (Annesley, 2003). Furthermore,
the degree of droplet evaporation in the ESI source alter the amount of charged ions in the
gas phase (Annesley, 2003). Cohort I metabolic profiles were prepared and acquired with
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UK samples (presented in Chapter 5) to allow comparability between the two studies, but,
that possibly influenced the molecular composition of the detected profiles by altering the
composition of the pooled QC samples.
4.5.3 The influence of gender and age on the metabolic profile
Analysis of gender differences showed that urine specimens from female participants had
significantly greater concentrations of creatine and citrate. The two metabolites have been
previously described to be most commonly associated with female metabolic signatures
(Kochhar et al., 2006; Psihogios et al., 2008; Slupsky et al., 2007). Metabolites associated
with men were related to fatty acid oxidation (l-carnitine and acetylcarnitine species) and
amino acid metabolism (creatinine), which were also reported to be characteristic of the
male urinary phenotype (Slupsky et al., 2007). A marker of dietary cocoa consumption, 5-
(3’,4’-dihydroxyphenyl)- -valerolactone sulfate (DHPV O-sulfate), was found to be greater in
female and younger adult urine samples (Urpi-Sarda et al., 2009).
However, the models computed to examine gender and age as co-founders are potentially bi-
ased because of the unequal male to female ratio among the diseased and healthy groups.
Out of 59 female participants, 57% were healthy, compared to only 29% healthy partici-
pants in the male cohort. For example, bile acids were significantly increased in males and
positivity correlated with age, which is related to more male participants having obstructive
jaundice. Additionally, compared to Cohort I, no compounds related to bone collagen degra-
dation (prolylhydroxyproline and 4-hydroxyproline) were up-regulated in female metabolic
profiles, which is potentially due to the younger age of female participants in this cohort.
4.5.4 The metabolic profile related to obstructive jaundice
Tumours arising along the biliary tract branches are either asymptomatic or cause non-
specific symptoms (e.g. weight loss, abdominal discomfort and malaise) in the early stages
of tumourogenesis. The malignant lesions often remain undetected until the patient seek
medical attention for clinical illness associated with advanced disease, such as jaundice
(Khan et al., 2012). Obstructive jaundice is one of the most common clinical manifestations
associated with CCA. It results when the bile canaliculi is obstructed due to the growing
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tumour and/or to the excessive accumulation of fibrous tissue induced by heavy parasitic
infection (IARC, 2012). Bile flow blockage and retention rises the ductal pressure, sub-
sequently, causing bilirubin, bile salts, bile acids, and fats to cross the hepatic sinusoidal
membrane and accumulate in the bloodstream. Jaundice, yellowing of the skin and whites
of the eyes, becomes clinically icteric when the serum level of the bile pigment, bilirubin,
exceeds 2-3 mg/dL (the normal range 0.3 to 1.9 mg/dL) (Bacon and Di Bisceglie, 2000).
Evidence of perturbation in bile acid homoeostasis and increased urinary elimination of ex-
cess bile acids in patients with obstructive jaundice have been acknowledged in the late 60’s
(Gregg, 1967). In the current study, dramatic increase in urinary bile acid excretion was the
most pronounced feature in jaundiced-CCA patients (fold change increase from 75 to 4),
compared to non-jaundiced. Taurine- and glycine-conjugated cholic acid (taurocholic acid,
glycocholic acid), conjugated glycocholic acid and glycochenodeoxycholic were significantly
increased in jaundiced-CCA patients, compared to non-jaundiced patients.
The hydroxylation of cholesterol (a core component of bile acid synthesis) in the liver is
the initial step of complex biochemical steps involved in the production of the primary bile
acids in humans, cholic acid and chenodeoxycholic acid (Hofmann and Hagey, 2008). In the
liver, five forms of bile acid conjugation are recognised: 1) N-acyl amidation with an amino
acid, glycine or taurine; 2) sulfation; 3) ester glucuronidation; 4) ethereal conjugation; and
5) N-acetylglucosamination (Hofmann and Hagey, 2008). The majority of the bile acids syn-
thesised and excreted from the liver in the amidated form, predominantly, glycine-amidated.
Conjugation converts each primary bile acid from an insoluble, uncharged molecule into a
molecule with high aqueous solubility. It decreases their membrane permeability and toxic-
ity. After meal intake, cholecystokinin secretion stimulates the gallbladder to release bile to
aid in digestion. Bile then flows into the intestine, where it is actively absorbed. The colonic
microbiota convert unabsorbed bile acids to secondary bile acids, where they are passively
absorbed along with unconjugated primary bile acids. Only 5% of bile acids excreted are
eliminated (mainly as secondary unconjugated bile acids) in faeces, whereas 95% are ef-
fectively reabsorbed (Alnouti, 2009). Under physiological equilibrium, enterohepatic recircu-
lation of bile acids maintain their homoeostasis. Bile acids are efficiently absorbed from the
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intestine and recycled in the liver (Alnouti, 2009).
The sulfation pathway plays an integral role in bile acid urinary elimination and the sulfated
form constitutes >89% of the total bile acids excreted. The addition of the sulfate moiety
(SO 3 , pKa <1) increases bile acid water solubility, reduces their toxicity, decreases their
intestinal recycling and promotes their elimination from the body through urine and faeces.
In the case of biliary flow obstruction, the formation of bile acid-sulfates increases, which is
proposed to be an adaptive mechanism to maintain bile acid homoeostasis by decreasing
the amount of bile acid returning to undergo enterohepatic recirculation and facilitate their
renal clearance (Alnouti, 2009).
To a lesser extent, the urinary excretion of acylcarnitine species was also dysregulated in
jaundiced patients. Two medium-chain hydroxylated acylcarnitines, acylcarnitine (C9-OH)
and acylcarnitine (C10:2-OH), were elevated in jaundiced patients compared to the non-
jaundiced group urine metabolome (FC= 1.97 and 1.42, respectively). Greater urinary con-
centrations of acylcarnitine (C9-OH) have been detected in Chinese colorectal cancer pa-
tients (Wang et al., 2010) and rise in the plasma level of acylcarnitine (C10:2-OH) was found
implicated in recovery after exercise (Lehmann et al., 2010). Acylcarnitine implication in
CCA with jaundice is uncertain, however, it is possibly due to compromised liver capacity to
oxidise fatty acid in clinically-icteric patients (Younes et al., 1991).
Reduction in the urinary relative abundance of citrate and its isomer, isocitrate, was gener-
ally associated with CCA patients, but, it was more pronounced in patients with biliary ob-
struction. This was contrary to the observation found in a recent Chinese LC-MS metabolic
profiling study of urine samples from extrahepatic CCA patients, where urinary citrate levels
were higher in cancer patients (Wang et al., 2016). Shao at el. identified general reduction
in urinary citrate in presence of liver disease, both benign (cirrhosis) and malignant (HCC),
but the metabolite had no significant difference between the two groups (Shao et al., 2014).
An observation which was confirmed by Chen and colleagues, where citrate was only signif-
icantly reduced in HCC patients with cirrhosis and hepatitis. (Chen et al., 2011). Thus, the
decrease in citrate excretion in urine is possibly related to TCA cycle perturbation, resulting
from mitochondria dysfunction in liver disease (Wei et al., 2008).
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A compound putatively identified as vanilpyruvate, a catecholamine and phenylpyruvate
derivative, was significantly associated with jaundiced patients (VIP= 3.5, p <0.0001 and
FC= 2.56). Vanilpyruvate is reported to be increased in the urinary metabolic profile of in-
dividuals with aromatic l-amino acid decarboxylase deficiency, a disorder that impairs the
synthesis of serotonin, dopamine and catecholamines (Abdenur et al., 2006). Several other
compounds were found to be differential between jaundiced and non-jaundiced CCA urine
samples, but not to a level of significance. Greater abundance of creatinine, creatine, pro-
line betaine, citrate, hippurate and indoxylsulfate was found to be associated with jaun-
diced patients, whereas, 4-phenylbutanic acid-O-sulfate and butyryl-L-carnitine were down-
regulated, compared to the non-jaundiced group.
4.5.5 Metabolic pathways altered in non-obstructive cholangiocarcinoma
A multivariate statistical model was computed using the spectral data of CCA patients (ex-
cluding jaundiced participants) versus healthy controls to identify a panel of urinary metabolic
markers related to CCA-genesis. Several metabolites belonging to various metabolic path-
ways, particularly related to acylcarnitine and steroid metabolism, were found to be per-
turbed. Assessment the validity of these metabolites and their relevance to hepatobiliary
disease was carefully reviewed before considering these for future evaluation as potential
markers in CCA.
As an example, leucyl- or iosleucyl- proline (belongs to the family of Peptides) was ruled
out from the diagnostic panel for two reasons. Firstly, leucyl-proline was significantly up-
regulated (p= 0.043) in the malignant group in this study, but, data from Cohort-I showed that
it was decreased in the urine profile of cancer patients. Secondly, the dipeptide was higher
in men and it is possibly influenced by protein intake. In vivo MS studies showed influence of
disease and diet on leucyl-proline levels. The urinary clearance of the peptide decreased in
rats with atherosclerosis (Zhang et al., 2009). In another study, the plasma levels of leucyl-
proline decreased after 7 weeks of hypercholesterolemic diet (Gonza´lez-Pen˜a et al., 2016).
Leucyl-proline was significantly (p <0.001) reduced in human MS urinary profiles in bladder
cancer patients (Huang et al., 2011), but was found to be higher in HCC (Chen et al., 2009).
Therefore, because of the ambiguous kinetics leading to these observations, leucyl-proline
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was not included as one of the diagnostic markers.
Furthermore, proline betaine was also excluded from the multivariate biomarker model. The
renal elimination of proline betaine was found to be greater in CCA patients. Interestingly,
the proline betaine excretion pattern seemed to be influenced by jaundice. It was signifi-
cantly increased (p= 0.006, FC= 2.74-fold) in jaundiced CCA patients compared to healthy
participants. In the current study, the lack of dietary records does not allow any conclusion
on the underlying mechanism leading to this finding. Regardless, proline betaine had limited
diagnostic utility (AUC= 61.8) and was excluded from the biomarker panel (Table 4.8).
Compounds classified as gut microbial co-metabolites and/or dietary phenolic (hippurate,
phenylacetylglutamine, indoxyl sulfate, pyrocatechol sulfate, 4-phenylbutanic acid-O-sulphate,
and phenylalanine) are influenced by a number of factors other than cancer. For instance,
hippurate excretion has been observed to be higher in females, as reviewed by (Lees et al.,
2013). Lees et al. also reported reduction in hippurate urinary clearance in obesity, diabetes,
inflammatory bowel disease, parasitic infection and cancer, as observed in numerous publi-
cations investigated using a metabonomic approach (Lees et al., 2013). Analysis of the diag-
nostic power of these markers generally showed poor performance (AUC <70) and/or wide
confidence intervals. These markers did not contribute greatly to the multipanel marker clas-
sification. The AUC values and the corresponding CIs of potential biomarker combinations,
illustrated in (Figure 4.11), yielded high values ranging from 0.942 using only 2 metabolites
to 0.99 using 20 or 25 molecules. The best diagnostic accuracy, 93.4%, was archived with
a total of 10 metabolic features, (Figure 4.12). The predicted class probabilities (average of
the cross-validation) for each sample using the best classifiers (10 metabolites) is visualised
in (Figure 4.13), along with the confusion matrix.
Acylcarnitine and steroid species yielded the best classification performance and were fre-
quently selected in the multipanel model, (Figure 4.14). Similar to Cohort I, accumula-
tion of hydroxylacylcarnitine species (C9-OH and C10-OH) was a distinctive pattern in the
CCA urine metabolome. Levels of saturated (C9) and unsaturated (C8:1, C10:1, C10:2 and
C10:3) long-chain acylcarnitine species were significantly reduced in CCA, particularly in
patients without obstructive jaundice. An acylcarnitine, 2-trans,4-cis-decadienoylcarnitine
146
(C10:2), was shown to be the most frequently selected metabolite based on a repeated
random sub-sampling cross validation (n= 50 runs).
Steroid-related analytes also showed excellent diagnostic utility. Four steroid metabolites,
tetra-hydroaldosterone-3-glucuronide, 3b,16a-dihydroxyandrostenone sulfate, pregnanediol-
3-glucuronide and steroid glucuronide (C25H38O8), were selected among the diagnostic panel.
Low urinary elimination of steroids was observed in all CCA patients, regardless of jaun-
dice and did not seem to be affected by the presence of PPF in Cohort I. Urine steroid
metabonomics studies revealed a promising diagnostic utility for distinguishing early HCC
from cirrhosis (Dai et al., 2014) and adrenocortical carcinoma from adrenocortical adeno-
mas (Arlt et al., 2011). The strong male predominance of HCC prompts the question on the
involvement of sex hormones (particularly androgens) in hepatocarcinogenesis (De Maria
et al., 2002). In Thailand, CCA incidence is estimated to be 87.7 per 100,000 in men and
36.3 per 100,000 in women, but, men are also more commonly infected with liver flukes
(Khuntikeo et al., 2015). The urinary elimination of steroid species was similar between men
and women, except for steroid glucuronide (C25H38O8). The database searches resulted
in a number of metabolite hits for its m/z value, androsterone glucuronide, etiocholanolone
glucuronide, 5-↵-dihydrotestosterone glucuronide and 3-↵-hydroxy-5-↵-androstane-17-one
3-D-glucuronide, (Figure 4.16).
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Figure 4.16: Gender influence on steroids urinary elimination.
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The role of various agents in modulating biliary carcinogenesis has been thoroughly studied
in experimental models (Glaser et al., 2009; Mancinelli et al., 2010). Steroid hormones, in
particular, have been shown to play a role in supporting the growth of the biliary epithelium
(Mancinelli et al., 2010). The bile epithelial network possess a number of biological func-
tions (such as secretion, absorption, proliferation, regenerative processes and signalling)
that is regulated by several agents including neuropeptides, steroid hormones, cytokines
and growth factors (Alvaro, 1999; Glaser et al., 2009). In presence of cholagiopathies, the
maintenance of biliary functions is greatly affected as the balance between proliferation/loss
of cholangiocytes is lost (Mancinelli et al., 2010).
Oestrogens, for example, are well known carcinogenic agents in estrogen-responsive tis-
sues and have been recently shown to play a role in promoting CCA cellular growth and
apoptosis (Mancinelli et al., 2010). Cholangiocytes of normal liver do not express oestro-
gen receptors, but in presence of biliary malignancy, oestrogen receptors were positive in
>80% of cholangiocarcinoma cells (Alvaro et al., 2006). Oestrogens were found to favour
the growth and proliferation of malignant mass by synergising the activities of growth factors
and by taking part at both receptor and post-receptor levels (Mancino et al., 2009). Thus,
they play a critical role in inducing neo-angiogenesis in oestrogen-sensitive cancers through
the activities of vascular endothelial growth factor (VEGF) receptors, which in turn, medi-
ate the proliferative effects of estrogens (Mancino et al., 2009). Mancinelli et al., suggested
that CCA tumours could be considered oestrogen dependent and the use of anti-oestrogen
drugs should control the growth of these tumours (Mancinelli et al., 2012).
Interestingly, glycochenodeoxycholate-N-sulfate was also selected among the biomarker
panel. The abundance of bile acid metabolites varied within the non-obstructive CCA group,
implicating that factors other than jaundice status affected bile acid homeostasis in a sub-
group of patients. Accumulation of bile acids in urine has been associated with an inflam-
matory signature in various forms of hepatobiliary diseases (Beyog˘lu and Idle, 2013). Dys-
regulation of bile acid metabolism was found to be implicated in biliary tract carcinogenesis
by activating pathways that promote cholangiocellular proliferation and increases CCA inva-
siveness, such as the G protein-coupled bile acid receptor TGR5 (Reich et al., 2015).
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4.6 Conclusion
The study highlights several metabolic alterations in biliary carcinoma. Pronounced bile acid
urinary excretion was mostly associated with clinically icteric CCA patients. In patients with-
out jaundice, acylcarnitine and steroid species were the most discriminant, compared to
the disease-free cohort. Targeted acylcarnitine and steroid assay could potentially be infor-
mative; it can provide a greater understanding with the benefits of higher specificity, lower
potential for false positive identifications and better control for environmental con-founders
(such as diet and drugs). Gut microbial co-metabolites (such as hippurate and indoxyl sul-
fate) and bile acids were shown to exhibit a different pattern in cancer patients. Emerging
evidence identified a distinct colonic microbial population ”on” and ”off” the tumour microen-
vironment, implicating an interplay between intestinal microbial ecology and carcinogenesis
(Marchesi et al., 2011). Better understanding of the gut microbial-mammalian co-metabolism
and the role of the oncogenic microbiome in disease initiation and progression may provide
novel diagnostic and therapeutic tools.
The rare occurrence of CCA in Western countries limits biomarkers validation in large human
cohorts. Nevertheless, CCA is one of the most common malignancies in Thailand and the
framework for a large-scale surveillance programme is already available. Preclinical valida-
tion of a urinary prognostic and diagnostic metabolic panel could be implemented in parallel
to the exciting ultrasound screening programme known as CASCAP (Seeree et al., 2015).
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Abstract
Background The previous two chapters identified a set of distinctive features associated with the
urine metabolome of liver fluke induced-CCA. The study presented here, undertaken in a patient
cohort with sporadic CCA from the UK, serves to validate or refute these findings.
Methods Samples were collected from healthy controls and from patients with benign hepatic dis-
ease (gallstone, biliary strictures, sphincter of Oddi dysfunction and viral hepatitis) and patients with
malignant conditions (hepatocellular carcinoma, pancreatic cancer, ovarian cancer and metastatic
cancer). Spot urine specimens were obtained from seven participating UKCRN centres across the
UK. The spectral metabolite profiles were generated using a LC-MS detector and data were analysed
using multivariate and univariate statistical analysis.
Results The greatest class differences were seen between the metabolic profiles of disease-free con-
trols compared to individuals with CCA. This profile bears some similarity to the urine metabolome
identified in the Thai cohort, in the form of altered acylcarnitine, bile acid, and purine levels. Indi-
viduals with benign strictures showed comparable urine profiles to patients with malignant bile duct
lesions. Patients with bile duct tumours were distinguishable from patients with hepatocellular and
ovarian tumours, but no reliable difference was observed between CCA cases and patients with pan-
creatic and metastatic cancers.
Conclusion It is possible to conclude from this small dataset that non-malignant hepatobiliary dis-
ease seems to cause subtle but detectable changes in the urine metabolic profile. The findings point
towards potential applications of metabonomics in early tumour detection. However, it is key to uti-
lize global and targeted metabonomics in a larger cohort for in-depth characterisation of the urine
metabolome in hepato-pancreato-biliary disease.
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5.1 Introduction
5.1.1 The problem in the UK
CCA is a devastating malignancy, including in the UK, where the tumours commonly present
late in the course of the disease and are sporadic in 80% of the cases (Zabron et al., 2013).
In 1993, Taylor-Robinson et al. reported that malignant liver tumours increased from 1.29 to
1.93 in women and from 2.56 to 3.70 in men in England and Wales during 1979–1996, addi-
tionally, they described doubling of the mortality rates of liver tumours during the same period
(from 967 to 1822 cases). Furthermore, mortality statistics analysis of hepatic anatomi-
cal subcategories showed that intrahepatic biliary duct tumours has overtaken HCC as the
leading cause of mortality from primary liver tumour in England and Wales (Taylor-Robinson
et al., 2001). This observed increasing trend in CCA is unexplained. It was claimed that the
improved case diagnosis and ascertainment as a result of advanced diagnostic tools (such
as imaging, image guided biopsies and ERCP), along with the misclassification of hepato-
biliary cancers could have influenced this temporal trend interpretation. However, the trend
has continued to increase steadily thereafter. In England and Wales, the incidence of iCCA
markedly increased with an annual percent change of 10% in both genders from 437 to 639
in men and from 473 to 672 in women between 2001 and 2008 (Ladep et al., 2014). The
recently published UK National Cancer Intelligence Network (NCIN) report also supports
the early findings and showed that the number of deaths for the years 2012 and 2013 were
higher than the incidence. This is also reflected in the population rates where incidence and
mortality per 100,000 is 3.58 and 3.64, respectively (NCIN, 2015).
Most cases of CCA are not related to established predisposing causes, except in areas en-
demic for liver flukes. The commonest known risk factor of CCA in developed countries is
PSC (Zabron et al., 2013). For the current study, selecting samples from a developed coun-
try where the majority of biliary tumours are sporadic and from Asian population, where it
is associated with a known risk, is critical in understanding the underlying tumour patho-
physiology in the two distinct groups. A study of UK and Egyptian populations by Hashim
Abdalla and colleagues identified a difference in the bile metabolic profile of CCA patients,
compared to benign liver disease patients. Egyptian patients had significantly lower biliary
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phosphatidylcholine levels compared with UK patients (AbdAlla et al., 2011). This result may
indicate differences in carcinogenic mechanisms and implications of the host physiology in
populations, which is an important aspect to be covered in my study.
5.1.2 Comparisons between Thailand and UK
Finding prognostic and diagnostic markers for CCA is urgent for liver fluke endemic regions,
particularly for Thailand, but is also critical for sporadic CCA in the UK where the disease
is fatal in majority of the cases (Khan et al., 2005). Due to the rarity of CCA in Western
countries; it is difficult to acquire sufficient number of samples to robustly identify and val-
idate metabonomics-based molecular markers using large-scale studies. It is estimated
that about 2,000 CCA patients per year undergo surgical treatment at Khon Kaan Hospital,
Khon Kaen, Thailand, the busiest CCA centre in the world. The overall figure in Thailand
is estimated to be around 10,000 to 20,000 new CCA cases per year, of which only a few
are curable (Khuntikeo et al., 2016). In addition to the great number of cases in Thailand,
at-risk population is well defined which permit the evaluation and verification of candidate
biomarkers. By comparison to Thailand, the Hammersmith Hospital in London, UK, receives
about 40 sporadic cases per year. We have thus collected samples across the UK to build-
up numbers in partnership with the UK Clinical Research Network (UKCRN). The samples
were originally collected for a 5-year project (2011-2016) entitled ”Profiling for Biomarkers in
Liver Malignancies” which aimed to collect biofluid and tissue for ”Omics” analysis. Adult pa-
tients with hepato-pancreato-biliary diseases and healthy volunteers were recruited. Initially,
a total of 200 samples from new cases of CCA were planned to be allocated for metabo-
nomics analysis. However, only 10 urine samples were available at the time of analysis for
this study.
The primary objective of the study is to evaluate differences between the urinary metabolite
profiles of CCA cases compared to healthy participants, patients with benign hepatic disease
(gallstones, strictures, sphincter of Oddi dysfunction (SOD) and viral hepatitis) and patients
with malignant conditions (hepatocellular, pancreatic and metastatic cancers). Ovarian can-
cer (OCA) urine samples, courtesy of Professor Hani Gabra, Department of Surgery and
Cancer, Imperial College London, were included as non-hepatic malignancy controls.
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5.2 Methodology
5.2.1 Patient and healthy volunteer recruitment
Urine samples were collected for the “Profiling for Biomarkers in Liver Malignancies” project.
Participant recruitment for the five year project was initiated in 2011 and was finalised in
2016. Collected biofluids were transported frozen from UKCRN centres to the Hepatology
Biobank at St. Mary’s Hospital, London, UK. A subset was selected for this project in 2013,
which included samples obtained from material collected as part of a previously approved
study at the principal site (St Mary’s Hospital). Potential participants were identified and
recruited by their clinician from the in-patient or out-patient population at the following NHS
participating institutions:
• Oxford Hospitals NHS Trust.
• Newcastle Hospitals NHS Trust.
• Plymouth Hospitals NHS Trust.
• Nottingham University Hospitals NHS Trust.
• Southampton University Hospitals NHS Trust.
• Central Manchester University Hospitals NHS Trust.
Inclusion criteria:
• Adult.
• Able to give informed consent.
• Established diagnosis of any hepato-pancreato-biliary malignancy, including:
– Cholangiocarcinoma.
– Hepatocellular carcinoma.
– Pancreatic carcinoma
– Liver metastases (any primary source).
• Established diagnosis of any benign hepato-pancreato-biliary condition, including:
– Gallstone disease.
– Primary sclerosing cholangitis.
• Matched control individuals with no hepatic-pancreato-biliary condition.
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Exclusion criteria:
• Under-18.
• Unable or unwilling to give informed consent.
Healthy volunteers were sought from amongst visitors to the hospital, staff and students.
After participants provided consent, they were assessed at baseline for demographic data,
medical history, drug history and dietary history. A case report form (CRF) was completed
for each participant (Appendix-2). Most recent blood laboratory tests were also recorded
when available.
5.2.2 Ethical approval
Ethical approval was obtained from Imperial College London REC, London, UK (REC Ref-
erence 09/H0712/82).
5.2.3 Sample processing
A fasting urine specimen of 20 mL were collected from each participant. Urine specimens
were kept on ice or in +4  C fridge while awaiting processing. Samples were centrifuged at
4  C at 1000g for 10 minutes then 2 mL of urine aliquots were transferred into 6 Eppendorf
tubes of which one was used for the current study.
5.2.4 Sample transport, preparation and mass spectrometry analysis
Urine samples were transported on dry ice to the South Kensington campus, Imperial Col-
lege London for MS analysis. They were prepared and analysed along side the Thai samples
presented in (Chapter 3) to enable comparison.
5.2.5 Statistical analysis
Statistical analysis was performed as outlined in the previous chapters. SIMCA-P+ version
13.0.2 (Umetrics, Sweden) was used for multivariate statistical analysis of the processed
spectral data. Multi-group PLS-DA classification was calculated using MetaboAnalyst 3.0 to
identify molecular features associated with each of the study groups.
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5.3 Results
5.3.1 Demographics, clinical data and cohort description
A total of 211 urine samples were acquired using global LC-MS metabolic profiling. Table
5.1 describes the demographics and clinical description of the study cohort. Overall, the
samples were categorised into 3 groups: healthy controls, participants with benign hepatic
conditions (including SOD, strictures, gallstones, and viral hepatitis C (HCV)) and partici-
pants with malignant tumours (including CCA, HCC, PCA, OCA and liver metastases cases).
Out of the ten participants with CCA, (n= 4) were diagnosed with pCCA, (n= 2) with dCCA,
one case with iCCA and three cases with unknown tumour origin. Healthy controls (n= 22)
were younger than those with hepatic conditions, both benign and malignant. With respect
to gender, the HCC group comprised mostly of men, (85.7%), followed by the PCA patient
group with 71.4% male participant. Many participants were missing BMI data, the mean BMI
for most of the study groups with available BMI values was in reference with the overweight
BMI ranges (25 to 29.9 kg/m2). Participants’ racial background was diverse but mostly white
European.
Total serum bilirubin was above the reference interval ( 25µmol/L) for patients with gall-
stones and non-malignant strictures. Increase in bilirubin levels was markedly noted in the
PCA, metastatic and CCA groups: 108 µmol/L, 103 µmol/L and 95 µmol/L, respectively. The
transaminase enzyme, ALT, was above the normal value for all groups excluding patients
with ovarian tumours. ALP levels were greatly increased in patients with liver metastases
(mean level= 643 IU/L) and bile duct carcinoma (mean level= 594 IU/L). Hypoalbuminemia,
generally defined by a serum albumin <35 g/L, was mostly characteristic of the clinical phe-
notype of patients with malignant conditions. Serum urea and creatinine concentrations were
within the reference intervals for all groups. No serum biochemistry tests were available for
the healthy group.
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5.3.1.1 Dietary and physiological influences on the metabolic profile
Multivariate analysis using binary (such as gender and dietary input) and continuous vari-
ables (including age, BMI and serum biochemistry values) were calculated to evaluate their
impact on the urinary metabolic profile. Only age and gender generated robust models as
co-variables in terms of cross-validation scores. Drug-related metabolic features (mainly
Paracetamol and Ciprofloxacin) were greatly abundant in the diseased groups compared to
healthy controls. Drugs and their related-metabolites were excluded from all subsequent
analysis. Table 5.2 lists the medicines consumed by CCA patients.
Table 5.2: Usage of medicines used by cholangiocarcinoma patients.
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5.3.1.2 Gender influence
A PCA model was calculated using the positive ESI (Figure 5.1a) and negative ESI (Figure
5.1b) spectral data of 118 women vs. 94 men. The models were poorly predictive in both
modes. Supervised OPLS-DA showed some gender-related difference in the ESI+ (Figure
5.1c&e), but not the ESI  model (Figure 5.1d&f). Table 5.3 lists the urinary metabolites that
contributed to the separation between men and women in the positive ESI mode spectral
data.
(a) PCA scores plot - positive mode
R2X= 14% and Q2X= 9% from 2 PC model.
(b) PCA scores plot - negative mode
R2X= 19% and Q2X= 4% from 2 PC model.
(c) OPLS-DA scores plot - positive mode
R2Y= 66%, R2X= 14% and Q2Y= 22% ,
from one predictive and two orthogonal components
model.
(d) OPLS-DA scores plot - negative mode
R2Y= 36%, R2X= 16% and Q2Y= 12% ,
from one predictive and one orthogonal components
model.
(e) Permutation test - positive mode
CV-ANOVA <0.001.
(f) Permutation test - negative mode
CV-ANOVA= NS.
Figure 5.1: PCA scores plots for (a) positive and (b) negative ion mode serum mass spectra
of males and females. OPLS-DA scores plots showing group separation for both (c) positive
and (d) negative ion mode data and the corresponding permutation tests for (e) positive and
(f) negative ion mode data.
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5.3.1.3 Age influence
Analysis of the impact of age on the molecular profile was generated using OPLS algorithm.
Similar to gender, age-discriminant metabolites were identified in the positive ESI mode
(Figure 5.2a&c). Age-influenced urinary compounds are listed in Table 5.4.
(a) OPLS scores plot - positive mode
R2Y= 55%, R2X= 8% and Q2Y= 21% ,
from one predictive and one orthogonal components model.
(b) OPLS scores plot - negative mode
R2Y= 42%, R2X= 16% and Q2Y= 10% ,
from one predictive and one orthogonal components model.
(c) Permutation test - positive mode
CV-ANOVA <0.001.
(d) Permutation test - negative mode
CV-ANOVA= NS.
Figure 5.2: OPLS scores plots of (a) positive and (b) negative ion mode data computed
using age as a continuous Y variable. The corresponding permutation tests for (c) positive
and (d) negative ion mode data.
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Table 5.3: Gender discriminant compounds - positive mode.
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 Table 5.4: Age discriminant compounds - positive mode.
m/z RT Tentative assignment Adduct VIP Trend†  Identiﬁcation* 
144.102 0.58 Proline betaine M+H 8.3 ↓ b 
105.033 3.81 Hippurate M+H 8.2 ↓ b 
114.065 0.51 Creatinine M+H 6.6 ↓ a 
302.233 5.55 2,6 Dimethylheptanoyl carnitine (C9) M+H 6.4 ↓ b 
310.202 5.35 Acylcarnitine (C10:3) M+H 6.4 ↓ b 
170.061 4.81 Unknown M+H 6.2 ↓ d 
286.201 4.92 Acylcarnitine (C8:1) - 5.7 ↓ b 
130.098 0.64 Unknown M+H 5.4 ↓ d 
354.102 5.71 Unknown - 5.2 ↓ d 
310.202 5.19 Acylcarnitine (C10:3) M+H 5.1 ↓ b 
Retention time (RT), variable importance in projection score (VIP). 
*Level of metabolite identiﬁcation: (a) Identiﬁed compound; (b) putatively annotated compound; (c) putatively characterised     
compound class; and (d) Unknown. 
†Increase with age (↑) and decrease with age (↑) 
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5.3.2 Cholangiocarcinoma patients vs. benign liver disease cases
5.3.2.1 General overview
The urinary spectral data from CCA patients were compared to benign groups using OPLS-
DA analysis (Table 5.5). The most discriminant OPLS-DA model was the one between the
urinary MS spectral profile from CCA cases, compared to healthy participants, as shown by
the cross-validation statistics and CV-ANOVA p-value. The model comparing CCA patients
versus HCV participants, the majority with chronic hepatitis C infection, also showed good
statistics which reflect differences in the detected profiles between the two groups. Similarly,
patients with SOD and gallstones were separated from CCA patients.
Interestingly, participants with benign strictures, including PSC cases, were poorly differ-
entiated from CCA patients (ESI+: Q2Y= 24%, CV-ANOVA= NS and ESI : Q2Y= 31%,
CV-ANOVA= NS). The explained variation in the X-matrix (R2X) was only 18% and 19% in
the positive and negative ionisation modes, respectively. Participants with benign strictures
showed a urinary profile different from disease-free individuals, whereas participants with
SOD were not distinguishable from those free from liver disease.
Table 5.5: OPLS-DA cross-validation statistics
 Statistic Healthy SOD GS Strictures HCV + - + - + - + - + - 
CCA 
Q2 81 81 50 57 29 35 24 31 74 72 
R2X 24 29 20 29 14 22 18 19 22 26 
R2Y 95 93 95 91 90 84 93 95 95 91 
CV-ANOVA <0.001 <0.001 0.048 0.012 0.049 0.017 NS NS <0.001 <0.001 
Healthy 
Q2 
 
9.0 11 51 55 50 43 45 35 
R2X 23 22 16 23 22 25 19 25 
R2Y 79 83 85 80 86 86 84 84 
CV-ANOVA NS NS <0.001 <0.001 <0.001 0.004 <0.001 0.009 
SOD 
Q2 
  
-40 -5.0 -13 -41 2.0 24 
R2X 16 21 19 29 23 24 
R2Y 82 75 93 89 88 91 
CV-ANOVA NS NS NS NS NS NS 
GS 
Q2 
   
-6.0 7.0 39 50 
R2X 16 21 15 25 
R2Y 80 73 88 80 
CV-ANOVA NS NS 0.003 <0.001 
Strictures 
Q2 
    
30 14 
R2X 23 30 
R2Y 86 85 
CV-ANOVA NS NS 
Abbreviations: cholangiocarcinoma (CCA), gallstones (GS), Hepatitis virus C  (HCV), sphincter of Oddi dysfunction (SOD).  
NS= not signiﬁcant (CV-ANOVA p<0.05). 
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5.3.2.2 Cholangiocarcinoma patients vs. healthy controls
(a) PCA - positive mode
R2X= 27% and Q2X= 8% from 2 PC model.
(b) PCA - negative mode
R2X= 31% and Q2X= 5% from 2 PC model.
(c) OPLS-DA - positive mode
R2Y= 95%, R2X= 24% and Q2Y= 81%,
from one predictive and one orthogonal components model.
(d) OPLS-DA - negative mode
R2Y= 93%, R2X= 29% and Q2Y= 81%,
from one predictive and one orthogonal components model.
(e) Permutation test - positive mode
p value= <0.001.
(f) Permutation test - negative mode
p value= <0.001.
Figure 5.3: PCA scores plots for (a) positive and (b) negative ion mode data of CCA patients
and healthy controls. OPLS-DA scores plots showing group separation for both (c) positive
and (d) negative ion mode data and the corresponding permutation tests for (e) positive and
(f) negative ion mode data.
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5.3.2.3 Cholangiocarcinoma patients vs. sphincter of Oddi dysfunction cases
(a) PCA - positive mode
R2X= 26% and Q2X= -6% from 2 PC model.
(b) PCA - negative mode
R2X= 32% and Q2X= -2% from 2 PC model.
(c) OPLS-DA - positive mode
R2Y= 95%, R2X= 20% and Q2Y= 50%,
from one predictive and one orthogonal components model.
(d) OPLS-DA - negative mode
R2Y= 91%, R2X= 29% and Q2Y= 57%,
from one predictive and one orthogonal components model.
(e) Permutation test - positive mode
p value= 0.048.
(f) Permutation test - negative mode
p value= 0.013.
Figure 5.4: PCA scores plots for (a) positive and (b) negative ion mode data of CCA patients
and SOD cases. OPLS-DA scores plots showing group separation for both (c) positive and
(d) negative ion mode data and the corresponding permutation tests for (e) positive and (f)
negative ion mode data.
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5.3.2.4 Cholangiocarcinoma patients vs. gallstones cases
(a) PCA - positive mode
R2X= 21% and Q2X= -5% from 2 PC model.
(b) PCA - negative mode
R2X= 24% and Q2X= -6% from 2 PC model.
(c) OPLS-DA - positive mode
R2Y= 90%, R2X= 14% and Q2Y= 29%,
from one predictive and one orthogonal components model.
(d) OPLS-DA - negative mode
R2Y= 83%, R2X= 22% and Q2Y= 33%,
from one predictive and one orthogonal components model.
(e) Permutation test - positive mode
p value= 0.050.
(f) Permutation test - negative mode
p value= 0.017.
Figure 5.5: PCA scores plots for (a) positive and (b) negative ion mode data of CCA patients
and gallstones cases. OPLS-DA scores plots showing group separation for both (c) positive
and (d) negative ion mode data and the corresponding permutation tests for (e) positive and
(f) negative ion mode data.
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5.3.2.5 Cholangiocarcinoma patients vs. biliary strictures patients
(a) PCA - positive mode
R2= 27% and Q2X= -5% from 2 PC model.
(b) PCA - negative mode
R2= 34% and Q2X= -4% from 2 PC model.
(c) OPLS-DA - positive mode
R2Y= 93%, R2X= 18% and Q2Y= 24% ,
from one predictive and one orthogonal components model.
(d) OPLS-DA - negative mode
R2Y= 95%, R2X= 19% and Q2Y= 31% ,
from one predictive and one orthogonal components model.
(e) Permutation test - positive mode
p value= 0.398
(f) Permutation test - negative mode
p value= 0.231.
Figure 5.6: PCA scores plots for (a) positive and (b) negative ion mode data of CCA patients
and biliary strictures patients. OPLS-DA scores plots showing group separation for both
(c) positive and (d) negative ion mode data and the corresponding permutation tests for (e)
positive and (f) negative ion mode data.
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5.3.2.6 Cholangiocarcinoma patients vs. hepatitis C patients
(a) PCA - positive mode
R2X= 27% and Q2X= 5% from 2 PC model.
(b) PCA - negative mode
R2X= 34% and Q2X= 8% from 2 PC model.
(c) OPLS-DA - positive mode
R2Y= 74%, R2X= 22% and Q2Y= 74%,
from one predictive and one orthogonal components model.
(d) OPLS-DA - negative mode
R2Y= 91%, R2X= 33% and Q2Y= 72%,
from one predictive and one orthogonal components model.
(e) Permutation test - positive mode
p value= <0.001
(f) Permutation test - negative mode
p value= <0.001
Figure 5.7: PCA scores plots for (a) positive and (b) negative ion mode data of CCA patients
and HCV patients. OPLS-DA scores plots showing group separation for both (c) positive and
(d) negative ion mode data and the corresponding permutation tests for (e) positive and (f)
negative ion mode data.
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5.3.3 Altered urinary metabolites between cholangiocarcinoma patients and benign cases
The urinary molecules influencing the OPLS-DA model separation between CCA cases and
benign disease conditions (SOD, HCV and gallstones) were similar to those identified from
the model comparing CCA to healthy participants. Therefore, to to avoid repetition of data;
Table 5.6 and Table 5.7 lists the metabolites driving the separation between the urinary
metabolic profiles from CCA patients compared to healthy controls. Differences in these
metabolic features between the groups were then evaluated using ANOVA with post hoc
testing (Figure 5.8-5.11).
Table 5.6: Altered metabolites between cholangiocarcinoma patients compared to healthy
controls - positive mode
m/z RT Tentative assignment Adduct VIP Trend  p-value† FC Identiﬁcation* 
162.113 0.49 L-Carnitine (C1) M+H 4.3 ↑ NS 2.62 a 
114.066 0.51 Creatinine M+H 5.9 ↓ 0.043 -1.40 a 
144.102 0.58 Proline betaine M+H 4.5 ↓ NS -0.67 b 
229.118 0.68 Hydroxyprolyl-Proline M+H 3.3 ↑ NS 1.94 b 
204.125 0.82 L-Acetylcarnitine (C2) M+H 7.7 ↑ NS 1.87 a 
229.155 0.98 Leucyl-Proline M+H 5.2 ↑ NS 1.45 b 
169.036 1.03 Uric acid M+H 3.0 ↓ NS -0.90 a 
215.016 1.06 Citrate M+Na 3.2 ↓ NS -3.58 a 
188.071 2.51 Unknown  - 4.8 ↑ NS 2.22 d 
232.155 2.84 Butyrylcarnitine (C4) M+H 4.4 ↓ 0.023 -2.22 a 
296.15 3.17 Unidentiﬁed acylcarnitine M+H 3.3 ↑ NS 0.14 a 
295.13 3.54 Glutamylphenylalanine M+H 3.2 ↑ <0.0001 12.194 b 
246.17 3.57 Valerylcarnitine (C5) M+H 3.4 ↓ NS -1.78 a 
318.191 3.78 Acylcarnitine (C9-OH) M+H 6.3 ↑ <0.0001 9.25 b 
178.05 3.80 Hippurate M+H 8.9 ↓ <0.0001 -3.0 a 
344.207 4.40 Acylcarnitine (C10:1) M+H 3.1 ↑ 0.001 4.43 b 
346.223 4.57 Acylcarnitine (C10) M+H 3.9 ↑ 0.0002 7.88 b 
170.061 4.81 Unknown - 5.2 ↓ 0.001 -3.41 d 
286.201 4.92 Acylcarnitine (C8:1) M+H 6.4 ↓ NS -0.79 b 
277.142 5.12 M+H 3.5 ↑ NS 0.1 b 
312.217 5.16 2-trans,4-cis-Decadienoylcarnitine (C10) M+H 3.9 ↓ NS -5.78 b 
310.202 5.19 Acylcarnitine (C10:3) M+H 5.2 ↓ NS -1.57 b 
310.202 5.35 Acylcarnitine (C10:3) M+H 5.4 ↓ 0.021 -1.85 b 
302.233 5.55 2,6 Dimethylheptanoyl carnitine (C9) M+H 7.6 ↓ 0.001 3.65 b 
314.233 5.78 Decenoylcarnitine (C10:1) M+H 3.1 ↓ NS 1.62 b 
328.248 6.11 Acylcarnitine (C10:2-OH) M+H 4.0 ↓ NS 1.43 b 
FC= fold change; RT= retention time; VIP= variable importance in projection score. 
*Level of metabolite identiﬁcation: (a) Identiﬁed compound; (b) putatively annotated compound; (c) putatively characterised compound 
class; and (d) Unknown.  
†False discovery rate (FDR) adjusted p-value (or q-value). 
Uknown
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Table 5.7: Altered metabolites between cholangiocarcinoma patients compared to healthy
controls - negative mode
m/z RT Tentative assignment Adduct VIP Trend  p-value† FC Identiﬁca
tion* 
96.962 0.60 Sulfate  M-H 3.8 ↓ 0.025 -4.83 b 
243.061 0.85 Uridine/Pseudouridine M-H 3.1 ↑ 0.0002 2.24 b 
191.018 0.94 Isocitrate M-H 5.8 ↓ 0.023 -1.58 b 
167.02 1.03 Uric acid M-H 3.1 ↑ 0.011 1.70 a 
191.018 1.06 Citrate M-H 4.7 ↓ NS -1.93 a 
227.996 2.65 Sulfated compound  3.2 ↓ 0.005 -6.12 d 
188.985 3.13 Pyrocatechol sulfate M-H 4.5 ↓ 0.030 -2.66 b 
172.991 3.45 Phenyl sulfate M-H 6.8 ↓ 0.039 -3.44 b 
203.001 3.75 O-methoxycatechol-O-sulfate M-H 3.0 ↓ 0.014 -2.45 b 
178.049 3.80 Hippurate M-H 8.5 ↓ 0.006 -2.20 a 
263.102 3.84 Phenylacetylglutamine M-H 4.4 ↑ NS 1.11 b 
212.001 3.87 Indoxylsulfate M-H 9.1 ↓ 0.021 -1.93 a 
241.118 3.92 L-gamma-glutamyl-L-isoleucine M-H2O-H 3.2 ↑ 0.008 3.14 b 
287.022 4.13 DHPV O-sulfate‡ M-H 4.2 ↓ 0.018 -6.32 b 
243.134 4.18 Hydroxyprolyl-Isoleucine M-H 2.9 ↑ 0.002 3.24 b 
187.005 4.41 p-Cresol sulfate M-H 17 ↓ 0.051 -1.85 b 
352.085 5.88 Fatty acid  3.6 ↓ 0.004 -5.31 d 
465.248 6.37 Steroid glucuronide (C25H38O8) M-H 3.0 ↓ 0.001 3.90 b 
419.228 6.48 Steroid compound   3.1 ↑ 0.005 15.3 d 
528.263 6.76 Glycochenodeoxycholate-N-sulfate M-H 4.4 ↑ 0.011 18.3 b 
FC= fold change; RT= retention time; VIP= variable importance in projection score. 
*Level of metabolite identiﬁcation: (a) Identiﬁed compound; (b) putatively annotated compound; (c) putatively characterised compound 
class; and (d) Unknown.  
†False discovery rate (FDR) adjusted p-value (or q-value). 
‡ 5'-(3',4'-Dihydroxyphenyl)-gamma-valerolactone sulfate 
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Figure 5.8: Box and whisker plots of compounds different between CCA cases and benign
controls - carnitine species.
Key: CCA= cholangiocarcinoma, GS= gallstones, SOD= sphincter of Oddi dysfunction, STRI= strictures,
HCV= hepatitis C virus. *p 0.05, **p 0.01 and ***p 0.001. Y-axis= relative intensity.
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Figure 5.9: Box and whisker of compounds different between CCA cases and benign con-
trols - ESI+ metabolites.
Key: CCA= cholangiocarcinoma, GS= gallstones, SOD= sphincter of Oddi dysfunction, STRI= strictures,
HCV= hepatitis C virus. *p 0.05, **p 0.01 and ***p 0.001. Y-axis= relative intensity.
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Figure 5.10: Box and whisker plots of compounds different between CCA cases and benign
controls - ESI  metabolites.
Key: CCA= cholangiocarcinoma, GS= gallstones, SOD= sphincter of Oddi dysfunction, STRI= strictures,
HCV= hepatitis C virus. *p 0.05, **p 0.01 and ***p 0.001. Y-axis= relative intensity.
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Figure 5.11: Box and whisker plots of compounds different between CCA cases and benign
controls - ESI  metabolites.
Key: CCA= cholangiocarcinoma, GS= gallstones, SOD= sphincter of Oddi dysfunction, STRI= strictures,
HCV= hepatitis C virus. *p 0.05, **p 0.01 and ***p 0.001. Y-axis= relative intensity.
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Multi-group PLS-DA analysis was calculated to further assess the molecular panel under-
pinning the urinary metabolic differences between the six distinct conditions. The statistical
model generated scores plot and a corresponding plot which rank metabolites, based on
their VIP scores. Based on the cross-validation statistics, differences in the urinary metabolic
signature was identified in the ESI+ spectral data (Figure 5.12), but not the ESI  (Figure
5.13).
A) B)
L-Acetylcarnitine (C2)
Hippurate
Creatinine
Acylcarnitine (C9-OH)
Unknown, m/z 170.061
2,6 Dimethylheptanoyl carnitine
L-Carnitine (C1)
Phenylacetylglutamine
Hippurate
Prolylhydroxyproline
Figure 5.12: Urine metabolites associated with the metabolic signatures of the six distinct
disease conditions - positive mode
A) Score-plot of the PLS-DA analysis, R2Y= 41% and Q2Y= 16% from 2 PC model, p-value= 0.01 from
permutation test and b) important metabolites selected on the basis of VIP score.
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Figure 5.13: Urine metabolites associated with the metabolic signatures of the six distinct
disease conditions - negative mode
A) Score-plot of the PLS-DA analysis, R2Y= 22% and Q2Y= -2% from 2 PC model, p-value= 0.44 from
permutation test.
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5.3.4 Cholangiocarcinoma patients vs. other cancers
5.3.4.1 General overview
The MS data acquired using urine samples from CCA patients were compared to those
acquired from patients with malignant pathologies (Table 5.8). Patients with CCA showed
a distinguishable urinary metabolic profile from patients with hepatocellular and ovarian tu-
mours, but no reliable difference was observed between CCA cases and patients with pan-
creatic and metastatic cancers. The urine profiles from patients with pancreatic tumours did
not also differ from metastatic cases.
Table 5.8: OPLS-DA cross-validation statistics
 
Statistic 
Hepatocellular Pancreatic Ovarian Metastatic 
+ - + - + - + - 
Cholangiocarcinoma 
Q2 39 55 -20 7.0 39 31 14 24 
R2X 12 23 11 24 12 18 14 30 
R2Y 86 92 91 71 84 71 94 81 
CV-ANOVA <0.001 <0.001 NS NS <0.001 <0.001 NS NS 
Hepatocellular  
Q2 
 
52 60 54 52 36 27 
R2X 12 20 13 16 15 21 
R2Y 83 77 78 71 75 68 
CV-ANOVA <0.001 <0.001 <0.001 <0.001 <0.001 0.002 
Pancreatic 
Q2 
  
39 40 -22 -14 
R2X 13 13 15 23 
R2Y 74 74 88 75 
CV-ANOVA <0.001 <0.001 NS NS 
Ovarian  
Q2 
   
18 28 
R2X 15 18 
R2Y 65 62 
CV-ANOVA 0.027 0.001 
NS= not signiﬁcant (CV-ANOVA p<0.05). 
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5.3.4.2 Cholangiocarcinoma patients vs. hepatocellular carcinoma
(a) PCA - positive mode
R2X= 18% and Q2X= 5% from 2 PC model.
(b) PCA - negative mode
R2X= 22% and Q2X= 2% from 2 PC model.
(c) OPLS-DA - positive mode
R2Y= 86%, R2X= 12% and Q2Y= 39%,
from one predictive and one orthogonal components model.
(d) OPLS-DA - negative mode
R2Y= 81%, R2X= 19% and Q2Y= 51%,
from one predictive and one orthogonal components model.
(e) Permutation test - positive mode
p value= <0.001.
(f) Permutation test - negative mode
p value= <0.001.
Figure 5.14: PCA scores plots for (a) positive and (b) negative ion mode data of CCA patients
and HCC patients. OPLS-DA scores plots showing group separation for both (c) positive and
(d) negative ion mode data and the corresponding permutation tests for (e) positive and (f)
negative ion mode data.
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Table 5.9: Altered urinary metabolites between cholangiocarcinoma and hepatocellular car-
cinoma cases.
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5.3.4.3 Cholangiocarcinoma patients vs. ovarian cancer
(a) PCA - positive mode
R2X= 18% and Q2X= 6% from 2 PC model.
(b) PCA - negative mode
R2X= 22% and Q2X= 1% from 2 PC model.
(c) OPLS-DA - positive mode
R2Y= 84%, R2X= 12% and Q2Y= 39%,
from one predictive and one orthogonal components model.
(d) OPLS-DA - negative mode
R2Y= 71%, R2X= 18% and Q2Y= 31%,
from one predictive and one orthogonal components model.
(e) Permutation test - positive mode
p value= <0.001.
(f) Permutation test - negative mode
p value= <0.001.
Figure 5.15: PCA scores plots for (a) positive and (b) negative ion mode data of CCA patients
and OCA patients. OPLS-DA scores plots showing group separation for both (c) positive and
(d) negative ion mode data and the corresponding permutation tests for (e) positive and (f)
negative ion mode data.
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Table 5.10: Altered metabolites between cholangiocarcinoma and ovarian cancer cases.
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5.3.5 Metabolites altered between cholangiocarcinoma patients and malignant cases
Figure 5.16: Box and whisker plots of compounds different between CCA cases and benign
controls - carnitine species.
Key: CCA= cholangiocarcinoma, HCC= hepatocellular carcinoma, METS= metastatic cancer, OCA= ovarian
cancer, PCA= pancreatic cancer. *p 0.05, **p 0.01 and ***p 0.001. Y-axis= relative intensity.
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Figure 5.17: Box and whisker plots of compounds different between CCA cases and benign
controls - ESI+ metabolites
Key: CCA= cholangiocarcinoma, HCC= hepatocellular carcinoma, METS= metastatic cancer, OCA= ovarian
cancer, PCA= pancreatic cancer. *p 0.05, **p 0.01 and ***p 0.001. Y-axis= relative intensity.
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Figure 5.18: Box and whisker plots of compounds different between CCA cases and benign
controls - ESI  metabolites
Key: CCA= cholangiocarcinoma, HCC= hepatocellular carcinoma, METS= metastatic cancer, OCA= ovarian
cancer, PCA= pancreatic cancer. *p 0.05, **p 0.01 and ***p 0.001. Y-axis= relative intensity.
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Figure 5.19: Box and whisker plots of compounds different between CCA cases and benign
controls - ESI  metabolites
Key: CCA= cholangiocarcinoma, HCC= hepatocellular carcinoma, METS= metastatic cancer, OCA= ovarian
cancer, PCA= pancreatic cancer. *p 0.05, **p 0.01 and ***p 0.001. Y-axis= relative intensity.
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Figure 5.20: Urine metabolites associated with the metabolic signatures of the six distinct
disease conditions - positive mode
A) Score-plot of the PLS-DA analysis, R2Y= 60% and Q2X= 3% from 5 PC model, p-value= 0.01 from
permutation test and b) important metabolites selected on the basis of VIP score.
Figure 5.21: Urine metabolites associated with the metabolic signatures of the six distinct
disease conditions - negative mode
A) Score-plot of the PLS-DA analysis, R2Y= 51% and Q2Y= 4% from 5 PC model, p-value= 0.03 from
permutation test and b) important metabolites selected on the basis of VIP score.
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5.4 Discussion
5.4.1 General overview
The study identified a coherent metabolic pattern associated with bile duct tumours. This
molecular pattern was similar to the one associated with participants with pancreatic and
metastatic cancers, yet distinct from individuals bearing hepatocellular and ovarian tumours.
The urine metabolic profiles from CCA patients were also distinguishable from patients with
benign liver pathologies (including SOD, gallstones and chronic viral hepatitis). However, the
urinary metabolome from individuals with benign biliary strictures revealed a relatively sim-
ilar underpinning metabolic processes, compared to malignant strictures. The endogenous
metabolic profiles reflective of the study groups are summarised in Figure 5.24.
The possibility to distinguish the healthy metabolome from both profiles of SOD and chronic
hepatitis was limited. None of the urinary metabolites achieved statistical significant differ-
ence between the three groups, and therefore were not listed in Figure 5.24. Whereas,
as expected, the greatest variability explained among the conditions was described be-
tween healthy controls, compared to CCA cases reflecting changes in several urinary mark-
ers. These markers were also representative of metabolic pathways altered in the urine
metabolome of pancreatic and metastatic liver cancers.
The section below discusses in summary potential sources of physiological variability ob-
served in the urine metabolome and metabolic perturbations associated with benign and
malignant pancreatobiliary disease.
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5.4.2 Physiological variation in the urine metabolome
In this cohort, information related to gender, age, BMI, serum biochemistry and racial back-
ground were used to assess their influence on the urinary metabolic profile. Only the
statistical models calculated using gender and age yielded a positive result based on the
cross-validation scores. Differences between males and females urinary metabolic profiles
were mainly related to altered concentrations of carnitine species (C2, C8:1, C10:2-OH and
C10:3), which were elevated in males. Urine from male participants also contain greater con-
centrations of 3-amino-2-naphthoic acid and leucyl-proline. These observations are poten-
tially confounded by meat intake and muscle mass, which are both greater in men (Lindelo¨f,
2012). Purine metabolites (uric acid and hypoxanthine) were gender discriminate. Uric acid
was significantly increased in females urine (p <0.001), whereas hypoxanthine was signifi-
cantly decreased (p= 0.042). The two metabolites were also associated with the metabolic
profiles of females with ovarian tumours (n= 48), and do not appear to have been described
in the literature as gender discriminant compounds.
Hippurate urinary excretion was influenced by both sex (" females) and age (# with increas-
ing age). Increase in hippurate concentrations in females urine is consistent with previous
metabonomics studies that have examined gender-related metabolic variations (Lees et al.,
2013). The association between hippurate and age in previous research findings provided
conflicting results as reviewed by Lees et. al (Lees et al., 2013). Dietary variation (such as
high intake of fish, tea or coffee) and/or population disparities in the gut microbiome may ex-
plain the differences in hippurate excretion pattern (Swann et al., 2013). Distinctive features
associated with older adults were primarily related to carnitine metabolism. The decrease
in carnitines, as well as in creatinine, with age possibly reflect decreasing muscle mass with
age (Swann et al., 2013).
5.4.3 Metabolic profile discrimination between CCA and benign disease groups
The best separation in the urinary metabolome was achieved between the spectral profiles
from CCA patients and healthy controls. Interestingly, the model comparing the profiles
of patients with CCA and benign strictures (including PSC cases) did not achieve statistical
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significance. Yet, participants with benign strictures showed a distinct molecular pattern from
healthy controls with Q2Y value of 50% in ESI+ and 43% in ESI  and significant CV-ANOVA
p-value of <0.001 and 0.004, respectively. Metabolites driving the separation between the
two classes (healthy vs. benign biliary strictures) were relativity similar to those separating
between CCA and healthy controls. Based on the VIP scores for the positive ionisation
mode spectral data, depletion in urinary acylcarnitine (C2, C8:1, C10:3) and creatinine were
associated with patients with biliary strictures. However, these markers were not significantly
different between the two groups (Figure 5.8 and 5.9). In the ESI , a decrease in the
levels of urinary p-cresol sulfate, indoxylsulfate, isocitrate and hippurate and higher level
of the sulfated glycoursodeoxycholic acid concentrations was characteristic of the urinary
metabotype of patients with bile duct strictures, compared to healthy controls. Only one
molecule, isocitrate, achieved statistical significance between patients with strictures and
healthy controls in the ANOVA test as shown in Figure 5.8.
The urinary metabolites altered between benign and malignant bile duct strictures were pri-
marily related to acylcarnitine metabolism, where the levels of (C9-OH, C10 and C10:1) car-
nitines being significantly down-regulated in participants with benign strictures. Participants
with biliary strictures had the greatest elevations in liver enzymes and bilirubin compared to
the other benign disease groups, indicating hepatic dysfunction and jaundice. Cholestatic
jaundice is a common feature associated with biliary strictures and is typically associated
with greater risk of malignancy (Singh et al., 2015). In this cohort, serum bilirubin levels
ranged from 10µmol/L to 189µmol/L with a mean value of 40µmol/L in patients with stric-
tures, and out of the nine participants, four were diagnosed with PSC. Aetiologies related
to benign biliary strictures include pancreatitis, PSC and iatrogenic injury. Nevertheless,
majority of detected biliary strictures are malignant (⇠70%), primarily due to pancreatic ade-
nocarcinoma and CCA (Singh et al., 2015). Definitive diagnosis to distinguish benign from
malignant lesions involve multiple tools including imaging, endoscopic investigations, tis-
sue sampling and diagnostic surgery (Dadhwal and Kumar, 2012). Even after pre-operative
evaluation, biliary strictures can remain indeterminate in up to 20% of the cases and only
15–24% of patients undergoing surgical resection for suspected biliary malignancy have
benign aetiology (Singh et al., 2015).
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The serum metabolic signatures of PSC patients in US population was profiled using LC
and GC mass-spectroscopic detection techniques (Bell et al., 2015). Markers related to in-
flammatory statues, as well as to perturbations in bile acid metabolism (elevations in choles-
terol, unconjugated, conjugated, and sulfated bile acid), lipid metabolism (elevations in fatty
acids, ketone bodies and several acylcarnitines) and protein metabolism (depletion in dipep-
tides) were associated with the PSC patient’s metabolome, compared to healthy controls
(Bell et al., 2015). The authors postulated that these changes reflect cholestatic liver state,
perturbations in cholesterol homeostasis and mitochondrial dysfunction which are typical
features associated with impaired fatty acid  -oxidation.
Its not clear why the urine metabolome of patients with benign biliary strictures was distin-
guishable from healthy controls but not from those with malignant biliary tumours. These
results may suggest that the presence of benign or malignant cholestatic liver disease are
likely to exhibit similar metabolic traits in the urine metabolome. However, it is difficult to
draw firm conclusions from these data due to the small sample size (CCA= 10 participants
and benign biliary strictures= 9 participants). In the current literature, metabolic pheynotyp-
ing studies in hepatobiliary disease were mainly focused on bile profiling. Differences in the
biochemical composition of bile between CCA and patients with non-malignant biliary dis-
ease (including various conditions such as (SOD, PSC, gallstones) were able to distinguish
between the two groups (AbdAlla et al., 2011; Sharif et al., 2010). One study examined bile
from PSC (n= 18) patients and from (n= 16) patients with CCA, but also included 11 who
had other benign findings. The spectra of bile from CC patients differed from the benign
group in the levels of phosphatidylcholine, bile acids, lipids, and cholesterol with sensitivity,
specificity and accuracy of 88.9%, 87.1%, and 87.8%, respectively (Albiin et al., 2008).
5.4.4 Metabolic profile discrimination between CCA and malignant disease groups
The metabolic profile acquired using urine specimens from CCA patients was distinguishable
from those with hepatic and ovarian malignancies, but not from individuals with metastatic
and pancreatic tumours. Blood investigations revealed signs of compensated liver function,
including low albumin, abnormal bilirubin, ALT and AST, in metastatic liver cancer cases.
Biomarkers associated with the urine metabolome from metastatic patients resembled those
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associated with CCA cases. Urinary acylcarnitine pattern and excess excretion of urinary
bile acids were comparable between the two groups. The urine profile from PCA patients
were not distinguishable from CCA and metastatic patients and also shared similarity based
on their urinary biochemical composition.
Pancreatic and bile duct tumours (particularly bile duct tumours arise in the distal extra-
hepatic region) share a close anatomical relation, similar growth pattern, close phenotypic
characteristics and are associated with poor prognosis; which may explain the similarity in
their urine metabolome (Schmuck et al., 2016). In a recently published review on the sub-
ject by Schmuck et al., the authors discussed the various similar aspects between the two
malignancies in terms of embryological, pathological, biological, clinical and surgical obser-
vations (Schmuck et al., 2016). For example, the most common mutations associated with
CCA and PCA is mutations in p53 and KRAS genes. Additionally, serum CA19-9 level, the
most widely used tumour marker in pancreatobiliary diseases, is used as a biomarker for the
clinical management of patients with CCA and PCA. However, its not possible to differentiate
between benign, precursor lesions and malignant pancreatobiliary conditions using CA 19-9
levels alone (Ballehaninna and Chamberlain, 2011). Schmuck et al., postulated that the two
malignancies should be regarded as a common tumour entity under a unified superfamily
titled ”tumours of the pancreatobiliary junction” (Schmuck et al., 2016).
Metabolic dysfunctions in several molecular pathways implicated in carcinogenesis such as
ketogenesis (increase in acetoacetate and decreased in citrate), were described to be asso-
ciated with the NMR urine metabolome from PCA patients (Napoli et al., 2011). A number of
candidate biomarkers in serum were proposed including bile acids, amino acids, nucleotides
and fatty acids (Di Gangi et al., 2016; Ritchie et al., 2013). Napoli et al., investigated the
spectral correlations, in the urine metabolic profile from individuals with PCA, with patho-
logical staging and tumour anatomical localisation. Patients with intermediate pancreatic
carcinoma stage showed different urinary metabolome from those with advanced tumour
stage. Also, a clear distinction was observed bases on anatomical location of PCA, partic-
ularly between carcinoma of the uncinate process of the pancreas and pancreatic cancers
of the body and head (Napoli et al., 2011). Unlike CCA, pancreatic cancer is not rare: it
190
is the fourth cause of cancer death in Europe (Malvezzi et al., 2015). Its has a rising pre-
dicted death trend in both genders, 4% in men and 5% in women between 2009 and 2015,
corresponding to 85 300 total deaths in 2015 (Malvezzi et al., 2015).
It is difficult to draw a complete pictures of the biological pathways implicated in pancreato-
biliary conditions from this small dataset. To enable accurate metabonomic characterisa-
tion of pancreatobiliary tumours, metabolic fingerprinting using large sample size and more
complete clinical information is needed. The possible application of metabolic profiling to
differentiate different tumour localisation and disease staging would helpfully provide a more
comprehensive picture of tumour development and progression in the tumours of the pan-
creatobiliary junction.
Compared to HCC and OCA cases, urine from CCA patients showed distinct pattern. A num-
ber of metabolites were significantly different between the urine profile from CCA patients,
compared to HCC and OCA cases and my possibly serve as candidate biomarkers in CCA.
These include acylcarnitine (C9:OH), uridine/pseudouridine, glucosmaine-6-phosphate and
bile acids. The key metabolic pathways most associated with cholangiocarcinogenesis are
discussed below.
5.4.5 Primary metabolic pathways contributing to the discrimination between CCA and con-
trol groups
5.4.5.1 Acylcarnitine metabolism
Several species of acylcanitines were dysregulated in individuals with CCA, compared to
control groups. An acylated carnitine compound, tentatively identified as acylcarnitine C9-
OH, was significantly greater abundant in CCA metabolic profile compared to all groups,
except patients with pancreatic and metastatic tumours. Findings from the Thai cohorts
presented in Chapter 3 and Chapter 4 showed acylcarnitine C9-OH to be consistently
up-regulated in urine from patients with CCA, but the metabolite was markedly increased
with the coexistence of jaundice. Moreover, multi-group PLS-DA identified carnitine-related
metabolites (carnitine (C1), acetylcarnitine (C2) and acylcarnitine (C9-OH)) to be most as-
sociated with CCA cases, compared to non-malignant conditions (Figure 5.22).
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Elevated urinary concentrations of acylcarnitine metabolites was also observed in individu-
als with gallstone. ANOVA analysis showed that individuals with gallstones had significantly
greater levels of acylcarnitine metabolites (including C2, C9-OH, C10 and C10:1), with re-
spect to healthy controls. Gallstone disease is a common disorder of the hepato-biliary
system, characterised by the formation of gallstones (or cholelithiasis) in the gallbladder,
common bile duct or hepatic bile duct. Cholelithiasis is a well-established risk factor for
gallbladder carcinoma; it causes severe injury to the biliary mucosa which triggers a se-
ries of events starting with chronic inflammation to metaplasia, dysplasia, in situ carcinoma
to invasive carcinoma (Reshetnyak, 2012). Gallbladder stone chemical composition is het-
erogeneous and the stones formation is aggravated by several lifestyle and environmental
factors, such as low physical activity, high dietary fat intake, female gender and genetic
predisposition (Stinton and Shaffer, 2012). The presence of metabolic disorders including,
adiposity, hypertension, diabetes mellitus and lipid abnormalities is associated with a higher
prevalence of gallstone disease (Stinton and Shaffer, 2012). Considering all these factors,
in addition to the lack of comprehensive metabolic profiling studies on the disease, makes it
difficult to attempt to capture and characterise the urinary biochemical perturbation in indi-
viduals with cholelithiasis. Impaired metabolism of cholesterol, phospholipids, bilirubin and
bile acids is known to be implicated in the pathogenesis of gallstone disease (Reshetnyak,
2012).
An acylated carnitine, 2,6 dimethylheptanoyl carnitine, was most associated with chronic
viral hepatitis and with HCC metabolic profiles. This could be related to underlying co-
morbidity such as diabetes. Metabonomics study of diabetes mellitus urinary metabolic
signature, identified an increased in 2,6 dimethylheptanoyl carnitine in diabetic patients with
low renal function (Ng et al., 2012).
5.4.5.2 Metabolism of pyrimidine and purine nucleotides
Nucleotides, purines and pyrimidines, are the nitrogenous bases of the genetic code (Alberts
et al., 2014). Nucleotides and their derivatives contribute to many biological processes such
as cellular signalling, energy production and lipids and proteins synthesis. Aberrant DNA
replication and damage occur early during cellular carcinogenesis, in which, imbalanced
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of nucleotides metabolism, particularly deoxyribonucleotide triphosphates (dNTP), drive tu-
morigenesis and leads to nucleotide pool imbalance in tissue and biological fluids (Aird and
Zhang, 2015). These nucleotide pool patterns may serve as a novel screening and diagnos-
tic biomarkers for various human cancers (Aird and Zhang, 2015). Increased concentrations
of modified nucleotides (such as pseudouridine, 1-methyladenosine and 1-methylguanosine)
in cancer patient’s urine is reflective of high whole-body RNA turnover or oxidative DNA dam-
age (Seidel et al., 2015). Nucleotide post-transcriptional chemical modifications, including
methylation, hydroxylation, acetylation and uridine isomerization, are believed to play a key
role in the translation of the genetic code, yet their exact biological function remains unclear.
Uridine or pseudouridine, a structural C-glycoside isomer of the nucleoside uridine, was sig-
nificantly increased in CCA compared to all groups except individuals with strictures and
pancreatic tumours. The pyrimidine nucleoside plays a crucial role in synthesis of RNA,
glycogen, and biomembrane (Yamamoto et al., 2011). Uridine is used clinically as a res-
cue agent that protect against 5-fluorouracil (chemotherapeutic drug used to treat different
cancers including breast, colorectal and pancreaticobiliary) toxicity (Ma et al., 2016). Medi-
cation history records (Table 5.2) showed that none of the individuals with CCA consumed
5-fluorouracil or uridine-containing prodrug. The circulating plasma uridine level is tightly
regulated in humans, yet several factors can result in elevated plasma uridine concentra-
tion such as enhanced ATP consumption, enhanced uridine diphosphate (UDP)-glucose
consumption via glycogenesis, increased urea synthesis and increased 5-phosphoribosyl-
1-pyrophosphate (PRPP) (Yamamoto et al., 2011). Ka et al., demonstrated positive corre-
lation between plasma uridine concentrations and the urinary excretions of urea, uric acid,
uridine, uric acid clearance and purine intake in healthy males (Ka et al., 2010). The liver
regulates and maintain the hepatic pools of uridine nucleotides via de novo uridine synthe-
sis and degradation which is essential for the homoeostatic control of plasma uridine pools
(Gasser et al., 1981). An in vivo study evaluated uridine homoeostasis in liver tissue and its
impact on hepatic cellular function (Le et al., 2013). The authors revealed that uridine ad-
ministration suppresses fatty liver by modulating liver protein acetylation profile and identified
an association between between uridine homeostasis, pyrimidine metabolism, and liver lipid
metabolism (Le et al., 2013).
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A state of homoeostatic imbalance of purine metabolism was noted in the urine metabolome
associated with individuals affected by carcinoma of the biliary tree. Purine-based metabo-
lites (" uric acid, " 7-methylguanine and # hypoxanthine) were consistently found in similar
pattern in the two Thai datasets (Chapter 3 and Chapter 4) and in this UK cohort. In the
discriminant analysis applied to generate metabolite patterns as a method of disease iden-
tification, uric acid, hypoxanthine and 7-methylguanine were associated with the metabolic
signatures in CCA cases compared to the malignant controls.
5.4.5.3 Bile acid metabolism
The greatest abundance of bile acid species was found in the urine metabolic profiles from
individuals with pancreatobiliary tumours. It is difficult to assess bile acid profile in bile duct
and pancreatic carcinomas as they are frequently complicated with profound jaundice, which
subsequently cause a marked increase in bile acid concentrations in both serum and urine
(Magyar et al., 1980; Trottier et al., 2011). Nevertheless, elevation in bile acid species, such
as tauroursodeoxycholic acid, taurocholic acid, deoxycholylglycine and cholylglycine, have
been observed in the plasma MS metabolic profile from none-jaundiced patients with early
stage pancreatic ductal adenocarcinoma (Urayama et al., 2010). In a recent metabonomics
study by Di Gangi et al., free plasma bile acid concentrations were significantly decreased
whereas conjugated (glycine and taurine) cholic and chenodeoxycholic acids were signif-
icantly increased in PCA cases than disease-free controls (Di Gangi et al., 2016). Cyto-
toxicity and -protection by bile acids varies depending on their hydrophobic/hydrophilic prop-
erties. In jaundiced serum of PCA cases, elevation in conjugated bile acids seems to exhibit
a protective effect against pancreatic cell proliferation (Wu et al., 2003). Possible mechanism
of the inhibitory action of bile acids involve their cytotoxic potency which reduce pancreatic
cancer cell lines proliferation and results in structural damages (Wu et al., 2003). Little is
known about bile acids causative role in metabolic perturbations and oncogenic pathways
preceding pancreatic cancer progression (Feng and Chen, 2016). In their review, Feng
and colleagues aimed to evaluate bile acids role in the aetiology of pancreatic carcinogen-
esis. However, more question are raised than have been answered, bile acids are not only
involved in multiple risk factors known to be implicated in pancreatic cancer initiation, includ-
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ing obesity, diabetes, high-fat diet and gallstones, they also exhibits a biologically complex
local tissue effects (Feng and Chen, 2016). They play a pathogenic and/or protective role in
tissue which is complex to simulate the in vivo environment.
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5.5 Conclusions
Primary data from this dataset identified multimolecular signature of pancreatobiliary dis-
ease and illustrated potential of MS-based metabolic profiling in generating a novel non-
invasive diagnostic tool for tumour detection and may further our understanding of the dis-
ease mechanisms. Discriminant metabolites related to cholastatic stricture conditions (be-
nign and malignant) showed a similar pattern. It was also not possible to differentiate be-
tween the metabolic profiles from patients with pancreatobiliary junction tumours. Yet, the
metabolic profiles of patients with cancerous cells invading the hepatic parenchyma were
different from the profiles of participants with tumours of the bile ducts and the pancreas.
Its important to highlight that its difficult to draw firm conclusions from limited sample size.
In-depth metabolic characterisation of biofluids from patients with various pancreatobiliary
conditions and sufficient clinical data is essential to accurately characterise their metabo-
nomic signature. Elimination of physiological and environmental confounding factors and
inter-individual variability is required to facilitate data interpretation.
Chapter 6
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Abstract
Background Phenotypic diversity in the urinary metabolome of different geographical population
groups has been recognised in recent epidemiological studies. In this study, the urinary metabolic
signature from Western (United Kingdom) and Southern Asian (Thailand) cohorts, under normal and
disease states (CCA), were characterised to gain better understanding of spectral variability due to
the host carcinogenic process and/or to exogenous differences (e.g. nutritional, environmental and
pharmaceutical) between the two distinct populations.
Methods Urine LC-MS spectral profiles from a Thai cohort (healthy= 20 and CCA= 14) and a British
cohort (healthy= 22 and CCA= 10) were selected, pre-processed and modelled using chemometric
data analysis.
Results Healthy metabolome disparities between the two distinct populations were primarily related
to differences in dietary practices and body composition. Metabolites excreted due to drug treatment
were highly dominant in the urine specimens from CCA patients, particularly in the Western patients.
Urine from participants with sporadic CCA contained greater levels of a nucleotide metabolite (uri-
dine/pseudouridine), compared to all three groups. Higher relative concentrations of 7-methylguanine
were observed in the urine specimens from Thai individuals with biliary tumours. The urinary excre-
tion of hippurate and methyladenine (gut microbial- host co-metabolites) showed a similar pattern of
lower levels in patients with malignant biliary tumours from both countries.
Conclusion Intrinsic (e.g. body weight and body composition) and extrinsic (e.g. xenobiotic metabolism)
factors were the main causes of disparities between the two populations. Regardless of the underly-
ing aetiology, biological perturbations associated with the CCA urine metabolome signature appeared
to be influenced by gut microbial community metabolism. Dysregulation in nucleotide metabolism
was associated with sporadic hepatobiliary disease, possibly indicating differences in mitochondrial
energy production pathways between CCA tumour subtypes. Mapping population-specific metabolic
disparities may aid in the interpretation of disease processes and the identification of candidate uri-
nary biomarkers related to cancer screening, prognosis, and stratification.
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6.1 Introduction
Metabolic signatures are largely the results of interactions among genetic, environmental (in-
cluding dietary) and gut microbial factors (Bictash et al., 2010). The unique characteristics of
”Isaan” Thai people, including host genetic variants, lower body weight and different dietary
practices, may lead to population-specific metabolic patterns in the urinary profile of both
heath and diseased individuals. In a study applying NMR-based metabonomics to a large-
scale dataset (n= 4630, from China, Japan, UK and USA), geographic differences were
found to contribute greatly to metabolic phenotype variation in urine, and were of greater
magnitude than gender-related metabolic differences (Holmes et al., 2008). Interestingly,
the metabolic signature across Western populations (American and British) were poorly dif-
ferentiated, whereas the metabolic phenotypes of East Asian and Western populations were
significantly differentiated (p< 10 16), owing to differences in metabolites of predominantly
dietary and microbial origin (Holmes et al., 2008).
Few studies, mostly in vitro, examined CCA tumourigenesis mechanisms in sporadic CCA,
compared to liver fluke-associated malignancy. Similarities and differences in cholangio-
carcinoma clinicopathological (Suzuki et al., 2000), histopathological (Shirai et al., 1992),
immunohistochemical (Hughes et al., 2006) and gene expression (Jinawath et al., 2006)
profiles between sporadic and O.viverrini-related tumours are summarised in (Table 6.1).
It is difficult to compare and interpret findings from these studies: Japanese studies were
mostly focused on intrahepatic bile duct tumours. From current evidence, bile duct tumours
exhibit different biological behaviour that can affect pathogenesis and outcome, depend-
ing on their anatomical location (Banales et al., 2016). Additionally, although CCA risk in
Japanese individuals remains unclear, CCA incidence in Japan is relatively greater com-
pared to Western counties and others Asian counties, such as Singapore and Philippines
(Bragazzi et al., 2011). The higher rates of CCA incidence in Japan could be attributed to
aetiological factors such as hepatolithiasis (intrahepatic gallstones) and infection with viral
hepatitis C (30% of CCA patients are positive for HCV-Ab in Japan) (Okuda et al., 2002).
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Intestinal goblet cell phenotypes (antigen 17NM-positive) were found to be more frequently
expressed in tissues from fluke-infested bile ducts, compared to sporadic cases from an
Australian cohort (Hughes et al., 2006). In a more recent publication by the same Australian
team, adenocarcinomas of the gallbladder also expressed a similar profile, 17NM was ex-
pressed significantly more by gallbladder (59%) and fluke-associated cancers (45%) than
by sporadic CCA (17%), suggesting a chronic inflammatory background in carcinoma of the
gallbladder and bile ducts (Hughes and Bhathal, 2012).
The main focus of this study was to compare the global urinary metabotype from a Thai
population with Opisthorchis-associated CCA, to a Western patients population where CCA
is sporadic. Another primary aim was to characterise the baseline healthy metabolome of
the two distinct populations.
Table 6.1: Summary of the in vitro studies on Opisthorchis-associated CCA compared to
sporadic CCA.
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6.2 Methodology
The methods used in this chapter, including recruitment criteria, ethical approvals, sample
preparation and analysis, were previously described in Chapter 3 (Thailand) and Chapter
5 (United Kingdom). Samples from both populations were simultaneously analysed using
LC-MS metabolic profiling to allow comparability. A subset of 66 raw spectral profiles were
selected and pre-processed for chemometric data analysis.
SIMCA-P+ version 13.0.2 (Umetrics, Umea, Sweden) was used for multivariate statistical
analysis of the processed data. MetaboAnalyst 3.0 was used for univariate analysis.
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6.3 Results
6.3.1 Demographics, clinical data and cohort description
The characteristics of the study population (n= 66) are described in Table 6.2. The partic-
ipants’ age ranged from 27 to 78 years with an average age over 60 years in patients with
CCA, whereas healthy controls were younger, particularly in the British cohort (mean age=
34 years). The gender distribution was in favour of males in the Thai group (healthy= 65%
and CCA= 71%), but was relativity equally distributed among the British group (healthy=
45.4% and CCA= 44.4%). The anatomical location of the tumours in the biliary tree var-
ied between the two disease groups. Patients from Thailand presented predominantly with
intrahepatic bile duct lesions, whereas lesions occurring in the perihilar region were more
common in the participants from United Kingdom.
Table 6.2: Demographics of study population.
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6.3.2 Drug exposure
Urine samples from all the cancer patients were dominated by metabolic features related to
drug exposure, and this was primarily seen in CCA cases from the United Kingdom (Table
6.3). Similar to previous chapters, correlation analysis was used to select and exclude spec-
tral features related to drug intake.
Table 6.3: Top 10 discriminant features between cholangiocarcinoma cases from Thailand
and United Kingdom.
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6.3.3 General overview
All possible comparisons using the spectral profiles from the dataset yielded statistically
significant models (Table 6.4). The healthy metabolome from the two populations was highly
distinguishable, ESI+= R2Y=95%, R2X= 21% and Q2Y=87% and ESI = R2Y=93%, R2X=
17% and Q2Y=79%, Figure 6.1, Table 6.5. The supervised OPLS-DA model comparing
the metabolic signature from patients with biliary carcinoma between the two populations
was also discriminant with Q2Y value of 48% in ESI+ and 50% in ESI  and significant
CV-ANOVA p-value= 0.009 and 0.003, respectively Figure 6.2 and Table 6.6.
Table 6.4: OPLS-DA cross-validation statistics.
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6.3.4 Comparison between the metabolic profiles of healthy controls
(a) PCA scores plot - positive mode
R2X= 30% and Q2X=14% from 2 PC model.
(b) PCA scores plot - negative mode
R2X= 26% and Q2X=-4% from 2 PC model.
(c) OPLS-DA scores plot - positive mode
R2Y=95%, R2X= 21% and Q2Y=87% ,
from one predictive and one orthogonal
components model.
(d) OPLS-DA scores plot - negative mode
R2Y=93%, R2X= 17% and Q2Y=79% ,
from one predictive and one orthogonal
components model.
(e) Permutation test - positive mode
CV-ANOVA= <0.001.
(f) Permutation test - negative mode
CV-ANOVA= <0.001.
Figure 6.1: PCA scores plots for (a) positive and (b) negative ion mode data of healthy partic-
ipants from Thailand and United Kingdom. OPLS-DA scores plots showing group separation
for both (c) positive and (d) negative ion mode data and the corresponding permutation tests
for (e) positive and (f) negative ion mode data.
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Table 6.5: Altered metabolites between healthy participants from United Kingdom (n= 22)
and Thailand (n= 20).
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6.3.5 Comparison between the metabolic profiles of cancer cases
(a) PCA scores plot - positive mode
R2X= 22% and Q2X=-2% from 2 PC model.
(b) PCA scores plot - negative mode
R2X= 27% and Q2X=-4% from 2 PC model.
(c) OPLS-DA scores plot - positive mode
R2Y=96%, R2X= 20% and Q2Y= 48% ,
from one predictive and one orthogonal
components model.
(d) OPLS-DA scores plot - negative mode
R2Y=97%, R2X= 21% and Q2Y= 50% ,
from one predictive and one orthogonal
components model.
(e) Permutation test - positive mode
CV-ANOVA= 0.009.
(f) Permutation test - negative mode
CV-ANOVA= 0.003.
Figure 6.2: PCA scores plots for (a) positive and (b) negative ion mode data of CCA patients
from Thailand and United Kingdom. OPLS-DA scores plots showing group separation for
both (c) positive and (d) negative ion mode data and the corresponding permutation tests for
(e) positive and (f) negative ion mode data.
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Table 6.6: Altered metabolites between participants with cholangiocarcinoma from United
Kingdom (n= 10) and Thailand (n= 14).
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6.3.6 Univariate analysis of discriminatory metabolites
The urinary levels of significantly discriminant metabolites (p < 0.05) generated from the
previous two OPLS-DA models comparing the metabolic profiles between the two distinct
populations in healthy and disease states are illustrated in Figure 6.3 and Figure 6.4. Sta-
tistical significance testing (presented in the whisker-box plots) was performed using ANOVA
with post-hoc test to account for false discovery rate.
Figure 6.3: Box and whisker plots of altered urinary compounds among the study groups -
ESI+.
Key: *p 0.05, **p 0.01 and ***p 0.001. Y-axis= relative intensity.
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Figure 6.4: Box and whisker plots of altered urinary compounds among the study groups -
ESI .
Key: *p 0.05, **p 0.01 and ***p 0.001. Y-axis= relative intensity.
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6.4 Discussion
MS-based metabolic profiling unveiled population differences between the urine metabolome
from the Thai and British cohorts. Urinary biomarkers of the dietary intake of citrus fruits
(proline betaine) (Heinzmann et al., 2010), caffeine (7-methylxanthine and paraxanthine)
(Rybak et al., 2015) and whole grains (2-aminophenol sulfate)(Zhu et al., 2016), were mostly
associated with healthy Western participants. Additionally, the relative levels of metabolites
related to proline-dipeptide metabolism (hydroxyprolyl-isoleucine and tyrosyl-proline/phenylalanyl-
hydroxyproline) were significantly (ANOVA q-value <0.001) more abundant in the urine
metabolite profiles from Western patients with CCA, compared to all other groups. Proline-
containing dipeptide loss in urine is most likely related to protein catabolism pathways (Em-
merson and Phang, 1993), unlike dipeptide containing different amino acids (such as gluta-
mate), which has been reported to be dysregulated in liver pathology (Kalhan et al., 2011;
Soga et al., 2011). Metabonomic analysis of sera revealed that the patterns of circulating
glutamate-dipeptides could discriminate between different liver disease aetiologies and were
proposed as markers of glutathione depletion and increased oxidative stress (Soga et al.,
2011).
Medium-chain acylated-carnitine species (C8:1, C10:1 and C10:3) were also significantly
more abundant in urine samples from the United Kingdom cohort, whereas the urinary ex-
cretion pattern of carnitine with short-chain acyl groups, l-carnitine (C1) and l-acetylcarnitine
(C2), was uniform in the two populations, with relatively elevated concentrations in partici-
pants with biliary tumours. Elevation in acylcarnitines with 8 and 10 carbon atoms have been
suggested to be associated with obesity (Rauschert et al., 2014). A targeted acylcarnitine
MS-assay of lean versus ”healthy” obese individuals identified a metabolic pattern of human
adiposity, which was characterised by imbalance in free fatty acid metabolism, overload of
branched-chain amino acid (BCAAs) catabolism and accumulation of acylcarnitines in serum
(e.g. C8:1 level in obese= 0.28µM and in lean= 0.18µM, p= 0.0006) (Newgard et al., 2009).
Obesity-induced insulin resistance, conventionally measured by the homoeostasis model
assessment (HOMA) index, was also greatly prevalent among the obese cohort with 2.3-fold
increase, compared to lean controls (p< 0.0001). Dysregulation in lipids (including fatty acid
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and acylcarnitine species) and BCAAs is a common theme across metabolic profiling stud-
ies, as described in a recent systematic review and meta-analysis (46 publications) evaluat-
ing metabolite markers of prediabetes and type 2 diabetes (Guasch-Ferre´ et al., 2016). The
interplay between lipids and BCAAs is proposed to modulate and promote the progression
of insulin resistance in obesity. Reduction in BCAA catabolic activity in adipose tissue, most
likely through the inhibition of peroxisome proliferator-activated receptor-  (PPAR- ) activity,
overnutrition, host genetics and/or the gut microbiome, leads to an increase in the circulating
BCAA levels (Newgard, 2012). Subsequently, the expanded circulating BCAA pool spills into
skeletal muscle and liver tissue promoting acylcarnitine generation from the transamination
and oxidative decarboxylation products of BCAA (acyl-CoA derivatives). This may contribute
to further metabolic adaptations observed in obesity and prediabetes states, such as inhi-
bition of active fatty acid oxidation, mitochondrial stress and impaired insulin sensitivity, and
ultimately impaired glucose homeostasis (Newgard, 2012). It was not possible to evaluate
the association between obesity (and related commodities) and acylcarnitine concentration
for this cohort because continuous data on BMI were not available. However, rural residents
with primary education in Thailand (typically farmers, with representative characteristics to
the study cohort) tend to have higher lean mass compared to urban residents (Aekplakorn
et al., 2014).
The urinary output of hippurate and a nucleoside compound putatively assigned as N-
methyladenine was significantly lower in the urine metabolome of individuals with biliary
carcinoma, regardless of the country from which they emanated. In the current study and
in the literature, urinary hippurate has been found consistently to be positively related to
the ”healthy” metabotype and is inversely correlated with BMI (Lees et al., 2013). Greater
urinary excretion of methyladenine has been demonstrated to be related to cigarette smoke
exposure (Hecht, 2002). Yet, another plausible hypothesis is that the gut microbiota may
also influence urine methyladenine excretion. A recent in vivo study investigated the effect
of manipulating bacterial communities on the urine metabolome of ataxia telangiectasia mu-
tated (Atm) knockout mice, which have an increased susceptibility to leukaemia/lymphoma
(Cheema et al., 2016). Atm-deficient and wild type mice with a restricted intestinal micro-
bial diversity showed a corresponding increase in metabolites reported to exert tumour-
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suppressor properties (including 3-methyladenine, kyneurenic and 3-methylbutyrolactone)
in urine, compared to mice with conventional gut microbiota (Cheema et al., 2016).
Elevated relative concentrations of uridine or pseudouridine appears to be specific to the
metabolic signature of CCA in the Western cohort. The nucleoside was also relatively
elevated in the urinary metabolic profiles from Western participants with pancreatic car-
cinoma and non-malignant biliary strictures (Chapter 5), suggesting a possible perturba-
tion across the nucleotide metabolic network resulting from an increase in the rate of RNA
turnover during precancerous and cancerous transformations (Nass, 1983; Seidel et al.,
2015). Metabolic reprogramming in the mitochondrial matrix (including nucleotide biosyn-
thesis) provides critical biosynthetic routes to support cell proliferation and is emerging as
a potential cancer therapeutic target. This observation may provide mechanistic insight into
differences in mitochondrial energy production between CCA subtypes (sporadic vs. liver
fluke parasitism related) (Ahn and Metallo, 2015).
Higher levels of 7-methylguanine was observed in patients with biliary carcinoma, compared
to the control groups in the two cohorts from Thailand. However, no statistically significant
difference was observed amongst the two populations (Thailand vs. United Kingdom). The
presence of such methylated purine derivatives in the urine has been found to be an indicator
of endogenous and exogenous background of DNA methylation and pathologies affecting
purine metabolism, such as gout (Di Pietro et al., 2001; Park and Ames, 1988). In Thailand,
the bioaccumulation of nitrogen species in the water reservoirs and food chain (such as
fermented pork and fermented fish) is believed to play an important carcinogenic role, along
the parasitic infestation, in the pathogenesis of hepatobiliary carcinoma (Kaewpitoon et al.,
2008; Wiwanitkit, 2009). A metabolite tentatively identified as erythronate/threonate was
associated with the urinary metabolic signature of liver fluke associated-CCA. The variation
in concentrations of erythronate/threonate (an end product of ascorbic acid degradation)
in biofluids, might be related to differences in dietary habits, drug use and/or underlying
comorbidities (such as hypertension) (Dunn et al., 2015; Wang et al., 2006).
CHAPTER 6. MAPPING OF POPULATION DISPARITIES IN CHOLANGIOCARCINOMA
URINE METABOLOME 213
6.5 Conclusion
Further understanding of intrinsic and extrinsic factors that affect the metabolic status of the
human urine metabolome is required to gain a better understanding of metabolic adapta-
tions and resulting metabolic end products ”metabolites” in health and disease (Goodacre,
2007). Herein, population-specific differences between the two ethnic groups were found to
be considerably influenced by factors related to variation in dietary habits and body compo-
sition.
The observations derived from this small dataset point towards potential host-gut micro-
biota metabolic interactions in CCA carcinogenesis, regardless of the underlying aetiology.
Whereas, metabolic markers implicated in nucleotide metabolism were associated with the
sporadic type of hepatobiliary disease most common in Western countries, possibly indicat-
ing increase flux through energy-providing pathways in the mitochondrial matrix to support
cellular proliferation.
Chapter 7
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Abstract
Background A distinct serum metabonomic pattern has been previously revealed to be associated
with various forms of liver pathologies. Here, the serum metabolome profiles from healthy controls
and individuals with benign and malignant hepatobiliary diseases were analysed to gain an insight
into the intricate mechanisms underlying liver disease pathogenesis.
Methods Serum samples were profiled using hydrophilic interaction liquid chromatography (HILIC)
platform, coupled to a mass spectrometer. A total of 47 serum specimen from 20 healthy controls, 8
benign bile duct strictures cases, 8 CCA cases and 11 HCC patients were included. Data analysis
was preformed using univariate and multivariate statistics.
Results The serummetabolome disparities between the metabolite profiles from healthy controls and
patients with hepatobiliary disease were predominantly related to changes in lipid and lipid-derived
compounds (phospholipids, bile acids and steroids) and amino acid metabolite (phenylalanine). A
metabolic pattern indicative of inflammatory response due to cirrhosis and cholestasis was associ-
ated with the disease groups. The abundance of phospholipid metabolites was altered in individuals
with liver disease, particularly CCA. Dysregulation of phospholipid metabolism in CCA could be influ-
enced by the genetic variants, e.g. ABCB4 gene, that impair biliary phospholipid secretion.
Conclusion Regardless of the underlying aetiology, biological perturbations associated with all liver
disease serum metabolomes exhibited changes in metabolites related to inflammation and altered
energy production. The level of phospholipid species varied among liver tumour subtypes, possibly
suggesting different homoeostatic regulation of phospholipid metabolism. Independent population-
based studies are needed to ascertain the reproducibility of the results and to evaluate the clinical
utility of these metabolites of interest.
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7.1 Introduction
7.1.1 Serum/plasma analysis in MS-metabonomic studies
The molecular phenotyping of blood matrices (serum/plasma) has been widely used to gen-
erate biomarker fingerprints for cancer diagnostic and screening applications. The mea-
surement of chemical constituents in multiple body fluids provides complementary and more
comprehensive snapshots of metabolic phenotypes in healthy and disease states. Urine is
a particularly attractive biofluid for biomedical screening; urine collection is non-invasive and
requires little or no sample preparation prior to chromatography. Yet, the urine matrix suffer
from inherent variability (influenced by several factors including diet, gender, health status
and diurnal cycles) and therefore, presents a complex analytical challenge and complicates
the biological interpretation of the data. The blood metabolome has the advantage of greater
stability, since its under tighter homoeostatic control, and can provide chemical information
of wide variety of molecular species including small molecular weight metabolites and lipids
(Gowda et al., 2008). Thus, a differentially expressed metabolite-set generated from the
metabolic profiling of both biological mediums (urine and blood) enables a greater represen-
tation of biological networks that underlie pathogenic mechanisms than either matrix alone.
A subtle difference has been observed in the overall chromatographic reproducibility be-
tween the two blood matrices (r= 0.83 and 0.80 between repeated measurements of metabo-
lite concentrations for plasma and serum, respectively) (Yu et al., 2011). The relatively lower
reproducibility in serum might be attributable to matrix effects resulting from sample treat-
ment after collection and coagulation cascade activation, which was found to influence the
concentrations of some metabolites such as peptides, hypoxanthine, xanthine and lysophos-
phatidic acid (Barri and Dragsted, 2013; Yu et al., 2011). In plasma, the presence of antico-
agulant agents (e.g. citrate and EDTA) was also a source of matrix effects, primary affecting
the detection of co-eluting polar metabolites. Therefore, the use of heparin plasma or plain
no-additive serum is advised for global LC-MS metabonomics profiling (Barri and Dragsted,
2013).
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7.1.2 Blood metabonomic patterns in hepatobiliary disease
Metabonomic-based studies described alterations of metabolic patterns in liver, biliary tract
and pancreatic pathologies (Beyog˘lu and Idle, 2013). Dysregulation in phospholipid home-
ostasis was a prominent finding in studies examining the CCA serum metabolome (reviewed
in Chapter 1, p.50). In non-malignant primary biliary disease, spectral data acquired us-
ing non-targeted NMR, LC-MS and GC-MS metabolic profiling revealed a differential serum
metabolite signature from healthy controls, collectively indicative of amino acid perturbation,
glycolysis, oxidative stress, lipid peroxidation, cholestasis and inflammation (Bell et al., 2015;
Hao et al., 2017). Interestingly, a panel of 22 metabolite markers, predominantly free amino
acids (such as phenylalanine, serine and aspartate) and several dipeptides, was found to
exhibit a high classification power (95% predictive accuracy) for distinguishing between pa-
tients with primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) (Bell
et al., 2015). More recently, Hao et al. identified a potential biomarker panel for discrim-
inating patients with PBC from patients with chronic hepatitis and healthy controls using
1H-NMR spectroscopy of serum. The PBC-specific panel, consisting of four metabolites,
4-hydroxyproline, 3-hydroxyisovalerate, citraconate and pyruvate, achieved an AUC of 0.81
(95% CI= 0.87–0.98) in the training set (n= 100) and the findings were reproducible in an
independent validation set (n= 37) generating an AUC value of 0.89 (95% CI= 0.74–0.97)
(Hao et al., 2017). Clinically, primary biliary duct diseases are distinct entities but show
some similar features, such as chronic cholestasis, idiopathic nature and high risk of malig-
nant transformation (Hrad et al., 2016). Moreover, the cholangiographic distinction between
PBC, PSC and malignant biliary strictures is often complicated (Hrad et al., 2016). Thus, the
differential metabolic phenotypes observed in serum amongst patients with malignant and
benign cholestatic biliary diseases may offer clinical value alongside available diagnostic
modalities.
The study presented in this chapter aimed to described the serum metabolite profile associ-
ated with benign bile duct strictures and malignant (CCA and HCC) hepatobiliary conditions
using hydrophilic interaction liquid chromatography (HILIC) coupled to a mass spectrometer.
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7.2 Methodology
7.2.1 Patient and healthy volunteer recruitment
Participants were recruited from the same United Kingdom patient population previously
described in (Chapters 5). A total of 47 serum specimens from 20 healthy controls, 8 cases
of benign bile duct strictures, 8 patients with CCA and 11 patients with HCC were included.
Plain no-additive serum (4 mL) was drawn per patient and allowed to clot for 30 minutes
prior to centrifugation. The clotted serum samples were centrifuged at 4  C at 1000g for 10
minutes before 4 aliquots of 250 µL were transferred to 4 Eppendorf tubes, of which one was
used for the current study. The samples were deep frozen at -80  C until chromatographic
analysis.
7.2.2 Sample preparation
Before MS analysis, frozen serum samples were left to thaw overnight at 4  C. A 100 µL of
thawed sample was mixed with 300 µL of acetonitrile and then vortexed for a minute and
refrigerated for 2 hours. The mixture was centrifuged at 4  C at 16089g for 5 minutes before
a 100 µL aliquot of the supernatant was transferred into 96-well 350 µL plates with cap mats
(Waters, Milford, MA, USA). A sample pool was generated from a 20 µL of each sample for
sample conditioning pre-analysis and quality control throughout the analysis. All samples
were kept refrigerated at 0-4  C and then at 4  C in the autosampler during the MS analysis.
7.2.3 Instrumentation and chromatographic conditions
UPLC separation was performed on a Waters ACQUITYTM UPLC system (Waters Corp.,
Milford, MA, USA). An ACQUITYTM UPLC BEH HILIC 2.1 x 100 mm, 1.7 µm column (Wa-
ters Corp., Milford, MA, USA) was used to retain and separate polar compounds in serum
samples. The mobile phases, chromatographic conditions and gradient program used for
HILIC-UPLC are summarised in Table 7.1.
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Table 7.1: Chromatographic conditions and gradient program of HILIC-UPLC.
An XevoTM G2 QTof (Waters MS Technologies, Manchester, UK) mass spectrometer with
an electrospray ionisation (ESI) interface was employed to acquired the spectral data in both
positive and negative polarities. The data were collected in centroid mode from 50 to 1200
m/z, scan time of 0.20s and interscan time of 0.014s. Leucine enkephalin was used for lock
mass correction with scan time of 0.15s and scan frequency of 30s. Mass spectrometry
conditions in positive ion mode were as follows: capillary voltage 1.5kV, sample cone volt-
age 30V, desolvation temperature 600 C, source temperature 120 C, desolvation gas flow
1000L/hr and cone gas flow 150.0L/hr. Conditions in negative ion mode: capillary voltage
1.5kV, sample cone voltage 30V, desolvation temperature 600 C, source temperature 120
 C, desolvation gas flow 1000L/hr and cone gas flow 48L/hr. MS/MS experiments, using
data dependent acquisition (DDA), were carried out with collision energy ramping from 20 to
40eV.
The conditions were initially optimised using the QC samples in terms of peak shape, repro-
ducibility and retention time. A QC sample was then injected every 10 samples to monitor
the analytical stability throughout the run. An injection of solvent blank samples was used to
detect solvent impurities and filter features resulting from contaminants, if present.
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7.2.4 Data processing and chemometric analysis
The raw spectral data files were converted to CDV format by MassLynxTM version 4.1 appli-
cation manager (Waters Corporation, Milford, U.S.A.). Peak picking and filtering, correction
for retention time drift, peak matching across samples and peak filling of the data were car-
ried out with R Project version 3.1.0 (The R Foundation for Statistical Computing, 2014)
using XCMS package version 2.14 (Bioconductor).
Statistical analysis was performed as outlined in the previous chapters. Significant variables
(metabolites) differentiating between groups were screened based on a threshold of variable
importance in the projection (VIP) value (VIP > 2.5) from a 7-fold cross-validated OPLS or
OPLS-DA model. These differential metabolites were subsequently assessed by univariate
statistics using one-way ANOVA with post-hoc tests (Tukey’s HSD) and presented graphically
as box and whisker plots. Correlation between metabolite-sets was calculated based on
pair-wise Spearman’s rank correlation as previously described (Chapter 3.3.9.1).
7.2.5 Metabolite identification
Accurate mass was first matched against on-line spectral libraries such HMDB (Wishart
et al., 2012), METLIN (Smith et al., 2005) and Lipid Maps (Fahy et al., 2007) for the tentative
assignment of discriminant metabolites. Evaluation of the analyte mass accuracy (within
range of 0–10 ppm), elution time, isotopic pattern and tandem MS fragmentation pattern was
employed for further structural elucidation. Precursor and/or natural loss scans in positive or
negative polarities are used for lipid head group identification, whereas fatty acid composition
is identified by precursor ion scan in negative ion mode.
The identification of lipid classes was based on characteristic and diagnostic fragmentation
pattens in tandem MS. Fragment patterns characteristic of the polar head groups typically
allows the differentiation between lipid classes. Diagnostic fragments and neutral loss of
fatty acyl chain provide information that permit the structural elucidation of the specific lipid
subclass (Godzien et al., 2015). Identification of lipid structures based only on mass accu-
racy is insufficient. As an example, a database search of [M+H]+ at m/z 834.601 generated
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30 matching hits with 0 ppm mass accuracy, including phosphatidylcholines (PCs) and phos-
phatidylethanolamines (PEs). The tandem MS spectrum ofm/z 834.601 (Figure 7.1) shows
the characteristic headgroup of PC (184.07 Da), which is formed by the loss of the phospho-
choline head group. However, no diagnostic fragments were ionised and the length of the
fatty acyl chains could not be determined.
Figure 7.1: The MS/MS spectrum of phosphatidylcholine (m/z 834.601) in positive ion mode.
The spectrum shows the characteristic fragment of phosphatidylcholine (184.07 Da) which is formed by the
loss of the phosphocholine head group. However, the molecule cannot be assigned to exact lipid because
diagnostic fragments were not formed.
Structural assignment of lipids was only provided if both characteristic and diagnostic frag-
ments were present in a MS/MS spectrum with adequate signal. Nevertheless, accurate
identification of phospholipid species remains challenging, due to the presence of structural
isomers and the formation of different ions with various adducts. Internal standards of lipid
species is required for accurate annotation.
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7.3 Results
7.3.1 Serum HILIC-UPLC-MS chromatogram
A non-targeted HILIC-UPLC-MS metabonomics approach was applied to characterise the
serum metabolome of patients with malignant and benign hepatobiliary conditions in com-
parison to disease-free controls. A total of 1,200 and 688 features were detected in the
positive and negative ESI modes, respectively. Figure 7.2 shows an example of HILIC
chromatogram in positive (a) and negative (b) ionisation mode. A possible contaminant, tri-
fluoroacetic acid, m/z 112.9 eluting at 5.63 min, was identified in the ESI  run (Keller et al.,
2008). This contamination was also found in system blanks and was later discarded from
the dataset.
Figure 7.2: Example of metabolites detected in the non-targeted hydrophilic interaction ultra-
performance liquid chromatography.
A chromatogram acquired in (a) positive and (b) negative electrospray ionisation mode.
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7.3.2 Demographics, clinical data and cohort description
The study included a total of 48 adult participant: 20 healthy individuals, 9 benign biliary
stricture cases, 8 CCA patients and 11 HCC patients. One outlier sample from the be-
nign biliary stricture group was identified from the PCA scores plots in both polarity modes
and was excluded from all subsequent analysis. Examination of the corresponding serum
spectra showed markedly higher creatinine, bile acid and lipid peak intensities, in compari-
son to the mean spectrum. An increase in total bilirubin pool (189 µmol/L), creatinine (131
µmol/L), urea nitrogen (16 µmol/L) and alanine aminotransferase (ALT) (100 U/L), was ob-
served in the serum biochemical measurements of the participant, possibly reflecting severe
cholestatic injury.
The age and sex distribution of enrolled participants was difficult to match between the
groups given the limited number of samples available (Table 7.2). Patients with CCA pre-
sented with higher mean levels of total serum bilirubin, ALT and alkaline phosphatase (ALP)
and lower mean serum concentrations of albumin, urea and creatinine, compared to the
other two disease groups. Accumulation of bilirubin ( 25 µmol/L) was also observed among
HCC patients (mean 32.2µmol/L, range 6-104 µmol/L) but was within the normal range for
most participants presented with with benign biliary strictures (mean 19.4µmol/L, range 10-
28 µmol/L). On the contrary, ALT and ALP levels were more elevated in cases with benign
strictures compared to HCC patients (124.0 versus 49.4 U/L and 195 versus 179.5 U/L,
respectively).
Table 7.2: Demographic and biochemical characteristics of the study population.
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7.3.3 Drug exposure
An initial OPLS-DA was computed using the peak intensity matrix of cases versus con-
trols. Features related to the intake of paracetamol, omeprazole, metronidazole, gliclazide,
metformin and warfarin were predominantly found in the serum metabolite profiles from par-
ticipants with hepatobiliary disease, based on the OPLS-DA VIP projection. Drug peaks and
their co-eluting ions and adducts were excluded from all subsequent analysis.
7.3.4 General overview of study samples
The PCA scores plots generated from the ESI-MS spectral data in negative and positive
polarities showed close grouping of QC samples, (Figure 7.3), indicating good instrument
stability throughout the analytical run. Group clustering trend was observed between the
data points, representing the healthy group around the second principal component coordi-
nates in the ESI  spectral profiles (Figure 7.3b). However, the differential patterns between
disease groups were partially attributable.
(a) PCA scores plot - positive mode
R2X=30% and Q2X= 9% from 2 PC model.
(b) PCA scores plot - negative mode
R2X= 25% and Q2X= 6% from 2 PC model.
Figure 7.3: PCA score plots of test samples and quality control (QC) samples.
Samples derived from HILIC-UPLC-MS serum data (n= 47 participants and n= 4 QCs) for (a) positive and (b)
negative ion mode.
CHAPTER 7. CHARACTERISATION OF THE SERUM METABOLIC SIGNATURE OF
CHOLANGIOCARCINOMA IN A UNITED KINGDOM COHORT 225
7.3.5 Gender effect on the serum metabolic profile
The spectral data from 23 males and 22 females were used to calculate PCA and OPLS-DA
models to examine the influence of gender on the metabolite profile (Figure 7.4). Gen-
der discrimination was observed in the OPLS-DA calculated using the data acquired in the
positive ionisation mode (Figure 7.4d) generating a Q2Y of 22% and CV-ANOVA p-value of
0.035. Metabolites contributing to gender discrimination in the multivariate model, listed in
Table 7.3, did not reveal significant differences between men and women using univariate
analyses (based on t-test with FDR cutoff of 0.05, data not shown).
(a) PCA scores plot - positive mode
R2X= 30% and Q2X= 8% from 2 PC model.
(b) PCA scores plot - negative mode
R2X= 23% and Q2X= 6% from 2 PC model.
(c) OPLS-DA scores plot - positive mode
R2Y=65%, R2X= 24% and Q2Y=22%,
CV-ANOVA= 0.035, from one predictive and one
orthogonal components model.
(d) OPLS-DA scores plot - negative mode
R2Y=75%, R2X= 18% and Q2Y=11%,
CV-ANOVA= 0.328, from one predictive and one
orthogonal components model.
Figure 7.4: PCA scores plots for (a) positive and (b) negative ion mode serum mass spectra
of males and females. The corresponding OPLS-DA scores plots for (c) positive and (d)
negative ion mode data.
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Table 7.3: Serum metabolites associated with gender difference - positive mode.
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7.3.6 The impact of age on the serum metabolic profile
Since age was a potential confounded, OPLS regression models were calculated using age
as a continuous outcome variable against the serum spectral matrices. The models were
highly discriminant in both ionisation modes with Q2Y= 57% and CV-ANOVA p-value <0.001
in positive ESI (Figure 7.5a) and Q2Y= 77% and CV-ANOVA p-value <0.001 in negative ESI
(Figure 7.5b). The relevant metabolites of age discrimination are listed in Table 7.4.
(a) OPLS scores plot- positive mode
R2Y=79%, R2X= 24% and Q2Y= 57%
CV-ANOVA <0.001, from one predictive and one orthogonal
components model.
(b) OPLS scores plot- negative mode
R2Y=89%, R2X=18% and Q2Y= 77%,
CV-ANOVA <0.001, from one predictive and one orthogonal
components model.
Figure 7.5: OPLS scores plots of (a) positive and (b) negative ion mode data computed
using age as a continuous Y variable.
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Table 7.4: Serum metabolites associated with age.
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7.3.7 Association between the serum spectral profile and conventional clinical measures
Each of the blood biochemical parameters was regressed as a dependent variable against
the serum spectral matrix. Only total serum bilirubin yielded robust OPLS models with Q2Y
values of 45% and 55% in positive and negative ESI modes, respectively (Figure 7.6).
Serum metabolites most influenced by circulating bilirubin levels are listed in Table 7.5.
Spearman’s rank correlation coefficients (r s) and their corresponding p-values were used to
evaluate the correlation between serum metabolite concentrations and blood bilirubin mea-
surements from a standard biochemical test.
(a) OPLS scores plot- positive mode
R2Y= 91%, R2X= 24% and Q2Y= 45%
CV-ANOVA= 0.013, from one predictive and one orthogonal
components model.
(b) OPLS scores plot- negative mode
R2Y= 96%, R2X= 21% and Q2Y= 55%,
CV-ANOVA= 0.004, from one predictive and one orthogonal
components model.
Figure 7.6: OPLS scores plots of (a) positive and (b) negative ion mode data computed
using total serum bilirubin measurements as a continuous Y variable.
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7.3.8 Discrimination of serum metabolic profiles between the study groups
The OPLS-DA cross-validation statistics obtained from pair-wise comparisons between the
four groups are shown in Table 7.6. The discriminant analysis identified serum metabolite
profile differences between the healthy metabotype, compared to patients with liver patholo-
gies. Poor class discrimination was observed amongst patients with hepatobiliary disease.
Yet, the model comparing benign biliary stricture cases to HCC patients generated higher
Q2Y values (Q2Y= 20% in ESI+ and 30% in ESI ) than the model comparing between
benign and malignant biliary stricture cases (Q2Y= 1% in ESI+ and 4% in ESI ). The
metabolic phenotypes of the two malignant groups (HCC vs. CCA) were not statistically
distinct from one another (CV-ANOVA p-value >0.05) .
PCA and OPLS-DA scores plots and permutation test plots were generated for the com-
parisons between healthy and disease classes, Figure 7.7-7.9. Biomarker candidates (VIP
>2.5) were subsequently tested for significance using one-way ANOVA analysis and multi-
ple testing correction of the p-values for positive ( Table 7.7, Figure 7.10-7.11) and negative
ion mode data (Table 7.8, Figure 7.12-7.13).
Table 7.6: OPLS-DA cross-validation statistics calculated from pair-wise comparisons be-
tween the study groups.
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7.3.8.1 Healthy controls vs. benign biliary strictures
(a) PCA scores plot- positive mode
R2X= 30% and Q2X= -3% from 2 PC model.
(b) PCA scores plot - negative mode
R2X= 22% and Q2X= -1% from 2 PC model.
(c) OPLS-DA scores plot - positive mode
R2Y= 88%, R2X= 26% and Q2Y= 41% ,
from one predictive and one orthogonal
components model.
(d) OPLS-DA scores plot - negative mode
R2Y= 92%, R2X= 21% and Q2Y= 60% ,
from one predictive and one orthogonal
components model.
(e) Permutation test - positive mode
CV-ANOVA= 0.013
(f) Permutation test - negative mode
CV-ANOVA <0.001
Figure 7.7: PCA scores plots for (a) positive and (b) negative ion mode data of healthy con-
trols and benign biliary strictures patients. OPLS-DA scores plot showing group separation
for both (c) positive and (d) negative ion mode data. The corresponding permutation tests
for (e) positive and (f) negative ion mode data.
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7.3.8.2 Healthy controls vs. cholangiocarcinoma patients
(a) PCA scores plot- positive mode
R2X= 36% and Q2X= 4% from 2 PC model.
(b) PCA scores plot - negative mode
R2X= 30% and Q2X= 1% from 2 PC model.
(c) OPLS-DA scores plot - positive mode
R2Y= 94%, R2X= 32% and Q2Y= 79%,
from one predictive and one orthogonal
components model.
(d) OPLS-DA scores plot - negative mode
R2Y= 94%, R2X= 27% and Q2Y= 81%,
from one predictive and one orthogonal
components model.
(e) Permutation test - positive mode
CV-ANOVA <0.001.
(f) Permutation test - negative mode
CV-ANOVA <0.001.
Figure 7.8: PCA scores plots for (a) positive and (b) negative ion mode data of healthy
controls and cholangiocarcinoma patients. OPLS-DA scores plot showing group separation
for both (c) positive and (d) negative ion mode data. The corresponding permutation tests
for (e) positive and (f) negative ion mode data.
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7.3.8.3 Healthy controls vs. hepatocellular carcinoma patients
(a) PCA scores plot- positive mode
R2X= 35% and Q2X= 14% from 2 PC model.
(b) PCA scores plot - negative mode
R2X= 27% and Q2X= 5% from 2 PC model.
(c) OPLS-DA scores plot - positive mode
R2Y= 90%, R2X= 32% and Q2Y= 70%,
from one predictive and one orthogonal
components model.
(d) OPLS-DA scores plot - negative mode
R2Y= 94%, R2X= 25% and Q2Y= 74%,
from one predictive and one orthogonal
components model.
(e) Permutation test - positive mode
CV-ANOVA <0.001.
(f) Permutation test - negative mode
CV-ANOVA <0.001.
Figure 7.9: PCA scores plots for (a) positive and (b) negative ion mode data of healthy con-
trols and hepatocellular carcinoma patients. OPLS-DA scores plot showing group separation
for both (c) positive and (d) negative ion mode data. The corresponding permutation tests
for (e) positive and (f) negative ion mode data.
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Figure 7.10: Box-and-whisker plots of altered serum metabolites detected in ESI+ mode.
Key: *p 0.05, **p 0.01 and ***p 0.001. Y-axis= relative intensity.
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Figure 7.11: Box-and-whisker plots of altered lipid species detected in ESI+ mode.
Key: *p 0.05, **p 0.01 and ***p 0.001. Y-axis= relative intensity.
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Figure 7.12: Box-and-whisker plots of altered serum metabolites detected in ESI  mode.
Key: *p 0.05, **p 0.01 and ***p 0.001. Y-axis= relative intensity.
240
Figure 7.13: Box-and-whisker plots of altered lipid species detected in ESI  mode.
Key: *p 0.05, **p 0.01 and ***p 0.001. Y-axis= relative intensity.
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7.3.9 Correlation between serum metabolite concentrations
Spearman’s rank-order correlation was performed to evaluate the interaction among discrim-
inant metabolites detected in positive (Figure 7.14) and negative (Figure 7.15) ionisation
modes.
Figure 7.14: A heatmap of Spearman’s correlations among discriminant serum metabolites
detected in ESI+ mode.
The blue circles represent positive correlations whereas the red ones show the negative correlations. The
larger the circle diameter the higher the correlation (the X indicates no significant correlation, p >0.05).
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Figure 7.15: A heatmap of Spearman’s correlations among discriminant serum metabolites
detected in ESI  mode.
The blue circles represent positive correlations whereas the red ones show the negative correlations. The
larger the circle diameter the higher the correlation (the X indicates no significant correlation, p >0.05).
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7.4 Discussion
A distinct serummetabolic phenotype was found to be associated with hepatobiliary disease,
globally indicative of dysregulation in lipid metabolism (phospholipid, steroid and bile acid)
in the diseased participant groups. However, no clear separation was observed in serum
metabolite profiles between the diseased cases, benign biliary stricture (n= 8), CCA (n= 8)
and HCC (n= 11), potentially due to the small sample size which resulted in an underpow-
ered study. The serum metabolic phenotypes were particularly indistinguishable between
patients with benign and malignant bile duct strictures.
7.4.1 Age- and gender-related differences in serum metabolite profiles
Differences in age were associated with altered serummetabolite profiles. However, the age-
related differential serum metabolites closely mirrored the metabolic signature discriminating
between cases and controls. This might be the result of average age difference between the
healthy group (mean= 34 years) and hepatobiliary disease groups (mean range between 64-
72 years). Therefore, age was regressed as a dependent variable against the serum spectral
data of healthy participants (n= 20, age range= 24-58 years). The OPLS regression model
yielded poor separation in both polarity modes (Q2Y= 7% and -31%, CV-ANOVA= 0.869 and
1.00 in ESI+ and ESI , respectively), indicating that the difference in age distribution among
the groups, rather than biological factors, may have potentially confounded the results.
The impact of gender on the serum metabolome was subtle. No significant differences (p
<0.05) in metabolite levels were found between men and women. Overall, the metabolic
signature related to female participants was characterised by increased levels of several
phospholipid species, proline betaine and hypoxanthine. Concentrations of lipid metabolites,
including sphingomyelins and PCs, in women were reported to be higher than those in men
in plasma and serum LC-MS lipidomics study (Ishikawa et al., 2014). Similar sex-specific
variations of the plasma lipidome were described in a large population-based cohort (3,300
participants) investigating sexual dimorphisms (Mittelstrass et al., 2011).
The male metabotype was associated with increased serum concentrations of cotinine and
caffeine, which have been reported to be markers of tobacco smoke exposure and caffeine
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intake, respectively (Kaluarachchi et al., 2016; Rybak et al., 2015). An increase in branched
chain amino acids (BCAAs), l-carnitine and creatinine was also characteristic of the serum
metabolite profiles in men, which is in accordance with previous studies investigating gender-
specific differences in the human serum metabolome (Krumsiek et al., 2015).
7.4.2 The effects of environmental factors on the serum metabolome
The discriminatory serum metabolite panel between the study groups reflected variation in
environmental factors related to diet and lifestyle. A metabolite identified as hypaphorine,
based on previously published fragmentation patterns of hypaphorine standard (Keller et al.,
2013), was found to be elevated in healthy participants. Hypaphorine, an N-methyl deriva-
tive of tryptophan, has been reported to be a marker of dietary legume consumption (Guertin
et al., 2014; Keller et al., 2013). Metabolite markers of caffeine (caffeine) and nicotine (coti-
nine) exposure were significantly increased in the serum metabolome of HCC compared to
all groups, which is potentially influenced by the greater number male participants (8 males
vs. 3 females). Similarly, the significant increased in creatinine concentrations in the serum
metabolome of patients with primary hepatic tumours (HCC) could also be attributed to dis-
parity in the number of men to women among participants with HCC. Creatinine levels were
up-regulated in HCC cases compared to patients with malignant and benign biliary strictures.
Yet, serum creatinine concentrations did not differ between HCC and healthy groups.
Additionally, a depletion in serum hypoxanthine levels was characteristic of men and HCC
metabotypes. The nucleotide also showed a decreasing trend in patient with benign and
malignant bile duct lesions. Whereas, xanthine levels were increased in the serum spectral
profiles of HCC and CCA. Perturbation of purine nucleotide metabolism (including xanthine,
hypoxanthine and inosine) in serum was reported to associated with cirrhosis, HCC and
CCA metabolic signatures in urine, blood and tissue (Fitian et al., 2014; Huang et al., 2013;
Kimhofer et al., 2015; Murakami et al., 2015; Yin et al., 2009). However, the direction of
these metabolites changes seems to be inconsistent as described in the relevant metabo-
nomic literature (Fitian et al., 2014; Kimhofer et al., 2015; Yin et al., 2009). The variation in
hypoxanthine concentrations might reflect differential nucleotide metabolism related to un-
derlying aetiological conditions. In addition, differences in sample treatment protocols and
CHAPTER 7. CHARACTERISATION OF THE SERUM METABOLIC SIGNATURE OF
CHOLANGIOCARCINOMA IN A UNITED KINGDOM COHORT 245
coagulation processes were found to have an impact on hypoxanthine concentrations in
blood (Barri and Dragsted, 2013).
7.4.3 Correlation between circulating bilirubin and serum metabolite profiles
The conventional measurement of total bilirubin levels in serum was found to be associated
with several serum spectral features, primarily phospholipid and bile acid metabolites. The
strength of these associations was assessed using Spearman’s rank correlation coefficients.
The strongest positive relationship (r s= 0.70, p-value= 0.0001) was observed between a pro-
tonated phospholipid at m/z 756.5 and circulating bilirubin levels. The test also revealed sig-
nificant correlations (p-value <0.05) with four other phospholipid species, [M+H]+ m/z 786.6,
[M+H]+ m/z 734.5, [M-H]  740.5 and glycerophosphocholine (18:1/18:1), with correlation co-
efficients of 0.49, 0.51, 0.59 and 0.46, respectively. Direct significant correlations were also
observed between the total serum bilirubin pool and glycine- and taurine-conjugated bile
acid fractions (r s range= 0.54-0.60). These associations indicate that high bilirubin levels,
often resulting from obstructive jaundice, possibly influenced phospholipid and bile acid ho-
moeostasis. Only one metabolite, tentatively assigned as docosahexaenoic acid, an omega
3 fatty acid, was inversely correlated with bilirubin with r s of -0.50 and p-value of 0.012.
7.4.4 Correlation among serum metabolite-sets
High positive and significant correlations were mainly observed between the differential
lipid features. A clustering trend was noted among co-eluting phospholipid ions, which
could potentially be structurally related (isomers/adducts) or biologically related. Signifi-
cant correlation patterns were also demonstrated among metabolites assigned as bile acids,
steroids and lysophosphatidylcholine (lysoPC). In addition, male/HCC metabotype charac-
teristic metabolites exhibited a significant positive relationship (between caffeine-valine and
creatinine-carnitine-cotinine). Lastly, a significant direct correlation between docosahex-
aenoic acid and hydroxyisobutyrate was observed. This is perhaps influenced by omega-3
fatty acids supplementation on ketogenesis (Plourde et al., 2009).
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7.4.5 Serum metabolic signatures of hepatobiliary disease
The most prominent difference between the groups was found in the serum concentrations
of metabolites that are chiefly markers of lipid metabolism perturbation, including phospho-
lipids, bile acids and steroids. The venn diagram (Figure 7.16) summarises the serum
metabolites, along with the urine metabolome alterations (presented in Chapter 4), found
to be characteristic of the United Kingdom dataset. In serum, dysregulation of lipid ho-
moeostasis was a common theme in patients with hepatobiliary disease relative to healthy
participants. Several lipid species were predominantly elevated in individuals with CCA, rel-
ative to HCC and biliary stricture cases. Whereas, few phospholipids were down-regulated
in HCC compared to individuals with benign and/or malignant biliary strictures. A decrease
in lysoPC and steroid metabolites in serum was implicated in all the three disease groups.
LysoPC is a major lysophospholipid generated through phospholipase A2-mediated hydrol-
ysis of phosphatidylcholine (Choi et al., 2010). It has been proposed that lysoPC exhibits
proinflammatory activities and is an important mediator of cardiovascular disease and can-
cer (Choi et al., 2010).
Perturbation of steroid metabolism was also observed in the metabolic profiles of urine
matched samples, primarily in the malignant groups. As discussed in previous chapters,
hepatocellular injury together with reduction of hepatic blood flow may explain the impaired
steroid hormone metabolism in liver disease. Altered acylcarnitine metabolism was primarily
observed in urine specimens. Serum phenylalanine levels were elevated in participants with
malignant liver disease. Upregulation of amino acids, including phenylalanine, in liver cancer
is possibly related to the greater protein turnover in cancerous tissue, together with altered
amino acid uptake and synthesis in liver injury (Beyog˘lu and Idle, 2013; Fitian and Cabrera,
2017).
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Figure 7.16: Venn diagram showing differential serum and urine metabolites between benign
biliary strictures, cholangiocarcinoma and hepatocellular carcinoma.
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7.4.6 A common metabotype in hepatobiliary disease
Regardless of the underlying aetiology, a ”core metabonomic phenotype” appearing from the
early onset of liver injury and persisting through hepatic fibrosis/cirrhosis and into carcinoma,
was found to be associated with hepatobiliary disease (Beyog˘lu and Idle, 2013). In their re-
view, Beyog˘lu and Idle summarised the cumulative evidence from various metabonomic ex-
periments addressing hepatobiliary conditions and proposed a simplified mechanistic model
of the changing biochemistry in liver disease progression, as illustrated in Figure 7.17.
Figure 7.17: The common core metabotype associated with hepatobiliary disease progres-
sion.
(A) Liver disease progression phases from healthy liver to hepatocellular carcinoma or cholangiocarcinoma,
(B) The metabolic remodelling initiate from the healthy liver (Phase 0) into the hepatic injury (e.g fibrosis and
cirrhosis) stage (Phase 1) where a Warburg shift from mitochondrial respiration to cytosolic glycolysis,
together with an increase in fatty acid  -oxidation occurs and persists through Phase 2 and Phase 3. Note
that the sum of the carcinoma energy production (right arrow) is greater than the summed energy production
(left arrow) in the healthy liver, and (C) The core metabotype characterised by perturbation of bile acid and
lysoPC homeostasis. Adapted from (Beyog˘lu and Idle, 2013)
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The hepatic metabolic rearrangements progresses from healthy liver (Phase 0) through in-
termediate chronic liver pathologies at Phase 1 (e.g viral hepatitis and fatty liver disease).
During this transition a metabolic switch from mitochondria-mediated respiration to glycol-
ysis occurs. Concurrently, the fatty acid oxidation ( -oxidation) pathway is activated at this
stage of metabolic stress. A corresponding metabotype, characterised by an accumulation
of bile acid species in serum and urine, together with a decline in serum lysoPC levels, de-
velops during the progression from healthy liver and is carried forward into any resultant liver
malignancy (Phase 3).
7.4.6.1 Inflammatory phenotype
Findings from metabonomics studies in human and animal models suggests that the dysreg-
ulation of bile acid and phospholipid homoeostasis is triggered by hepatic inflammatory sig-
nalling pathways, rather than being indicative of the tumour status (Beyog˘lu and Idle, 2013;
Lu and Hooi, 2017; Tanaka et al., 2012). Tanaka et al., investigated the serum metabolome
and gene expression profile in a diet-induced animal model of non-alcoholic steatohepatitis
(Tanaka et al., 2012). The serum metabolite profile of steatotic mice was associated with a
significant depletion in lysoPC species (including 16:0, 18:0 and 18:0) and a marked eleva-
tion in bile acids, compared with normal mice. The gene expression analysis revealed sig-
nificant up-regulation in hepatic mRNAs encoding enzymes and proteins involved in lysoPC
degradation and bile acid excretion, with a marked suppression in genes involved in bile
acid uptake into hepatocytes. In addition, the hepatic mRNA expression of proinflammatory
cytokines, such as tumour necrosis factor-↵ and transforming growth factor- 1, interleukin
(IL)-1, and IL-6, was up-regulated in mice with steatohepatitis and was found to be closely
associated with the changes observed in lipid and bile acid species in serum. Interestingly,
the differential serum metabolites and related gene expression profile was independent to
dietary variation between animals (e.g. choline-deficiency) or hepatic steatosis, yet closely
associated with steatohepatitis and inflammation. This steatohepatitis-specific phenotype is
most likely induced by enhancement of hepatic inflammatory signalling and may apply not
only to non-alcoholic steatohepatitis but other inflammatory liver diseases (Beyog˘lu and Idle,
2013; Tanaka et al., 2012).
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In this study and previous literature, the metabolic pattern observed in cholestatic biliary
disease and biliary carcinoma is in close agreement with the ”core metabotype” observed in
steatotic and cirrhotic liver disease. Bile MS-based metabolic profiling revealed that biliary
lysoPC concentrations were similar among PSC and CCA patients, indicating that shared
metabolic pathways underpin both disorders (Gauss et al., 2013). Bell et al., identified aber-
rant lipid and bile acid metabolism in the global serum metabolome of patients with scleros-
ing cholangitis conditions (Bell et al., 2015). Serum markers suggestive of systemic inflam-
mation (such as kynurenine), endogenous oxidative stress and lipid peroxidation (including
dimethylarginine and 7 -hydroxycholesterol) were reflected in the serum metabolome of
sclerosing cholangitis patients (Bell et al., 2015). The pathogenesis of chronic cholestatic
biliary disease is idiopathic. However, their manifestation is known to be associated with pro-
gressive inflammation of the biliary epithelium along with destruction of intra- and/or extra-
hepatic bile ducts (Boonstra et al., 2012).
Attenuation of circulating lysoPC appears to be influenced to some degree with other solid
tumour entities. Taylor et al., examined lysoPC patterns and their relationship with parame-
ters of inflammation, including C-reactive protein (CRP) and whole blood hydrogen peroxides
(HPO), and nutritional status, such as weight loss, body composition and BMI, in a group
of 59 cancer patients (including cancer of the breast, lung, gastrointestinal tract and other)
(Taylor et al., 2007). The ranges of lysoPC concentration in cancer patients were found to
be lower or near the lower value of the reference interval reported for a healthy population
(177-232 µM vs. 200-300 µM, respectively). Measures of oxidative stress (HPO) and inflam-
matory activation (CRP) were found to be inversely correlated with lysoPC concentrations
(r= -0.50 and -0.48, P< 0.5). In relation to nutritional parameters, lysoPC levels were only
influenced by weight loss since diagnosis, (r= 0.31, P= 0.017), particularly in a subgroup
with severe weight loss and hypoalbuminemia (r= -0.71 and P= 0.019). Similarly, the rela-
tionship between lysoPC levels and inflammatory markers were found to be stronger in a
number of subgroups, suggesting that cachexia, systemic inflammation and oxidative stress
are co-dependent and closely interrelated processes with lipid peroxidation in malignant dis-
ease.
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These results suggest that the attenuation of lysoPC species in blood serves as a marker
pertaining to the severity of malignancy in general. It is unclear whether lysoPC displays
shared or distinct patterns between liver tumours and other tumour entities. Nevertheless,
the liver is the major site of lysoPC biogenesis, and phospholipid catabolism has been found
to be impaired in the early stages of liver disease progression (Beyog˘lu and Idle, 2013;
Tanaka et al., 2012). Overall, the literature is inconclusive and comprehensive studies em-
ploying a targeted quantitative lipidomic approach are required to validate cancer-specific
metabolite abundance patterns.
It is also worth noting that the regulation of bile acid could be affected differently in liver
disease. In this cohort, the increase in circulating bile acid levels was more pronounced in
HCC, most likely due to the underpinning inflammation that underlies cirrhosis. Conversely,
elevation in bile acid urinary excretion was associated with pancreatobiliary cancer. Com-
prehensive characterisation of bile acid species patterns in different forms of hepatobiliary
tumours is necessary to understand their pathogenic role in carcinogenesis.
7.4.7 Differential phospholipid metabolism in cholangiopathy
Marked elevations in the relative abundance of a number of phospholipid molecular species
were associated with cholestatic liver disease, particularly in malignant conditions. Yet,
down-regulation of phospholipids/PCs in bile was elucidated in the early CCA-metabonomics
studies (AbdAlla et al., 2011; Albiin et al., 2008; Khan et al., 2005; Sharif et al., 2010). It is
postulated that genetic variations in biliary transporter proteins, such as multidrug-resistant
protein 3 (MDR3), mediates the reduction in biliary phospholipid secretion in cholangio-
pathic disorders (Khan et al., 2005; Wadsworth et al., 2011). ABCB4, the gene that encodes
for MDR3, is an ATP-binding cassette (ABC) transporter in the canalicular membrane. In
the liver, ABCB4 is responsible for the secretion of phospholipids into bile; it facilitates the
translocation of phospholipid, preferentially PC, from the inner to the outer leaflet of the
hepatocanalicular membrane (Morita and Terada, 2014). Biliary phospholipid preserves the
biliary epithelium integrity against the cytotoxic detergent effect of bile salts (as monomers
and as simple micelles) by facilitating the formation of mixed micelles (bile salt-cholesterol-
phospholipid mixtures), which strongly attenuates the toxicity of the bile salt pool (Morita and
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Terada, 2014).
Further support for the involvement of ABCB4 gene in the pathogenesis of cholestatic liver
disease was presented in recent studies. A mutant ABCB4 genotype was detectable in 18
out of 90 patients with cholangiopathy (20.0%; 95% CI= 12.3–29.8%). ABCB4 mutation-
related PSC phenotype was found to be more frequent in patients with a personal or family
history of other cholestatic liver disease (28.6 vs 8.7%) and was associated with earlier
ages at diagnosis (Degiorgio et al., 2016). Emerging direct evidence revealed that non-
synonymous polymorphic variants of ABCB4 have deleterious effects at the protein level
(e.g. low expression levels, maturation defect, retention in the endoplasmic reticulum) (An-
dress et al., 2017). The mutants compromised the ABCB4-mediated efflux of phospholipid,
resulting in a significant reduction in PC secretion from cells.
The ABCB4 genotype is likely to underlie the pathophysiology of cholestatic liver disease
in a specific sub-population of patients. A low or absent ABCB4 expression may therefore
favours the formation of ‘toxic bile’, as a result of decreased biliary phospholipid secretion,
and aggravates inflammatory bile duct injury. Chronic cholestasis and cholangitis may fur-
ther drives secondary sclerosis or cirrhosis and predisposes to hepatobiliary cancer. This
proposed pathogenetic mechanism implies that future therapeutic strategies that address
the underlying cholestasis by targeting specific and potent nuclear receptor ligands may
provide a window of opportunity for cholestatic liver diseases management and treatment.
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7.5 Conclusion
A serum metabolic panel, including metabolites involved in lipid metabolism (phospholipids,
bile acids and steroids) and amino acid metabolism, distinguished between healthy controls
and individuals with hepatobiliary diseases. Markers related to inflammation (lysoPC species
and bile acids), hepatobiliary injury (steroid-related metabolites), high protein turnover (pheny-
lalanine) were characteristic of liver disease, particularly in malignant cases. No robust mul-
tivariate differentiation was observed between the liver disease subgroups. Yet, the abun-
dance of a number of phospholipid metabolites exhibited statistically significant difference
across the diseased groups.
Further studies are needed to gain better understanding of metabolic alterations throughout
the oncogenic processes in liver disease. Targeted metabonomics approach would be ideal
as it provides both qualitative and quantitative analysis of the metabolites of interest.
Chapter 8
CONCLUSIONS AND FUTURE REMARKS
The incidence of sporadic CCA is increasing worldwide (Shaib and El-Serag, 2004). A
clear aetiology of the disease pathogenesis remains to be fully elucidated. In Southeast
Asia, liver fluke infection still remains alarmingly high and long-term exposure to the parasite
often results in severe hepatobiliary complications. O.viverrini-associated CCA is predicted
to cause thousands of deaths in the coming decades, affecting the poorest of the poor in
Southeast Asian countries, including Thailand, Laos and Vietnam. Undeniably, CCA remains
a condition with a uniformly poor prognosis. There is an urgent need to utilise innovative
technological advancements, along with primary prevention, to combat this fatal malignancy
and improve early detection. Metabonomics could potentially offer an exciting opportunity
to fill knowledge gaps in biological mechanisms of biliary carcinogenesis. Urinary metabolic
phenotyping, in particular, could present a new non-invasive, rapid and efficient tool for CCA
diagnosis, prognosis and monitoring. The discovery of a panel of metabolite markers would
be of considerable value for a timely diagnosis of O.viverrini-related hepatobiliary diseases
in resource-poor settings. Moreover, owing to the complexity of CCA diagnosis, biomarkers
that can hold clinical potential in a definitive differentiation between benign and malignant
bile duct lesions should improve clinical care and patient outcomes.
The overall quest of this exploratory research project was to investigate and characterise
metabolome perturbations in biliary tree cancer using a MS-based metabonomics approach.
The results throughout this thesis point towards differential metabolic rearrangements and
adaptations in hepatobiliary cancer (Section 8.1). The secondary hypothesis aimed to ex-
plore the diagnostic and surveillance applications of discriminatory metabonomic biomark-
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ers in CCA. In essence, my findings showed that a panel of 10 urinary metabolite markers
achieved a promising diagnostic potential (93.4% accuracy). Yet, further assessment of
biomarker performance in CCA detection is required to determine their utility in preclinical
and clinical settings.
8.1 Overview of results
The metabolic signature of CCA was found to be associated with several changes in the ex-
pression of metabolites in urine (Chapter 3-6) and serum (Chapter 7). These perturbation
revealed that a metabotype, globally indicative of increased cellular turnover, DNA methy-
lation, aberrant lipid metabolism, inflammation, hepatic injury and a potentially altered gut
microbiome, to be characteristic of the CCA metabolite profile. The anatomical location of
biliary tumours was shown to have a subtle impact on the urinary profile, whereas the pres-
ence of obstructive jaundice significantly altered bile acid and acylcarnitine homoeostasis.
Among Thai participants living in endemic liver fluke provinces, disease-free individuals,
participants with opisthorchiasis and periportal fibrosis (PPF) exhibited similarities in the
composition and abundance of metabolites in urine, yet they were differentiated from CCA
cases. In the dataset from the United Kingdom, it was also possible to discriminate between
the CCA urinary metabolome from benign liver pathologies (gallstones, viral hepatitis and
sphincter of Oddi dysfunction), malignant hepatocellular tumours and ovarian cancer. How-
ever, the biochemical signature was indistinguishable between urine samples from patients
with CCA and pancreatic cancer. These results imply that tumours arising along the pan-
creatobiliary junction may share a common biological entity. In serum, a similar metabotype,
primarily indicative of inflammatory response, was identified in individuals with CCA, biliary
strictures and HCC. The pattern of serum phospholipids was distinct in CCA profiles, pos-
sibly due to genetic variants in phospholipid transporter genes, which contribute to hepatic
cholestasis and increased risk of malignant transformation (Degiorgio et al., 2016). Over-
all, it was possible to classify CCA from a number of pathological conditions, indicating a
potential role of molecular phenotyping in hepatobiliary disease diagnostic applications.
The two distinct populations (from Thailand and the United Kingdom) were recruited to ex-
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plore the influence of different underlying pathogenesis on the urinary metabolome. The
phenotypic diversity amongst the two cohorts was predominantly related to differences in
exogenous sources (nutritional, environmental and pharmaceutical) rather than endogenous
host carcinogenic mechanisms. Gut microbial-host co-metabolites were found to be altered
in both sporadic and opisthorchis-associated CCA. Nucleotide metabolism was mostly af-
fected among Western patients, potentially reflecting greater mitochondrial energy produc-
tion in sporadic CCA.
It is critical to consider the confounding effect of non-tumour-related factors, such as thera-
peutic treatment, dietary practices, inflammation and cancer cachexia, to definitively confirm
or refute the associations between the metabolite markers and CCA signature. Additionally,
the identification of metabolome diversity and similarities for various tumour phenotypes is
also required to verify cancer-specific biomarkers.
Overall, although results are not conclusive, a number of novel observations may be high-
lighted. These include:
• MS-based metabonomics successfully uncovered several metabolic dysregulations in
bile duct cancer urinary and serum profiles. Mapping functional and regulatory relation-
ships among metabolites of interest is essential to translate findings from metabolite
signatures into a comprehensive pattern of pathway signatures.
• The urinary molecular profiles underlying PPF cases were differentiated from those
with CCA. In addition, the acylcarnitine profile was altered in patients with biliary fi-
brosis, compared to high risk participants exposed to O.viverrini. This may hold a
diagnostic potential in the detection of heptobiliary abnormalities in liver fluke endemic
areas and prevent delayed diagnosis.
• The obstruction of bile flow highly influenced the urinary excretion of bile acid and
acylcarnitine species. Better understanding of the impact of physiological and clinical
variants on metabolome profiles is necessary to avoid misinterpretation of disease-
related biochemical signatures.
CHAPTER 8. CONCLUSIONS AND FUTURE REMARKS 257
• Shared embryological development, as well as, clinical, biological and pathological
features were previously identified in pancreatic and bile duct tumours. Here, a similar
global urinary fingerprint was also observed to be characteristic of the two malignan-
cies, yet distinct from HCC cases. This could possibly indicate a common carcinogenic
processes in pancreatobiliary tumours, which in turn, may offer treatment window for
potential therapies.
• An inflammatory signature was found to be associated with the metabolite profiles of
benign and malignant hepatobiliary diseases in serum. In-depth understanding of pro-
inflammatory processes preceding fibrosis and malignant transformation might offer an
opportunity for early CCA detection.
• Linking between genotypic and phenotypic characteristics could potentially elucidate
genetic triggers of cholestasis, which may promote oncogenesis in biliary tract cancers.
8.2 Strengths and limitations of the study
There were inevitable limitations in the studies presented throughout this thesis. The main
drawback was the limited sample size, which may have underpowered the detection of class
and subclass differences. The limited clinical data availability, along with the small cohort
size, challenged the analysis of the data with respect to sex, BMI, ethnicity or other potential
confounding covariates. Moreover, it was not feasible to match the groups in terms of par-
ticipants number and demographic characteristics. The difficulty in recruiting participants,
particularly in the Western cohort owing to the rare occurrence of CCA, prevented the val-
idation of the findings in an external cohort. With regard to the Thai population, sample
availability is not problematic, yet the sample size was smaller than desirable due to eco-
nomic, logistical and cultural reasons. In addition, comprehensive clinical data were difficult
to obtain. In spite of sampling limitations, this is the first multicentric study investigating CCA
urinary and blood metabolome in the United Kingdom. It is also the first study address-
ing O.viverrini-associated CCA urinary metabotype. The characterisation of healthy and
diseased metabolome differences among ethnically and geographically distinct populations
was one of the main strengths of the study. Additionally, the study highlighted similarities
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and differences in metabolite levels in biofluids between various forms of hepatobiliary con-
ditions, both benign and malignant.
With respect to the assessment of nutritional variations on the metabolic profiles, food in-
take from the 24-hr dietary recall had a limited value. It only allowed the identification
of biomarkers of short-term nutrients intake (such as caffeine). The assessment of diet-
induced changes on the endogenous metabolome is complex. Several inherent challenges
remain to be addressed for robust dietary evaluation in population-based metabolic profiling
studies, these include: 1) diet standardisation/restrictions to reduce intra- and inter-subject
variability is often impossible; 2) current tools for the assessment of dietary consumption
are time-consuming, subject to recall bias, require trained interviewer and expensive; 3)
comprehensive MS-based metabolite databases of food components/additives and their co-
eluting metabolites is lacking; 4) other covariates such as age, gender, disease statues and
gut microbiome could mask true metabolic signals of nutrients in an individual’s molecular
fingerprint; 5) computational strategies to account for nutritional variability and to integrate
dietary exposure data with metabonomic matrices are required (Scalbert et al., 2009; Shim
et al., 2014).
A number of other pitfalls are typically encountered in MS-based metabonomics investiga-
tions. Known inherent challenges associated with the sensitivity, reproducibility and compre-
hensiveness of mass spectral data are widely discussed (Gowda and Djukovic, 2014; Scal-
bert et al., 2009). Standardisation in protocols and computational approaches are required to
improve the quality of the generated datasets and allow compatibility across different labora-
tories. Moreover, the structural annotation of metabolites in global fingerprinting experiments
is a major bottleneck of the field. Unknown metabolites and putative chemical structures elu-
cidation can potentially lead to misleading or incomplete biological interpretation of the data.
Absolute metabolite quantification of target metabolites might offer a solution to overcome
these limitations. Quantitative data can be used to generate accurate computational models
to extract meaningful biological data across metabonomics studies (Gowda and Djukovic,
2014). Nevertheless, as the technology rapidly expands new solutions to address the data
complexity continues to emerge and evolve.
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8.3 Closing remarks
Global spectroscopic phenotyping is a hypothesis-generating discipline that often raise more
questions than answers. Optimally, findings uncovered from these studies are used to guide
and prioritise future research activities. From the experimental results presented throughout
this thesis, it is possible to conclude that metabonomic profiling can identify disease-related
metabotypes and contribute to uncovering novel candidate diagnostic biomarkers in CCA.
The relationship between metabolites expressed in biofluids and their regulatory role in a
metabolic network remains to be elucidated. Functional analysis of dysregulated metabolic
pathways is key to provide in-depth biological knowledge of CCA pathogenesis.
To date, the translation from metabonomics-based biomarker discovery to clinical metabo-
nomics is still immature. Several challenges that hinder this progression remain to be
addressed by the metabonomics community as the field expands. Improving data shar-
ing and standardising the analytical pipeline are of key importance in accelerating clini-
cal metabonomics implementation. Innovative bioinformatics strategies for the integration
of metabolome-driven data into the other ‘omics’ sciences are required to define disease-
associated metabolic patterns and map a blueprint of disease mechanisms and targets.
Without doubt, over recent years, numerous developmental milestones were achieved in
metabolic profiling. The Human Metabolome Database (HMDB), for example, currently
archive 40,153 metabolites information in its most recent version, compared to only 2,180
metabolites in the first release in 2007 (Wishart et al., 2012). Moreover, tools for automated
chemical annotation are becoming more accessible (e.g. ClassyFire)(Feunang et al., 2016).
With respect to clinical metabonomics implementation, innovative instruments such as Spi-
derMass (Fatou et al., 2016) and iKnife (Balog et al., 2013) offer possibilities for real-time
cancer diagnosis.
In the context of CCA research, international research collaboration is vital to accelerate the
pipeline of biomarker discovery. Further validation studies using complementary platforms
(e.g. NMR, GC–MS and LC-MS) and targeted assays, including acylcarnitine, nucleotides,
steroid, bile acid and lipidomics, can potentially unveil molecular drivers of CCA progression,
and ultimately uncover diagnostic and therapeutic targets.
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